CURRICULUM VITAE PRESENT TITLE AND AFFILIATION Ensign ... 2019-07-22.pdf · Thoracic Oncology Research Award, Dana Farber Cancer Institute, 1997 Young Investigator Award, American

CURRICULUM VITAE

Roy S. Herbst, MD, PhD

July 18, 2019

PRESENT TITLE AND AFFILIATION Ensign Professor of Medicine (Medical Oncology) Professor of Pharmacology Chief of Medical Oncology Associate Cancer Center Director for Translational Research Director, Thoracic Oncology Research Program Interim Director, Yale Center for Immuno-oncology

Dual/Joint/Adjunct Appointment Adjunct Professor of Medicine, Thoracic/Head and Neck Medical Oncology (THNMO), Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center (UT-MDACC), Houston, TX

Honorary Professor, University College London (UCL) Cancer Institute

CITIZENSHIP United States

OFFICE ADDRESS Yale Cancer Center Section of Medical Oncology 333 Cedar Street New Haven, CT 06520-8028

Phone: (203) 785-6879 Fax: (203) 785-4116 Email: [email protected]

EDUCATION Degree-Granting Education

Yale University, New Haven, CT, BS, 1984, Molecular Biophysics and Biochemistry

Yale University, New Haven, CT, MS, 1984, Molecular Biophysics and Biochemistry

The Rockefeller University, New York, NY, PhD, 1990, Molecular Cell Biology (Thesis Advisors: James E. Darnell, Jr., MD, and Lee E. Babiss, PhD)

Cornell University Medical College, New York, NY, MD, 1991, Medicine

Harvard University, Cambridge, MA, MS, 1997, Clinical Translational Research

Yale University, New Haven, CT, Honorary MA, 2013


Page 2 of 103

Postgraduate Training Clinical Fellowship in Medicine (Internship and Residency), Harvard Medical School, Boston, MA, (Residency Director: Dr. Marshall Wolf), 1991−1994

Chief Medical Residency, West Roxbury VA Hospital, Dedham, MA, (Residency Director: Dr. George Thibault), 1994

Medical Oncology Fellowship, Dana Farber Cancer Institute, Boston, MA, (Director: Dr. Robert Mayer), 1994−1996

Clinical Investigator Training Program, MIT-Harvard (HST Program), Cambridge, MA, (Directors: Dr. Donald Kufe and Dr. Robert Rubin), 1995−1997

Medical Hematology Fellowship, Brigham and Women's Hospital, Boston, MA, (Director: Dr. Robert Handin), 1996−1997

Harvard School of Public Health: Leadership Development for Physicians in Academic Health Centers, Oct. 2013

CREDENTIALS Board Certification

Internal Medicine, 1994−2014

Medical Oncology, 1997−2027

Licensures Active

CT, 049756 current

Inactive TX 1997−2011

MA, 1993-1997

EXPERIENCE/SERVICE Academic Appointments

Clinical Fellow, Harvard Medical School, Boston, MA, 1991−1996

Instructor in Medicine and Attending Physician, Harvard Medical School, Boston, MA, 1996−1997

Assistant Professor of Medicine, THNMO and Department of Cancer Biology (CB), UT-MDACC, Houston, TX, 1997−2002

Assistant Professor, CB, UT-MDACC, Houston, TX, 1998−2002

Chief, Section of Thoracic Medical Oncology, THNMO, UT-MDACC, Houston, TX, 2001−2011

Associate Professor, THNMO and CB, UT-MDACC, Houston, TX, 2002−2005

Professor of Cancer Biology, CB, UT-MDACC, Houston, TX, 2005−2009

Professor of Medicine, THNMO, Division of Cancer Medicine, UT-MDACC, Houston, TX, 2005−2011

Barnhart Family Distinguished Professor of Targeted Therapy, UT-MDACC, 2011

Chief of Medical Oncology, Yale Cancer Center. 2011-present

Professor of Medicine (Tenure), Yale University. 2011 – present

Professor of Pharmacology, (secondary) Yale University. 2012 – present

Ensign Professor of Medicine (Medical Oncology). 2013-present


Page 3 of 103

Adjunct Professor of Medicine, THNMO, Division of Cancer Medicine, UT-MDACC, Houston, TX. 2013-present

Honorary Professor, University College London (UCL) Cancer Institute. 2015-present

Administrative Appointments/Responsibilities Director, Journal Club, THNMO, UT-MDACC, Houston, TX, 1997−1999

Clinical Core Director-U54 Targeted Therapy Grant, UT-MDACC, Houston, TX, 2001−2011

Editor and Founder, the Protocol Review, THNMO, UT-MDACC, Houston, TX, 2002−present

Co-Chairman, Phase I Working Group, UT-MDACC, Houston, TX, 2003−2011

Co-Director, Lung Cancer Program, Department of Defense Grant, UT-MDACC, Houston, TX, 2004−2011

Leader, Lung Cancer Program, Cancer Support (CORE) Grant, UT-MDACC, Houston, TX, 2004−2011

Director, Fellowship Program, THNMO, UT-MDACC, Houston, TX, 2007−2011

Leader of the Phase I Cancer Disease Center at Smilow Cancer Hospital. 2011-2013

Co-Program Director, Developmental Therapeutics, Yale Cancer Center, 2011 – 2015

Leader of the Clinical Research Program in Thoracic Oncology at the Yale Cancer Center. 2011-2019

Associate Cancer Center Director for Translational Research, Yale Cancer Center. 2011-present

Interim Director, Yale Center for Immuno-oncology, Yale Cancer Center. 2018-present

Other Appointments/Responsibilities N/A

Endowed Positions Barnhart Family Distinguished Professor in Targeted Therapies, UT-MDACC, Houston, TX, 6/2009−2011

Ensign Professor of Medicine (Medical Oncology), Yale University, New Haven, CT, 2013-present

Consultantships Bayer Pharmaceuticals, Pittsburgh, PA, Consultant, Drug Development, 1998

Eli Lilly and Company, Indianapolis, IN, Consultant, Lung Cancer Therapy, 1998−1999

Imclone Systems Incorporated, Somerville, NJ, Consultant, Clinical Trial Design and Drug Development, 1998−2000

TAP Pharmaceuticals, Lake Forest, IL, Consultant, TNP-470 Drug Development, 1998−2000

Pfizer Pharmaceuticals, Groton, CT, Consultant, Drug Development, 1998

Schering Plough Pharmaceuticals, Kenilworth, NJ, Consultant, Interferon Drug Development, 1999

AstraZeneca Pharmaceuticals, Wilmington, DE, Consultant, Drug Development, 2000−2008

Center for Biologic and Continuing Education (CBCE-CME), Board member, 2002−2008

Eli Lilly and Company, Indianapolis, IN, Consultant, Lung Cancer Therapy, 2003−2009

Pfizer Pharmaceuticals, Groton, CT, Consultant, Drug Development, 2003

ACLARA BioSciences, Inc., Mountain View, CA, Scientific Advisory Board member, 2004−2008


Page 4 of 103

Genentech, South San Francisco, CA, Consultant, 2004−2008

Exelixis, So. San Francisco, CA, Consultant, 2007

Biothera, Eagan, MN, Clinical Advisory Board Member, 2014-present

Merck, Whitehouse Station, NJ, NSCLC Global Advisory Board member, 2014-present

Transgene, Illkirch Graffenstaden-France, TG-4010 US NSCLC Advisory Board member, 2014-present

Genentech, South San Francisco, CA, Lung Cancer National Advisory Board member, 2014-present

Astra Zeneca, New York, NY, NSCLC Advisory Board member, 2014-present

Endocyte, New York, NY, Oncology Advisory Board member, 2014-present

Clovis Oncology, Boulder, CO, Expert Advisory Board member, 2014-2015

Infinity Pharmadeutials, Scientific Advisory Board member, 2016-present

NextCure, Scientific Advisory Board member, 2017-present

Neon Therapeutics, Scientific Advisory Board member, 2018-present

Military or Other Governmental Service NA

Institutional Committee Activities University of Texas M.D. Anderson Cancer Center Computer-based Clinical Record Committee, Member, 1997−1999

Patient Care Committee, Member, 1997−1999

Clinical Research Committee, Member, 1997−2000

Committee on Institutional Awards, Member, 1999−2000

Clinical Research Committee II, Member, 1999−2001

PET Steering Committee, Member, 1999−2002

Clinical Translational Research Center Advisory Committee, Member, 1999−2003

Intellectual Property Oversight Committee, Member, 2000−2003

Study Section Review Committee of the Cancer Therapeutics Discovery Program, Member, 2000−2011

External Data Monitoring Committee, Member, 2000−2011

Cancer Center Support Grant (CCSG) Histology Core Oversight Committee, Member, 2001

Search Committee for Chairman, Department of Experimental Diagnostic Imaging, Member, 2001

Multidisciplinary Research Advisory Committee (MRAC), Member, 2003−2009

Institutional Review Board II (IRB2), Alternate Member, 2004−2007

Symposium on Fundamental Cancer Research, Member, 2005−2011

Credentials Committee of the Medical Staff, Alternate Member, 2005−2011

Graduate Medical Education (GME) Institutional Review Subcommittee, Member, 2006−2007


Page 5 of 103

Promotion and Tenure Committee, Member, 2006−2009

American Association for Cancer Research (AACR) Task Force on Tobacco and Cancer, 2010-2013

Molecular Markers Task Force, Member, 2006−2011

Clinical and Translational Research Center (CTRC) Steering Committee, Member, 2006−2011

Southwestern Oncology Group (SWOG) Executive Committee, Chairman, 2007−2011

Institute of Personalized Cancer Therapy (IPCT) Steering Committee, Member, 2008−2011

Institute of Personalized Cancer Therapy (IPCT) Thoracic MCC (Multi-Care Center) Scientific Steering Committee, Chairman, 2008−2011

Executive Committee for the development of the new PhD Program in Clinical Science, Member, 7/2009−2011

Yale University Tumor Committee, Sarah Cannon Research Institute and Yale Cancer Center, Nashville, TN 12/2011

Yale Cancer Center, Cancer Center Executive Committee, 2011 – Present

Yale Cancer Center, Protocol Review Committee, 2011 – Present

Yale Cancer Center, Clinical Research Committee, 2011 – Present

Yale Scholar Awards Committee 2011- Present

Department of Internal Medicine, Faculty Appointment and Promotions Committee, 2012 – 2014

Molecular Profiling Committee 2014-2015

Cancer Biology Institute Advisory Committee, 2018-2020

HONORS AND AWARDS Research Award, Yale Science and Engineering Association, 1982

Distinction in Molecular Biophysics and Biochemistry, Yale University, 1984

Phi Beta Kappa, Summa cum Laude, Yale University, 1984

Dean's Research Prize, Cornell Medical College, 1990−1991

Landberg Prize, Cornell Medical College, 1991

Polk Prize, Cornell Medical College, 1991

HST/Pfizer Clinical Investigator Training Program, Harvard Medical School, 1995−1997

Dana Farber Recognition Award, Dana Farber Cancer Institute, 1997

Thoracic Oncology Research Award, Dana Farber Cancer Institute, 1997

Young Investigator Award, American Society of Clinical Oncology (ASCO), 1997

Physicians Referral Service Research Award, MDACC, 1998

SPORE Development Award, The University of Texas Southwestern Medical Center-Dallas, 1998−1999

Career Development Award, American Society of Clinical Oncology, 1999−2002

Physician Scientist Program Award, MDACC, 1999−2002


Page 6 of 103

Best Doctors in America, Inside Houston, 2003−2004, 2005−2006, 2007−2011

Guide to America's Top Physicians, 2004−2005

America's Top Doctors, Castle Connolly Medical Ltd., 2006−2013

Rofeh Yedid Award, Aishel House, 2006

Special Honoree, Golfers Against Cancer, 2006

David Ben Guiron Leadership Award, 2007

New Frontiers Award, American Society of Cytopathology, 2007

Irwin H. Krakoff Award for Excellence in Clinical Research, MDACC, Division of Cancer Medicine Faculty Recognition and Awards Program, 2008

Fellow, American College of Physicians, 2010

Fifth Annual Division of Cancer Medicine Waun Ki Hong Award for Excellence in Team Science, MDACC Division of Cancer Medicine, 2010

Sikand Orator, Yale University, 2011

Best Doctors, New York Magazine – 2012-2014

Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research, Dana-Farber/Brigham and Women’s Cancer Center, 2014

7th Annual Addario Lectureship Award, 2014

Bonnie J. Addario Excellence in Collaboration and Innovation Award, 2014

Herbert Pardes Clinical Research Excellence Award, Clinical Research Forum, 2015

Elected Member, Association of American Physicians, 2015

Waun Ki Hong Visiting Professorship Award, MDACC Division of Cancer Medicine, 2015

IASLC Science/ Paul A Bunn, Jr. MD Award, 2016

Association for Clinical and Translational Science (ACTS) Translational Team Science Award, 2018

RESEARCH Grants and Contracts

Funded PI, 25% effort, Yale SPORE in Lung Cancer (YSILC): The biology and personalized treatment of lung cancer; 1P50CA196530-01; NIH/NCI; 8/1/2015 – 7/31/2020; $2.2M x 5 years.

Principal Investigator, 5%, Yale Cancer Center Fellows Training Program. T32 (pending), NIH/NCI, 2/01/2018-11/30/2023, $422,864

Principal and Co-leader of the Clinical Trials Core, Dream Team: Targeting KRAS mutant lung cancers; Stand Up to Cancer (SU2C); 20% effort, 9/1/2015-8/31/19; $690,000 annually.

Co-PI, Steering Committee Chair, Lung Master Protocol (Lung-MAP), associated with protocol SWOG1400, NIH/NCI, 6/1/2014 – 6/1/2022, $60,315.00 annually. Total US Budget $150,000,000

Co-Investigator, 5% effort, Novel tools for in vivo study of genetic interactions in cancer progression. 1R01CA231112-01(Chen, PI), NIH, 09/01/18-08/31/23, $344,255


Page 7 of 103

Associate Director (AD), Translational Sciences; Co-Program Director (PD), Developmental Therapeutics, 10% effort (5% for AD and 5% for Co-PD), Yale Cancer Center Support Grant P30 CA 016359, NIH/NCI, Lynch (PI), 08/09/13-07/31/23

Co-investigator, 2% effort, Personalized Task-Based Respiratory Motion Correction for Low-Dose PET/CT, R01CA224140, NIH, 07/02/2018- 06/30/2023, $415,378

Site PI, Integrating Radiomics into S0819 and Lung-MAP, Biomarker Driven Clinical Trials for Lung Cancer, 1U01CA225431-01 (Schwartz), NIH, 6/1/18 – 5/31/23, $17,197

Co-investigaor, 4% effort, Rapidly scalable platforms for direct in vivo screening of functional drivers in lethal cancers. To develop and validate rapidly scalable platforms for direct in vivo screening of functional drivers in lethal cancers. 1R33CA225498-01A1 (Chen, PI), NIH, 04/01/19-03/31/22, $243,000

Co-PI, 5% effort, Viktriy Early Clinical Trials Consortium (ECTC), 5UM1CA186689-03, NIH/NCI, 7/10/2014 – 2/29/2020, Direct Costs: $2,032,243

Vice Chair, Lung Cmte, 20% effort, SWOG Network Group Operations Center of the NCTN, 2U10CA180888-06, NIH/NCI, 04/26/2019-02/28/2025. $4,948

Completed PI, 10%, A preclinical and clinical study of antiangiogenesis agents in combination with cytotoxic chemotherapy, ASCO-Young Investigator Award, 7/1/1997−6/30/1999, $65,000 ($32,500/year)

PI, 10%, Multiparametric in situ mRNA hybridization analysis using markers of metastasis and angiogenesis to predict disease recurrence in patients with lung carcinoma, UT-MDACC Physicians Referral Service Research Award, 1/1/1998−12/31/1998, $35,529

PI, 10%, Prognostic markers of metastasis and angiogenesis in lung cancer, 2P50 CA70907-4, The University of Texas Lung Cancer SPORE Development Award, 9/1/1998−8/31/2000, $67,290 ($33,645/year)

PI, 5%, Preclinical and clinical studies with human endostatin, Golfers Against Cancer-Charitable Trust, 1/1/2000−12/31/2000, $100,000

PI, 10%, The biology and treatment of lung cancer metastasis, UT-MDACC Physician Scientist Program Award, 1/1/1999−1/1/2002, $360,000 ($120,000/year)

PI, 10%, The biology and treatment of lung cancer metastasis, ASCO-Career Development Award, 7/1/1999−6/30/2002, $170,000 ($55,000/year)

Co-PI, 5%, Restoration of apoptosis in cancer, CA78778-01A1, NIH/NCI, PI - Jack A. Roth, M.D., 7/1/1999−6/3/2004, $3,465,330 ($693,065/year)

PI, 5%, Evaluate the antiangiogenic, antivascular, and anti-tumor activities of ZD1839 and ZD7474 in primary and metastatic human lung cancer, Golfers Against Cancer-Charitable Trust, 6/1/2002−5/31/2005, $75,000

Co-PI of Project 10, 10%, T.A.R.G.E.T. (Translational Approaches for the Reversal, Genetic Evaluation, and Treatment of) Lung Cancer (Project 10 - Development of novel murine models of lung cancer and in vivo evaluation of antiangiogenic agents), DAMD 17-02-1-0706, Department of Defense (DOD), PI - Waun Ki Hong, MD, 9/1/2002−8/31/2006, $74,724

Core D Co-Director, 10%, Targeted assessment of antiangiogenic therapy (Core D - Clinical trials), 5 U54 CA 90810 2 (PC-D), NIH/NCI, PI - James L. Abbruzzese, MD, 7/16/2001−12/31/2006, $590,700 ($82,063/year)


Page 8 of 103

Co-PI of Project 4, 10%, Targeted assessment of antiangiogenic therapy (Project 4 - A phase I trial of the antiangiogenic agent SU6668 in patients with solid tumors), 5 U54 CA90810 2 (PP-DP4, NIH/NCI, PI - James L. Abbruzzese, M.D., 7/16/2001−12/31/2006, $775,170 ($128,600/year)

Project 2 PI, 10%, SPORE in Head and Neck Cancer (Project 2 - Targeted angiogenesis for therapy of head and neck cancer), P50 CA79007-01 (PP-2), NIH/NCI, PI - Waun Ki Hong, MD, 7/1/2002−6/30/2007, $1,002,500 ($200,664/year)

Co-Investigator, 5%, Phase I studies of targeted anti-cancer therapies, CA062461, PI - Razelle Kurzrock, MD, 2/1/2003−1/31/2008, $2,406,368 ($444,281/year)

PI, Vascular target therapy of primary and metastatic lung cancer, UT-MDACC Multidisciplinary Research Program, 1/1/2004−1/1/2008, $25,000

PI, 10%, TGF-alpha and phosporylated EGFR protein levels impact the survival of patients with stage I-IIIA non-small cell lung cancer, Golfers Against Cancer-Charitable Trust, 5/1/2006−4/30/2008, $30,000

PI, 5%, Vascular Targeted Therapy for Lung Cancer, Lung Cancer Research Foundation, 7/1/2007−6/30/2008, $50,000

PI, 5%, Proposal to evaluate the antiangiogenic, anti-vascular, and anti-tumor activities of ZD1839, ZD6474, AZD2171 and ZD6126 in primary and metastatic human lung cancer, LS2004-0001066LE, AstraZeneca, 2/13/2004−12/31/2010, $620,456 ($410,030/year)

Co-PI of Project 2, Co-Director of Administration Core, Co-Leader of Cancer Development Program, 10%, IMPACT (Imaging and Molecular Markers for Patients with Lung Cancer: Approaches with Molecular Targets and Complementary, Innovative and Therapeutic Modalities) (Project 2 - Molecular imaging of EGFR expression and activity in targeted therapy of lung cancer), W81XWH-05-2-0027, DOD, PI - Waun Ki Hong, MD, 2/1/2005−3/1/2011

Co-PI, 20%, BATTLE (Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination), W81XWH-06-1-0303, DOD, PI - Waun Ki Hong, MD, 4/1/2006−4/30/2011

Co-Leader, Project 2, 5%, PROSPECT (Profiling of Resistance Patterns & Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification), W81XWH-07-1-0306, DOD, PI - Waun Ki Hong, MD, 6/1/2007−5/31/2011 ($1,347,411/year)

Co-Investigator, 2%, AARA: CYCORE: Cyberinfrastructure for Comparative Effectiveness Research, 1 RC2 CA148263-01, NIH/NCI, PI - Susan Peterson, 9/30/2009−8/31/2011 ($1,931,695/year)

Dream Team Principal, 20%, Dream Team Award, SU2C-AACR-DT0309, Stand Up 2 Cancer (SU2C), PI - Daniel Haber, 12/1/2009−11/30/2012, $1,452,889 ($183,831/year)

Co-Investigator, 5%, Phase I Studies of Targeted Anti-Cancer Therapies (PC-A), 5 U01 CA062461 17, NIH/NCI, PI - Razelle Kurzrock, 3/1/1994−2/28/2013, $602,240 ($433,266/year)

Leader, Lung Cancer Program, 10%, Cancer Center Support (CORE) Grant, 5 P30 CA016672, NIH/NCI, PI - John Mendelsohn, MD, 7/1/2008−6/30/2013, $19,825 ($17,354/year)

Investigator, 5%, Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC), 1 U24 CA143883-01, NIH/NCI, PI - Weinstein, John N, 9/29/2009−7/31/2014 ($111,655/year)

PI, 5%, U10 Full Membership Application Affiliated with SWOG, 2 U10 CA105409-07, NIH/NCI, 3/5/2010−12/31/2015 ($206,130/year)

Protocol Principal Investigator (PI), Biomarker, Imaging and Quality of Life Funding Program (BIQSFP) associated with Protocol SWOG0819, NIH/NCI, Baker (PI)1/1/2011−12/31/2015, $1,973,506


Page 9 of 103

Co-PI, Biomarker, Imaging and Quality of Life Funding Program (BIQSFP) associated with Protocol), SWOG 0819, NIH/NCI, 01/01/11-12/31/15

Co-Investigator, 3%, Novel Treatment to Enhance Smoking Cessation before Cancer Surgery, 1R21CA181569-01, NIH/NCI, Toll (PI), 9/23/2014—8/31/2016, $181,069

PI, 10%, Personalizing NSCLC Therapy: Exploiting KRAS Activated Pathways, 1R01CA155196, NIH/NCI, 9/15/2011−7/31/2017, $2,450,000

Co-investigator, 2% effort, Chi3l1 Regulation of Checkpoint Regulating, Costimulatory and Coinhibitory Molecules in Primary and Metastatic Lung Cancer, W81XWH-17-1-0196, DOD, 06/15/2017-06/14/2019, $50,000

Co-investigator, 6% effort, Discovering Checkpoint Blockade Resistance Genes in Metastatic Lung Cancer, W81XWH-17-1-0235, DOD, 06/01/2017- 05/31/2019, $175,000.

Protocols Funded, as Principal Investigator A phase I study of safety, pharmacokinetics, and tolerability using TNP-470 in combination with paclitaxel in adult patients with solid tumors, 1998−2001, $489,354, TAP Holdings, Inc.

A phase II trial of gemcitabine and vinorelbine chemotherapy in patients with either untreated or once treated advanced stage non-small cell lung cancer, 1998−2002, $175,000, Eli Lilly and Company

An open, label, multicenter extension study of recombinant humanized monoclonal anti-VEGF antibody (rhuMAB VEGF) in subjects responsive to treatment with rhuMAB VEGF in a previous Genentech-sponsored cancer study, 1998−2003, $88,500, Genentech

Phase II study of SPI-77 in patients with advanced non-small cell lung cancer, 1998−2003, $210,000, Sequus Pharmaceuticals

A phase II study of SCH 54031 (PEG Interferon Alfa-2B/PEG Intron) in recurrent squamous cell tumors of the head and neck: Clinical efficacy and biomarker analysis, 1999−2003, $296,000, Integrated Therapeutics Group, Inc.

A phase IIA trial of continuous five-day infusion of MSI-1256F (squamous lactate) plus carboplatin and paclitaxel in IIIB (pleural effusion and IV non-small cell lung cancer, DM99-097, 1999−2003, $150,000, Magainin Pharmaceuticals

A phase I study of a continuous infusion of TNP-470 alone or with a combination of paclitaxel and carboplatin in adult patients with solid tumors, 1999−2004, $301,938, TAP Pharmaceuticals, Inc.

Phase II multidose, single arm, single institution clinical trial of cisplatin and gemcitabine in combination with recombinant humanized anti-p185 monoclonal antibody (herceptin) in patients unselected for HER2/new expression level who have untreated locally or metastatic (stage IIIB or IV) non-small cell lung cancer, 1999−2004, $187,476, Genentech

Phase II multidose, single-arm, single institutional clinical trial of cisplatin and gemcitabine in combination with recombinant humanized anti-p185 HER2 monoclonal antibody (herceptin) in patients who have untreated locally or metastatic (stage IIIb or IV) non-small cell lung cancer, 1999−2004, $193,000, Eli Lilly and Company

Phase II study of anti-epidermal growth factor antibody C225 in combination with chemotherapy in patients with recurrent or metastatic squamous cell head and neck carcinoma, 1999−2004, $185,819, Imclone Systems Inc.

A phase I/IIA exploratory multiple-dose level pharmacokinetic and pharmacodynamic trial of ZD1839 in subjects with four selected tumor types known to overexpress epidermal growth factor receptor, 1999, $300,000, AstraZeneca


Page 10 of 103

Randomized, double-blind, parallel group, phase II/III multi-center trial of two doses of ZD1839 in patients with advanced non-small cell lung cancer who have failed at least two previous chemotherapy regimens; at least one or both contains platinum and a taxane, 2000−2002, $461,848, AstraZeneca

Continued/extended access to TNP-470 for cancer, 2000−2003, $102,135, TAP Pharmaceuticals, Inc.

A randomized, double-blind phase III comparative trial of two doses of ZD1839 (IRESSA) in combination with paclitaxel and carboplatin versus placebo with paclitaxel and carboplatin in chemo-naïve patients with advanced non-small cell lung cancer, 2000−2004, $2,259,209, AstraZeneca

Phase I, single-center, open label, dose escalating, safety and pharmacokinetic study of recombinant human endostatin administered by continuous intravenous infusion to cancer patients, 2001−2003, $530,000, EntreMed

Phase II study of anti-epidermal growth factor receptor antibody cetuximab (C225) in patients with recurrent or metastatic squamous cell head and neck carcinoma following cisplatin/paclitaxel therapy, 2001−2003, $279,000, Imclone Systems Inc.

A phase I dose escalation and pharmacokinetic evaluation of oral LY317615 (an angiogenesis inhibitor) in patients with advanced cancer, 2001−2004, $184,875, Eli Lilly and Company

A phase III, randomized, double-blind, multicenter trial of OSI-774 (Erlotinib) plus chemotherapy (Carboplatin and Paclitaxel) versus chemotherapy alone in patients with advanced (stage IIIB or IV) non-small cell lung cancer who have not received prior chemotherapy, 2001−2004, $684,718, Genentech

Phase II study of anti-epidermal growth factor receptor antibody cetuximab in combination with docetaxel in patients with recurrent or progressive non-small cell lung cancer, 2001−2005, $424,304, Imclone Systems Inc.

Multicenter, open-label extension trial of treatment with ZD1839 (IRESSA) in patients who have been treated in other ZD1839 clinical trials and may benefit from continued monotherapy ZD1839, 2002−2004, $19,000, AstraZeneca

A phase I/II, multidose multicenter clinical trial to evaluate the safety and efficacy of the combination of recombinant humanized monoclonal anti-VEGF antibody rhuMAB VEGF (Avastin) and the EGFR tyrosine kinase inhibitor OSI-774 (Tarceva) for locally advanced or metastatic non-squamous cell non-small cell lung cancer in patients who have been previously treated, 2002−2005, $260,928, Genentech

A randomized, double-blind, multicenter, phase II study to assess the safety, tolerability, and efficacy of ZD6474 in combination with docetaxel (Taxotere™) in subjects with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy, 2002−2005, $731,226, AstraZeneca

Phase I, open-label, multicenter, dose-escalation study of the tyrosine kinase inhibitor of VEGFR-2, AG013736 in patients with advanced solid tumors, 2002−2005, $705,900, Agouron

Randomized study of docetaxel versus docetaxel plus Genasense™ (Bcl-2 antisense oligonucleotide) in patients with previously treated non-small cell lung cancer, 2002−2005, $304,000, Genta

A phase I, first in human, open-label, dose finding study evaluating the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors, 2003−2005, $316,855, Amgen

A phase II, open-label, multicenter study to evaluate the effect of tumor-based Her2 activation on the efficacy of rhuMAB 2C4 (Pertuzumab) in subjects with advanced (stage IIIB or IV) non-small cell lung cancer, 2003−2005, $332,193, Genentech


Page 11 of 103

An expanded access clinical program with ZD1839 (IRESSA) for patients with advanced NSCLC, 2003−2005, $141,000, AstraZeneca

Continuing access to the tyrosine kinase inhibitor of VEGFR-2, AG013736 (A406) for patients previously receiving AG013736 in clinical trials, 2003−2005, $30,000, Agouron

Multicenter phase II trial of OSI-774 (Erlotinib, Tarceva) in patients with advanced bronchioloalveolar cell lung cancer, 2003−2005, $40,001, Genentech

A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of avastin (Bevacizumab) in combination with docetaxel or tarceva (Erlotinib Hydrochloride) compared with docetaxel alone for treatment of recurrent or refractory non-small cell lung cancer, 2004−2006, $253,368, Genentech

Phase II study of the antiangiogenesis agent AG-013736 as second-line treatment in patients with advanced non-small cell lung cancer, 2004−2006, $314,430, Pfizer

Phase II selection design trial of concurrent chemotherapy + cetuximab vs. chemotherapy followed by cetuximab in advanced non-small cell lung cancer, 2004−present, SWOG

A phase I, open-label, dose-escalation study of the safety and pharmacokinetics of PRO1762 administered intravenously to subjects with advanced or metastatic solid malignancies, or non-Hodgkin's lymphoma, 2005, $710,038, Genentech

A Phase I Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of AMG386 in Adult Patients with Advanced Solid Tumors, 2005−2006, $766,040, Amgen, Inc.

An open-label, non-randomized, multicenter, three stage, phase 2 study of S-1 in as 2nd line therapy for patients with advanced non-small cell lung cancer (stage IIIB/stage IV), 2005−2006, $200,320, Taiho

An open-label, non-randomized, multicenter, three stage, phase 2 study of S-1 in combination with cisplatin as 1st line therapy for patients with advanced non-small cell lung cancer (stage IIIB/stage IV), 2005−2006, $200,320, Taiho

A Phase I, Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG655 in Subjects with Advanced Solid Tumors, 2005−2010, $592,900, Amgen, Inc.

A multicenter, open-label, single-arm, two-stage study of AVE007 (VEGF Trap) administered every 2 weeks in patients with platinum and erlotinib-resistant, locally advanced or metastatic NSCLC, 2005−present, $93,454, Sanofi-Aventis

A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinets of Apomab Administered Intravenoulsy to Subjects with Advanced or Metastatic Solid Malignancies, or Non-Hodgkins Lymphoma, 2005-0731, 2006−2007, $776,512, Genentech, Inc.

A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial To Evaluate The Efficacy Of Bevacizumab In Combination With Tarceva (Erlotinib) Compared With Tarceva Alone For Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC)After Failure Of Standard First-Line Chemotherapy, 2005-0517, 2006−2007, $122,630, Genentech, Inc.

Study Chair, Treatment of Malignant Pleural Effusion with ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth factor Receptor (EGFR) Tyrosine Kinase Inhibitor, 2005-0929, 2006−2009, $150,001 ($50,000/year), MDACC/DOD/AstraZeneca

A Phase I Dose-Finding Study of the Anti-Angiogenesis Agent, AG-013736, in Combinations of Paclitaxel/Carboplatin and Docetaxel/Carboplatin in Patients with Advanced Solid Tumors, 2005-0999, 2006−2011, $453,750, Pfizer, Inc.


Page 12 of 103

A phase III, randomized, double-blinded, multi-center study to assess the efficacy of docetaxel (TAXOTERE) in combination with ZD6474 (ZACTIMA) versus docetaxel (TAXOTERE) in combination with placebo in patients with locally advanced or metastatic (stage IIIb-IV) non-small cell lung cancer after failure of 1st line anti-cancer therapy, 2006−2011, $115,653, AstraZeneca

Phase I Dose Escalation Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors, 2006-0467, 2006−2011, $298,173, Bristol Myers Squibb

A Phase I, Open-label, Dose-Escalation Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD4877 Administered Weekly or Every Two Weeks in Patients with Advanced Solid Malignancies, 2006-0578, 2006−2012, $312,345, AstraZeneca Pharmaceuticals, LP

A Randomized, Double-Blind, Phase II Trial of Paclitaxel + Carboplatin + Bevacizumab with or without APOMAB in patients with previously untreated, advanced-stage non-small cell lung cancer, 2007-0551, 2007−2009, $490,938, Genentech, Inc.

A Phase 1 Trial of Oral PX-478 (a HIF-1 Inhibitor) in Patients with Advanced Solid Tumors or Lymphoma (CT), 2007-0363, 2007−2010, $649,404, ProlX

A Phase I Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of GRN163L in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (CT), 2007-0621, 2008−2013, $122,740, Geron

A Phase I Trial of Oral PX-866 (a PI-3K Inhibitor) in Patients with Advanced Solid Tumors, 2007-0935, 2008−present, $500,000 ($179,939/year), Oncothyreon

A Feasibility Study Investigating Translational Science in Chemo-Naive Patients with State IIIb or NSCLC Treated with Erlotinib, 2007-0928, 2009−present, Genentech, Inc.

Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), funding based on $2000 per patient enrolled, SWOG-S019, 2009−present, SWOG

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC); SWOG-S0819,

A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer, MD Anderson Cancer Center, Battle 2 $2,118,725.

A Phase I/IIa, First time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency, Glaxo Smith Kline; $498,633.

A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies, Genetech; $2,611,584

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT). Merck. Steering Committee Chair

A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PLD1 Antibody) Compared With A Platinum Agent (Cisplatin or Carboplatin)& in Combination with Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naïve Patients with Stage IV Non Squamous or Squamous Non-Small Cell Lung Cancer. F. Hoffman-La Roche Ltd

An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus Pembrolizumab in Patients with Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction


Page 13 of 103

Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium (WIRB). Eli Lilly and Company

S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer (CIRB). Southwest Oncology Group (SWOG). Steering Committee Chair

Patents and Technology Licenses Patents Powis G, Powis G, Herbst R, Jacoby J. Composition and Methods for Treating Lung Cancer, United States, PCT/US09/034060, 9/14/2010, Filed

Board of Regents, UT System, Herbst RS, Kim ES, Hong WK. Biomarker-based approaches of Targeted Therapy for Lung Cancer Elimination, United States, 61/325,132, 4/16/2010−4/16/2011, Pending

Technology Licenses N/A

Grant Reviewer/Service on Study Sections Cancer Therapy Evaluation Program (CTEP), NCI, Reviewer, Lung Cancer Concept Evaluation Panel, 2002−2003

CTEP Drug Development Group, NCI, Ad Hoc Reviewer, 2003−2004

Lung Cancer Research Program, Commonwealth of Kentucky, Grant Reviewer, 2003

Topical 'Biofilm' Treatment of Oral Leukoplakia, NIH, 1 R01 CA104543-01, 2003

Combination EGFR and COX-2 Inhibition in Advanced NSCLC, NIH, Grant Reviewer, 2005

Immuno/Immunogene Therapies for Thoracic Malignancies P01, NIH, Grant Reviewer Chair, 2005

Therapeutic Index of Acute Lymphoblastic Leukemia, NIH, Grant Reviewer, 2005

CTEP Drug Development Group, NIH, Ad Hoc Reviewer, 2006−2007

Clinical Oncology Study Section A, NCI, Ad Hoc Member, 2008−2011

Israel Cancer Research Fund, Grant Reviewer, 2013

NCI Special Emphasis Panel, SPORE reviews, 2015, 2016 (discussion leader)

PUBLICATIONS Peer-Reviewed Original Research Articles

1. van den Pol AN, Herbst RS, Powell JF. Tyrosine hydroxylase-immunoreactive neurons of the hypothalamus: a light and electron microscopic study. Neuroscience 13(4):1117-56, 12/1984.

2. Babiss LE, Herbst RS, Bennett AL, Darnell JE, Jr. Factors that interact with the rat albumin promoter are present both in hepatocytes and other cell types. Genes Dev 1(3):256-67, 5/1987.

3. Herbst RS, Hermo H, Jr, Fisher PB, Babiss LE. Regulation of adenovirus and cellular gene expression and of cellular transformation by the E1B-encoded 175-amino-acid protein. J Virol 62(12):4634-43, 12/1988.

4. Herbst RS, Friedman N, Darnell JE, Jr, Babiss LE. Positive and negative regulatory elements in the mouse albumin enhancer. Proc Nat’l Acad Sci U S A 86(5):1553-7, 3/1989.

5. Herbst RS, Boczko EM, Darnell JE, Jr, Babiss LE. The mouse albumin enhancer contains a negative regulatory element that interacts with a novel DNA-binding protein. Mol Cell Biol 10(8):3896-905, 8/1990.

6. Herbst RS, Pelletier M, Babiss LE. Cis effect of the type 5 adenovirus E1A gene enhancer element on cellular transformation. J Cell Biochem 42(1):33-44, 1990.


Page 14 of 103

7. Herbst RS, Pelletier M, Boczko EM, Babiss LE. The state of cellular differentiation determines the activity of the adenovirus E1A enhancer element: evidence for negative regulation of enhancer function. J Virol 64(1):161-72, 1990.

8. Herbst RS, Nielsch U, Sladek F, Lai E, Babiss LE, Darnell JE, Jr. Differential regulation of hepatocyte-enriched transcription factors explains changes in albumin and transthyretin gene expression among hepatoma cells. New Biol 3(3):289-96, 3/1991.

9. Wong JS, Ara G, Keyes SR, Herbst R, Coleman CN, Teicher BA. Lisofylline as a modifier of radiation therapy. Oncol Res 8(12):513-8, 1996.

10. Teicher BA, Maehara Y, Kakeji Y, Ara G, Keyes SR, Wong J, Herbst R. Reversal of in vivo drug resistance by the transforming growth factor-beta inhibitor decorin. Int J Cancer 71(1):49-58, 3/1997.

11. Herbst RS, Dang NH, Skarin AT. Chemotherapy for advanced non-small cell lung cancer. Hematol Oncol Clin North Am 11(3):473-517, 6/1997.

12. Teicher BA, Ara G, Herbst R, Takeuchi H, Keyes S, Northey D. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy. In Vivo 11(4):301-11, 7/1997.

13. Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis. Semin Oncol 24(4 Suppl 12):S12-73-S12-80, 8/1997.

14. Teicher BA, Kakeji Y, Ara G, Herbst RS, Northey D. Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo 11(6):453-61, 11/1997.

15. Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo 11(6):463-72, 11/1997.

16. Wen PY, Alyea EP, Simon D, Herbst RS, Soiffer RJ, Antin JH. Guillain-Barre syndrome following allogeneic bone marrow transplantation. Neurology 49(6):1711-4, 12/1997.

17. Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E, 3rd. Acute in vivo resistance in high-dose therapy. Clin Cancer Res 4(2):483-91, 2/1998.

18. Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res 18(4A):2567-73, 7/1998.

19. Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chemother Pharmacol 41(6):497-504, 1998.

20. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5(9):2638-45, 9/1999.

21. Herbst RS, Lilenbaum R. Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer. Semin Oncol 26(5 Suppl 16):67-70; discussion 71-2, 10/1999.

22. Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 6(3):790-7, 3/2000.

23. Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 6(3):957-65, 3/2000.


Page 15 of 103

24. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 60(17):4959-67, 9/2000.

25. Lilenbaum RC, Herbst RS. Vinorelbine and gemcitabine combinations in advanced non small-cell lung cancer. Clin Lung Cancer 2(2):123-7, 11/2000.

26. Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 157(6):1893-903, 12/2000.

27. Herbst R, Hess K, Mulliani N, Charnsangavej C, Baker C, Ellis L, Kim EE, Bucana C, Pluda J, Fidler I, Abbruzzese J. A phase I clinical trial of recombinant human endostatin in patients with solid tumors: Surrogate analyses to determine a biologically effective dose. Clin Cancer Res 6:478, 2000.

28. Herbst RS, Khuri FR, Jung M, Fossella FV, Lee JS, Glisson B, Shin DM, Pisters K, Papadimitrakopoulou V, Kurie J, Perez-Soler R, Liu D, Lu C, Zinner R, Guerra M, Munden R, Hong WK. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Lung Cancer 29(1):12, 2000.

29. Lee JS, Pisters KM, Komaki R, Terry K, Glisson BS, Perez-Soler R, Fossella FV, Shin DM, Herbst RS, Khuri FR, Kurie JM, Hong WK. Systemic chemotherapy as a primary treatment of brain metastasis in patients with non-small cell lung cancer. Lung Cancer 29(1):4, 2000.

30. Herbst RS, Lee AT, Tran HT, Abbruzzese JL. Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep 3(2):131-40, 3/2001.

31. Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Ann Oncol 12(6):739-44, 6/2001.

32. Skarin AT, Herbst RS, Leong TL, Bailey A, Sugarbaker D. Lung cancer in patients under age 40. Lung Cancer 32(3):255-64, 6/2001.

33. Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 1(4):719-32, 7/2001.

34. Herbst RS, Lynch C, Vasconcelles M, Teicher BA, Strauss G, Elias A, Anderson I, Zacarola P, Dang NH, Leong T, Salgia R, Skarin AT. Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol 48(2):151-9, 8/2001.

35. Herbst RS, Khuri FR, Fossella FV, Glisson BS, Kies MS, Pisters KM, Riddle JR, Terry KA, Lee JS. ZD1839 (I) in non-small-cell lung cancer. Clin Lung Cancer 3(1):27-32, 8/2001.

36. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13(6):506-13, 11/2001.

37. Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92(9):2364-73, 11/2001.

38. Kim ES, Lu C, Khuri FR, Tonda M, Glisson BS, Liu D, Jung M, Hong WK, Herbst RS. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer 34(3):427-32, 12/2001.

39. Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Angiogenesis inhibitors in clinical development for lung cancer. Semin Oncol 29(1 Suppl 4):66-77, 2/2002.


Page 16 of 103

40. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 29(1 Suppl 4):27-36, 2/2002.

41. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94(5):1593-611, 3/2002.

42. Herbst RS. Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. Clin Lung Cancer 3(Suppl 1):S30-8, 3/2002.

43. Yang DJ, Kim KD, Schechter NR, Yu DF, Wu P, Azhdarinia A, Roach JS, Kalimi SK, Ozaki K, Fogler WE, Bryant JL, Herbst R, Abbruzzes J, Kim EE, Podoloff DA. Assessment of antiangiogenic effect using 99mTc-EC-endostatin. Cancer Biother Radiopharm 17(2):233-45, 4/2002.

44. Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol 14(3):334-42, 5/2002.

45. Waxman ES, Herbst RS. The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. Semin Oncol Nurs 18(2 Suppl 2):20-9, 5/2002.

46. Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, Bucana CD, Pathak S, Kruzel E, Herbst RS, Onn A, Roach JS, Onda M, Wang QC, Pastan I, Fidler IJ. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther 1(8):595-600, 6/2002.

47. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs 11(6):837-49, 6/2002.

48. Kim ES, Herbst RS. Angiogenesis inhibitors in lung cancer. Curr Oncol Rep 4(4):325-33, 7/2002.

49. Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 37(1):17-27, 7/2002.

50. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 95(2):340-53, 7/2002.

51. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20(18):3804-14, 9/2002.

52. Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20(18):3792-803, 9/2002.

53. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20(18):3815-25, 9/2002.

54. Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Daniel Ayers G, Herbst RS, Abbruzzese JL. Study of the media's potential influence on prospective research participants' understanding of and motivations for participation in a high-profile phase I trial. J Clin Oncol 20(18):3785-91, 9/2002.


Page 17 of 103

55. Herbst RS. Targeted therapy in non-small-cell lung cancer. Oncology (Williston Park) 16(9 Suppl 9):19-24, 9/2002.

56. Kaban K, Herbst RS. Angiogenesis as a target for cancer therapy. Hematol Oncol Clin North Am 16(5):1125-71, 10/2002.

57. Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol 29(5 Suppl 14):18-30, 10/2002.

58. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20(22):4440-7, 11/2002.

59. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20(1):110-24, 2002.

60. Komaki R, Lee JS, Kaplan B, Allen P, Kelly JF, Liao Z, Stevens CW, Fossella FV, Zinner R, Papadimitrakopoulou V, Khuri F, Glisson B, Pisters K, Kurie J, Herbst R, Milas L, Ro J, Thames HD, Hong WK, Cox JD. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol 12(1 Suppl 1):46-9, 2002.

61. Herbst RS, Kies MS. ZD1839 (Iressa) in non-small cell lung cancer. Oncologist 7(Suppl 4):9-15, 2002.

62. Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol 30(1 Suppl 1):30-8, 2/2003.

63. Davis DW, McConkey DJ, Zhang W, Herbst RS. Antiangiogenic tumor therapy. Biotechniques 34(5):1048-50, 1052, 1054 passim, 5/2003.

64. Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 4(6):366-9, 5/2003.

65. Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Janne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. Clin Cancer Res 9(5):1698-704, 5/2003.

66. Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 30(3 Suppl 7):34-46, 6/2003.

67. LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res 9(6):2040-8, 6/2003.

68. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, Munden RF. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21(13):2574-82, 7/2003.

69. Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 89(1):8-14, 7/2003.

70. Herbst RS, Kies MS. Gefitinib: current and future status in cancer therapy. Clin Adv Hematol Oncol 1(8):466-72, 8/2003.


Page 18 of 103

71. Herbst RS, O'Reilly MS. The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. Semin Oncol 30(4 Suppl 9):113-23, 8/2003.

72. Herbst RS, Hammond LA, Carbone DP, Tran HT, Holroyd KJ, Desai A, Williams JI, Bekele BN, Hait H, Allgood V, Solomon S, Schiller JH. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 9(11):4108-15, 9/2003.

73. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290(16):2149-58, 10/2003.

74. Herbst RS, Khuri FR. Mode of action of docetaxel - a basis for combination with novel anticancer agents. Cancer Treat Rev 29(5):407-15, 10/2003.

75. Onn A, Isobe T, Itasaka S, Wu W, O'Reilly MS, Ki Hong W, Fidler IJ, Herbst RS. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 9(15):5532-9, 11/2003.

76. Herbst RS, Bunn PA, Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 9(16 Pt 1):5813-24, 12/2003.

77. Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F, Herbst RS. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39(1):55-61, 2003.

78. Onn A, Herbst RS. Angiogenesis, metastasis, and lung cancer. An overview. Methods Mol Med 74:329-48, 2003.

79. Yano S, Herbst RS, Sone S. In vitro and in vivo assays for the proliferative and vascular permeabilization activities of vascular endothelial growth factor (VEGF) and its receptor. Methods Mol Med 74:391-8, 2003.

80. Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB, Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9(1):93-101, 2003.

81. Blumenschein GR, Jr, Herbst RS. Integration of targeted therapies in gemcitabine chemotherapy regimens. Clin Lung Cancer 4(4):217-23, 2003.

82. Herbst RS, Onn A, Mendelsohn J. The role of growth factor signaling in malignancy. Cancer Treat Res 115:19-72, 2003.

83. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, Von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 22(5):777-84, 3/2004.

84. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 22(5):785-94, 3/2004.


Page 19 of 103

85. McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. J Immunother 27(2):161-75, Mar-Apr, 3/2004.

86. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Jr, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369-77, 4/2004.

87. Zinner RG, Herbst RS. Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data. Clin Lung Cancer 5(Suppl 2):S67-74, 4/2004.

88. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Jr, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 44(1):99-110, 4/2004.

89. Herbst RS. Imaging in drug development. Clin Adv Hematol Oncol 2(5):268-9, 5/2004.

90. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 10(9):2968-76, 5/2004.

91. Sandler AB, Johnson DH, Herbst RS. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10(12 Pt 2):4258s-4262s, 6/2004.

92. Lynch TJ, Adjei AA, Bunn PA, Jr, DuBois RN, Gandara DR, Giaccone G, Govindan R, Herbst RS, Johnson BE, Khuri FR, Perez-Soler R, Rosell R, Rowinsky EK, Sandler AB, Scagliotti GV, Schiller JH, Shapiro GI, Socinski MA, Hart CS. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res 10(12 Pt 2):4199s-4204s, 6/2004.

93. Herbst RS, Frankel SR. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 10(12 Pt 2):4245s-4248s, 6/2004.

94. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22(11):2184-91, 6/2004.

95. Zinner RG, Fossella FV, Herbst RS. Pemetrexed in advanced NSCLC: a review of the clinical data. Oncology (Williston Park) 18(8 Suppl 5):54-62, 7/2004.

96. Tran HT, Blumenschein GR, Jr, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54(4):308-14, 10/2004.

97. Gridelli C, Massarelli E, Maione P, Rossi A, Herbst RS, Onn A, Ciardiello F. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. Cancer 101(8):1733-44, 10/2004.


Page 20 of 103

98. Xiong HQ, Herbst R, Faria SC, Scholz C, Davis D, Jackson EF, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej CA, Abbruzzese JL. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22(4):459-66, 11/2004.

99. Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'Reilly M S, Fidler IJ, Herbst RS. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Clin Cancer Res 10(24):8613-9, 12/2004.

100. Herbst RS, Fukuoka M, Baselga J. Gefitinib--a novel targeted approach to treating cancer. Nat Rev Cancer 4(12):956-65, 12/2004.

101. Herbst RS, Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 6(Suppl 1):S7-19, 12/2004.

102. Herbst RS, Kurzrock R, Parson M, Benjamin R, Chen L, Ng C, Ingram M, Wong S, Chang D, Rosen L. AMG 706 first inhuman, open-label, dose-finding study evaluating the safety and pharmacokinetics in subjects with advanced solid tumors. Eur J Cancer 2(8):48, 2004.

103. Wu W, Shintani T, O'Reilly MS, Herbst RS. Blocking VEGF and EGF receptor signaling with ZD6474 sensitizes human non-small cell lung cancer to chemotherapy with paclitaxel. Eur J Cancer 2(8):50, 2004.

104. Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 9(Suppl 1):19-26, 2004.

105. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10(1 Pt 1):33-42, 2004.

106. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59(2 Suppl):21-6, 2004.

107. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10(1 Pt 1):136-43, 2004.

108. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 11(2 Pt 1):678-89, 1/2005.

109. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 23(6):1136-43, 2/2005.

110. Herbst RS. Erlotinib. Clin Adv Hematol Oncol 3(2):125, 141, 2/2005.

111. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Jr, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(11):2544-55, 4/2005.

112. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23(14):3243-56, 5/2005.

113. Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23(13):2946-54, 5/2005.


Page 21 of 103

114. Gaspar LE, Gay EG, Crawford J, Putnam JB, Herbst RS, Bonner JA. Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer 6(6):355-60, 5/2005.

115. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 32(3):315-28, 6/2005.

116. Onn A, Herbst RS. What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer? Nat Clin Pract Oncol 2(6):290-1, 6/2005.

117. Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Jr, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 23(24):5464-73, 8/2005.

118. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23(24):5474-83, 8/2005.

119. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 23(24):5578-87, 8/2005.

120. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, Ince WL, Janne PA, Januario T, Johnson DH, Klein P, Miller VA, Ostland MA, Ramies DA, Sebisanovic D, Stinson JA, Zhang YR, Seshagiri S, Hillan KJ. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23(25):5900-9, 9/2005.

121. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, Ramies D, Johnson DH, Miller VA. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23(25):5892-9, 9/2005.

122. Onn A, Choe DH, Herbst RS, Correa AM, Munden RF, Truong MT, Vaporciyan AA, Isobe T, Gilcrease MZ, Marom EM. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 237(1):342-7, 10/2005.

123. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23(31):8081-92, 11/2005.

124. Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res 65(24):11478-85, 12/2005.

125. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23(36):9089-96, 12/2005.


Page 22 of 103

126. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56, 12/2005.

127. Gandara DR, Vallières E, Gaspar LE, Kelly K, Albain KS, Herbst RS, Lara PN, Mack P, Gumerlock PH, Crowley JJ. Therapeutic strategies for combined-modality therapy of locally advanced-stage non-small-cell lung cancer: rationale for consolidation docetaxel therapy. Clin Lung Cancer 7(Suppl 3):S93-7, 12/2005.

128. Herbst RS. Current therapeutic strategies in non-small-cell lung cancer: evolving role of docetaxel. Clin Lung Cancer 3:S76, 2005.

129. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Jr., Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. Cancer 104(11):2449-56, 2005.

130. Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ. Clinical cancer advances 2005: Major research advances in cancer treatment, prevention, and screening--A report from the American Society of Clinical Oncology. J Clin Oncol 24(1):190-205, 1/2006.

131. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Jr, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-31, 3/2006.

132. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):4441s-4445s, 7/2006.

133. Govindan R, Natale R, Wade J, Herbst RS, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer 53(3):331-7, 9/2006.

134. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24(25):4092-9, 9/2006.

135. Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 5(11):2685-95, 11/2006.

136. Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 11(4):635-50, 11/2006.

137. Herbst RS. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 8(Suppl 1):S23-30, 12/2006.

138. Vokes E, Herbst RS, Sandler A. Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol 4(11 Suppl 23):1-12, 2006.

139. Sandler A, Herbst RS. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res 12(14 Pt 2):4421s-4425s, 2006.

140. Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, Herbst RS, Carducci M, Britten CD, Basche M, Eckhardt SG, Thornton D. Development and validation of a drug activity biomarker


Page 23 of 103

that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin Cancer Res 12(11 Pt 1):3408-3415, 2006.

141. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thorton, DE, Herbst RS. Enzastaruin (LY317615), an oral PKCbeta (PKCβ) inhibitor, in patients with advanced cancer: a phase I dose escalation and pharmacokinetic study. J Clnic Oncol 24(25):4092-9, 2006.

142. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, Eisenberg BL, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Reaman GH, Sawaya R, Schilsky RL, Schuchter LM, Sweetenham JW, Vahdat LT, Winn RJ. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 25(1):146-62, 1/2007.

143. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6(2):471-83, 2/2007.

144. Itaska S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'rielly MS. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys 67(3):870-8, 3/2007.

145. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13(10):2890-6, 5/2007.

146. Rosen LS, Kurzrock R, Mulay M, Van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 25(17):2369-76, 6/2007.

147. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR Jr, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68(3):779-85, 7/2007.

148. Cohen MZ, Slomka J, Pentz RD, Flamm AL, Gold D, Herbst RS, Abbruzzese JL. Phase I participants' views of quality of life and trial participation burdens. Support Care Cancer 15(7):885-890, 7/2007.

149. Herbst RS, Oh Y, Wagle A, Lahn M. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer. Clin Cancer Res 13(15 Pt 2):s4641-6, 8/2007.

150. Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Novel agents in the treatment of lung cancer: Fourth Cambridge Conference. Clin Cancer Res 13(15 Pt 2):s4583-8, 8/2007.

151. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25(27):4270-7. Erratum 1/2008 in: J Clin Oncol 26(1):165-6, 9/2007.

152. Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson


Page 24 of 103

BE. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 13(20):6175-81, 10/2007.

153. Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 6(10):2652-63, 10/2007.

154. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 25(30):4743-50, 10/2007.

155. Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69(5):1534-43, 12/2007.

156. Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Xu Z, Herbst RS, Abbruzzese JL. Who should go first in trials with scarce agents? The views of potential participants. IRB 29(4):1-6, Jul-Aug, 2007.

157. Herbst RS. Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men? Clin Lung Cancer 9(2):75-6, 3/2008.

158. Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 26(7):1135-41, 3/2008.

159. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26(9):1472-8, 3/2008.

160. Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL. Tumor Blood Flow Measured by PET Dynamic Imaging of First-Pass 18F-FDG Uptake: A Comparison with 15O-Labeled Water-Measured Blood Flow. J Nucl Med 49(4):517-23, 4/2008.

161. Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Onn A. Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 3(4):351-7, 4/2008.

162. Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer. J Thorac Oncol 3(5):545-55, 5/2008.

163. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112(12):2710-9, 6/2008.

164. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest 118(6):1979-90, 6/2008.

165. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26(20):3351-7, 7/2008.

166. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 359(13):1367-80, 9/2008.


Page 25 of 103

167. Herbst RS, Sandler A. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 13(11):1166-76, 11/2008.

168. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, Ranade AA, Cohen G, Trigo JM, Sandler AB, Bonomi PD, Herbst RS, Krebs AD, Vasselli J, Johnson BE. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 26(33):5407-15, 11/2008.

169. Rice D, Swisher S, Pisters K, Fossella F, Herbst R, Hofstetter W, Kies M, Komaki R, Lippman S, Mehran R, Roth J, Stewart D, Vaporciyan A, Walsh G, Cox J. Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)." Chest 134(6):1349; author reply 1350, 12/2008.

170. Xian Zhou, Suyu Liu, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer -- a step toward personalized medicine. Clin Trials 5(3):181-93, 2008.

171. Herbst RS, Lynch TJ, Sandler AB. Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy. Review. Clin Lung Cancer 10(1):20-7, 1/2009.

172. Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose Escalation of Gemcitabine Is Possible with Concurrent Chest Three-Dimensional Rather than Two-Dimensional Radiotherapy: A Phase I Trial in Patients with Stage III Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 73(1):119-27, 1/2009.

173. Giaccone G, Iacona RB, Fandi A, Janas M, Ochs JS, Herbst RS, Johnson DH. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. J Cancer Res Clin Oncol 135(3):467-76, 3/2009.

174. Kim ES, Mauer AM, William WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 115(8):1713-22, 4/2009.

175. Craft BS, Kurzrock R, Lei X, Herbst R, Lippman S, Fu S, Karp DD. The changing face of Phase 1 cancer clinical trials: new challenges in study requirements. Cancer 115(8):1592-7, 4/2009.

176. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 15(10):3600-9, 5/2009.

177. Ng CS, Kodama Y, Mullani NA, Barron BJ, Wei W, Herbst RS, Abbruzzese JL, Charnsangavej C. Tumor blood flow measured by perfusion computed tomography and 15O-labeled water positron emission tomography: a comparison study. J Comput Assist Tomogr 33(3):460-5, May-Jun, 5/2009.

178. Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen. J Thorac Oncol 4(6):689-96, 6/2009.

179. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27(21):3557-65, 7/2009.

180. Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West HJ, Herbst R, Johnson D, Bunn P, Govindan R. Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. J Thorac Oncol 4(7):930-5, 7/2009.


Page 26 of 103

181. Pao W, Kris MG, Iafrate AJ, Ladanyi M, Jänne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, Lynch TJ. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 15(17):5317-22, 9/2009.

182. Bar J, Herbst RS, Onn A. Targeted drug delivery strategies to treat lung metastasis. Expert Opin Drug Deliv 6(10):1003-16, 10/2009.

183. Gandara DR, Mack PC, Li T, Lara PN, Herbst RS. Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012. Clin Lung Cancer 10(6):392-4, 11/2009.

184. Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. e-Pub 12/2009.

185. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs. e-Pub 1/2010.

186. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 16(4):1256-63, 2/2010.

187. Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G. Comparison of Patient Outcomes According to Histology Among Pemetrexed-Treated Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer in Two Phase II Trials. Clin Lung Cancer 11(2):126-31, 3/2010.

188. Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G. Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor. Mol Cancer Ther 9(3):706-17, 3/2010. PMCID: PMC2837366.

189. William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ES. Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer as Frontline and Second-Line Therapy. Am J Clin Oncol 33(2):148-52, 4/2010.

190. Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy With or Without AE-941 in Stage III Non-Small Cell Lung Cancer: A Randomized Phase III Trial. J Natl Cancer Inst. e-Pub 5/2010.

191. Viswanath K, Herbst RS, Land SR, Leischow SJ, Shields PG. Tobacco and Cancer: An American Association for Cancer Research Policy Statement. Cancer Res 70(9):3419-30, 5/2010.

192. Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular origins of lung cancer: prospects for personalized prevention and therapy. J Thorac Oncol 5(6 Suppl 3):S207-13, 6/2010.

193. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28(17):2839-46, 6/2010. e-Pub 5/2010.

194. Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS. A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in


Page 27 of 103

Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung. J Thorac Oncol 5(7):1054-9, 7/2010.

195. Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol 5(7):940-9, 7/2010.

196. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11(7):619-26, 7/2010.

197. Zoog SJ, Ma CY, Kaplan-Lefko PJ, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu CP, Friberg G, Herbst R, Hill J, Juan G. Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling. Cytometry A 77(9):849-60, 9/2010.

198. Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES, Redman M, Crowley JJ, Gandara DR. Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non-Small-Cell Lung Cancer: Southwest Oncology Group Study S0342. J Clin Oncol 28(31):4747-54, 11/2010. e-Pub 10/2010.

199. Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang Y, Wong S, Hill JS, Friberg G, Lorusso P. A First-in-Human Study of Conatumumab in Adult Patients With Advanced Solid Tumors. Clin Cancer Res 16(23):5883-91, 12/2010. e-Pub 10/2010.

200. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, Peyton M, Roth JA. Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo. PLoS One 5(11):e14124, 2010. e-Pub 11/2010.

201. Sandler A, Graham C, Baggstrom M, Herbst RS, Zergebel C, Saito K, Jones D. An open-label, multicenter, three-stage, phase II study of S-1 in combination with cisplatin as first line therapy for patients with advanced non-small cell lung cancer. J Thorac Oncol 6(8):1400-6, 8/2011.

202. Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 8(3):135-41, 3/2011.

203. Govindan R, Morgenzstern D, Kommor MD, Herbst R, Schaefer P, Gandhi J, Saito K, Zergebel C, Schiller J. Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 6(4):790-5, 4/2011.

204. Kim ES, *Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies M, Papdimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery AACR June 2011;1(1) 43:51

205. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MD, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse exenograft models of angiogenesis inhibitor-resistant human lung adenocrcinoma. J Clin Invest 121(4):1313-28, 4/2011.

206. Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and Practical Challenges for Personalized Cancer Therapies. Nat Rev Clin Oncol 8(3):135-41, 3/2011.

207. Herbst RS, Ansari R, Bustin F, Flynn P, Lowell H, Otterson G, Vlahovic G; Soh C, O’Connor P, Hainsworth J. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-bline, placebo-controlled, phase 3 trial. Lancet 377( 9780):1846-1854, 5/2011.


Page 28 of 103

208. Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Med Cancer Chemother Pharmacol 69(1):165-72, 1/2012.

209. Blumenschein GR Jr, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki, R. Phase II Study of Cetuximab in Combination With Chemoradiation in Patients with Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324. J Clin Oncol 29(17):2312-8, 6/2011.

210. Yang F, Tang X, Riquelme E, Behrens C, Nilsson MB, Giri U, Varella-Garcia M, Byers LA, Lin HY, Wang J, Raso MG, Girard L, Coombes K, Lee JJ, Herbst RS, Minna JD, Heymach JV, Wistuba II. Increased VEGFR-2 Gene Copy Is Associated With Chemoresistance and Shorter Survival in Patients with Non-small Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Res 71(16):5512-21, 8/2011.

211. Pan Y, Xu R, Peach M, Huang CP, Branstetter D, Novotny W, Herbst RS, Eckhardt SG, Holland PM. Evaluation of pharmacodynamics biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours. Br J Cancer 105(12):1830-8, 12/2011.

212. Takahashi O, Komaki R, Smith PD, Jurgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O’Reilly MS. Combined MEK and VEGRE inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res 18(6):1641-54, 3/2012.

213. Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials. Clin Cancer Res 18(3):638-44, 2/2012.

214. Byers LA, Diao L,Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clin Cancer Res 19(1): 279-90, 1/2013.

215. Gaspar LE, McNamara EJ, Gay EG, Putnam JB, Crawford J, Herbst RS, Bonner JA. Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment over 15 Years. Clin Lung Cancer 13(2):115-22, 3/2012.

216. Hirsch FR, Herbst RS. EGFR Expression and the Flexibility of Flex. Lancet Oncol 13(1): 3-5, 1/2012.

217. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A Multicenter Phase I Trial of Px-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res18(15): 4173-82, 8/2012.

218. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of Kras Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. J Natl Cancer Inst 104(3): 228-39, 2/2012.

219. Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS. A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Azd4877, an Intravenous Eg5 Inhibitor in Patients with Advanced Solid Tumors. Cancer Chemother Pharmacol 69(1): 165-72, 1/2012.


Page 29 of 103

220. Koo PJ, Morgensztern D, Boyer JL, Herbst RS. Targeting Vascular Endothelial Growth Factor in Patients with Squamous Cell Lung Cancer. J Clin Oncol 30(10): 1137-9, 4/2012.

221. Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, De Castro Carpeno J, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Phase I Trial of Axitinib Combined with Platinum Doublets in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumours. Br J Cancer 107(8): 1277-85, 10/2012.

222. Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A,Cohen RB. Phase I Study of Axitinib Combined with Paclitaxel, Docetaxel or Capecitabine in Patients with Advanced Solid Tumours. Br J Cancer 107(8): 1268-76, 10/2012.

223. Morgensztern D, Herbst RS. Miscellaneous Agents. J Thorac Oncol 7(16 Suppl 5): S390-1, 12/2012.

224. Peters EN, Torres E, Toll BA, Cummings KM, Gritz ER, Hyland A, Herbst RS, Marshall JR, Warren GW. Tobacco Assessment in Actively Accruing National Cancer Institute Cooperative Group Program Clinical Trials. J Clin Oncol 30(23): 2869-75, 8/2012.

225. Redman MW, Crowley JJ, Herbst RS, Hirsch FR, Gandara DR. Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819. Clin Cancer Res 18(15): 4004-12, 8/2012.

226. Takahashi O, Komaki R, Smith PD, Jurgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined Mek and Vegfr Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis. Clin Cancer Res18(6): 1641-54, 3/2012.

227. Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR Mutation, KRAS Mutation, and ALK Gene Rearrangement in Cytological Specimens of Primary and Metastatic Lung Adenocarcinoma. Cancer Cytopathol 121(9):500-7, 9/2013.

228. Goldberg SB, Schlessinger J, Boyer JL, Herbst RS. A Step Towards Treating KRAS-Mutant NSCLC. Lancet Oncol 14(1): 3-5, 1/2013.

229. Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS. Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer. J Thorac Oncol 8(2): 140-6, 2/2013.

230. Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma. Cancer Res 73(2): 571-82, 1/2013.

231. Soria JC, Baselga J, Hanna N, Laurie SA, Bahleda R, Felip E, Calvo E, Armand JP, Shepherd FA, Harbison CT, Berman D, Park JS, Zhang S, Vakkalagadda B, Kurland JF, Pathak AK, Herbst RS. Phase I-IIa Study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 Oral Tyrosine Kinase Inhibitor, in Patients with Advanced or Metastatic Solid Tumours. Eur J Cancer 49(8): 1815-24, 5/2013.

232. Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS. Assessing Tobacco Use by Cancer Patients and Facilitating Cessation: An American Association for Cancer Research Policy Statement. Clin Cancer Res 19(8): 1941-8, 4/2013.

233. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the Battle Trial. J Thorac Oncol 7(11): 1645-52, 11/2012.

234. Ujhazy P, Herbst R. Personalized Therapy. J Thorac Oncol 7(16 Suppl 5): S401-3, 12/2012.


Page 30 of 103

235. Blumenschein GR Jr, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J Jr, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the Battle Trial. Clin Cancer Res 19(24): 6967-75, 12/2013.

236. Bracke KR, Verhamme FM, Seys LJ, Bantsimba-Malanda C, Cunoosamy DM, Herbst R, Hammad H, Lambrecht BN, Joos GM,Brusselle GG, Role of CXCL13 in Cigarette Smoke-Induced Lymphoid Follicle Formation and Chronic Obstructive Pulmonary Disease, Am J Respir Crit Care Med 188(3): 343-55, 8/2013.

237. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming Egfr Inhibitor Resistance. Clin Cancer Res 19(1): 279-90, 1/2013.

238. Kim ES, Moon J, Herbst RS, Redman MW, Dakhil SR,Velasco MR Jr, Hirsch FR, Mack PC, Kelly K, Heymach JV, Gandara DR. Phase Ii Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer: SWOG S0536. J Thorac Oncol 8(12): 1519-28, 12/2013.

239. Tsao S, Liu S, Lee JJ, Alden CM, Blumenschein GR Jr, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the Battle Trial. J Thorac Oncol 8(5): 658-61, 5/2013.

240. Warren GW, Marshall JR, Cummings KM, Toll B, Gritz ER, Hutson A, Dibaj S, Herbst R, Dresler C, IASLC Tobacco Control, and Committee Smoking Cessation. Practice Patterns and Perceptions of Thoracic Oncology Providers on Tobacco Use and Cessation in Cancer Patients. J Thorac Oncol 8(5): 543-8, 5/2013.

241. Warren GW, Marshall JR, Cummings KM, Toll BA, Gritz ER, Hutson A, Dibaj S, Herbst R, Mulshine JL, Hanna N, Dresler CA. Addressing Tobacco Use in Patients with Cancer: A Survey of American Society of Clinical Oncology Members. J Oncol Pract 9(5):258-62, 9/2013.

242. Yamaguchi H, Hsu JL, Chen CT, Wang YN, Hsu MC, Chang SS, Du Y, Ko HW, Herbst R, Hung MC. Caspase-Independent Cell Death Is Involved in the Negative Effect of Egf Receptor Inhibitors on Cisplatin in Non-Small Cell Lung Cancer Cells. Clin Cancer Res 19(4): 845-54, 2/2013.

243. Balogh EB, Dresler C, Fleury ME, Gritz ER, Kean TJ, Myers ML, Nass SJ, Nevidjon B, Toll BA, Warren GW, Herbst RS. Reducing Tobacco-Related Cancer Incidence and Mortality: Summary of an Institute of Medicine (IOM) Workshop. Oncologist 19(1): 21-31, 1/2014.

244. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer. Lab Invest 94(1):107-16, 1/2014.

245. Jürgensmeier JM, Eder JP, Herbst RS. New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs. Clin Cancer Res 20(17):4425-35, 9/2014.

246. Gettinger S, Herbst RS. B7-H1/PD-1 Blockade Therapy in Non-Small Cell Lung Cancer: Current Status and Future Direction. Cancer J 20(4):281-9, 7-8/2014.

247. Hirsch FR, Bunn PA Jr, Herbst RS. "Companion diagnostics": has their time come and gone? Clin Cancer Res 20(17):4422-4, 9/2014.

248. Heymach JV, Lockwood SJ, Herbst RS, Johnson BE, Ryan AJ. EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of


Page 31 of 103

second line treatment for patients with advanced non-small cell lung cancer. Ann Oncol 25(10):1941-8, 10/2014.

249. Massarelli E, Onn A, Marom EM, Alden CM, Liu DD, Tran HT, Mino B, Wistuba II, Faiz SA, Bashoura L, Eapen GA, Morice RC, Jack Lee J, Hong WK, Herbst RS, Jimenez CA. Vandetanib and Indwelling Pleural Catheter for Non-Small-Cell Lung Cancer With Recurrent Malignant Pleural Effusion. Clin Lung Cancer 15(5):379-86, 9/2014.

250. Vasan N, Boyer JL, Herbst RS. A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer. Clin Cancer Res 20(15):3921-30, 8/2014.

251. Herbst RS, Hobin JA, Gritz ER; Writing Committee for the AACR Subcommittee on Tobacco and Cancer. AACR celebrates 50 years of tobacco research and policy. Clin Cancer Res 20(7):1709-18, 4/2014.

252. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, Garrett-Mayer E, Herbst RS, Lilenbaum RC, Sima C, Venook AP, Gonen M, Schilsky RL, Meropol NJ, Schnipper LE. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 32(12):1277-80, 4/2014.

253. Onn A, Bar J, Herbst RS. Angiogenesis inhibition and lung-cancer therapy. Lancet Oncol 15(2):124-5, 2/2014.

254. Toll BA, Rojewski AM, Duncan LR, Latimer-Cheung AE, Fucito LM, Boyer JL, O'Malley SS, Salovey P, Herbst RS. "Quitting smoking will benefit your health": the evolution of clinician messaging to encourage tobacco cessation. Clin Cancer Res 20(2):301-9, 1/2014.

255. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011. PMID: 25428504

256. Kris MG, Arenberg DA, Herbst RS, Riely GJ. Emerging science and therapies in non-small-cell lung cancer: targeting the MET pathway. Clin Lung Cancer 15(6):475, 11/2014.

257. Henick BS, Herbst RS, Goldberg SB. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opin Ther Targets 18(12):1407-20, 12/2014.

258. Brandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, Ostroff JS, Shields PG, Toll BA, Tyne CA, Viswanath K, Warren GW. Electronic Nicotine Delivery Systems: A Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology. Clin Cancer Res 21(3):514-25, 2/2015.

259. Ma B, Herzog EL, Lee CG, Peng X, Lee CM, Chen X, Rockwell S, Koo JS, Kluger H, Herbst RS, Sznol M, Elias JA. Role of Chitinase 3-like-1 and Semaphorin 7a in Pulmonary Melanoma Metastasis. Cancer Res 75(3):487-96, 2/2015.

260. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 10 (1):S1-S63, 1/2015.

261. Brandon TH, Goniewicz ML, Hanna NH, Hatsukami DK, Herbst RS, Hobin JA, Ostroff JS, Shields PG, Toll BA, Tyne CA, Viswanath K, Warren GW. Electronic Nicotine Delivery Systems: A Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology. J Clin Oncol 33(8):952-63, 3/2015.

262. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke


Page 32 of 103

CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clin Cancer Res 21(7):1514-24, 4/2015.

263. Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman M, Hirsch F, Mack PC, Ramalingam SS, Gandara DR. Innovative Clinical Trials: The LUNG-MAP Study. Clin Pharmacol Ther 97(5):488-91, 5/2015.

264. Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst 107(3):dju435, 2/2015.

265. Hirsch FR, Herbst RS, Gandara DR.EGFR tyrosine kinase inhibitors in squamous cell lung cancer.Lancet Oncol. 2015 Aug;16(8):872-3. doi: 10.1016/S1470-2045(15)00126-6.

266. Park SA, Platt J, Lee JW, López-Giráldez F, Herbst RS, Koo JS.E2F8 as a Novel Therapeutic Target for Lung Cancer. J Natl Cancer Inst. 2015 Jun 18;107(9). pii: djv151. doi: 10.1093/jnci/djv151.

267. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236.

268. Lee JW, Park HS, Park SA, Ryu SH, Meng W, Jürgensmeier JM, Kurie JM, Hong WK, Boyer JL, Herbst RS, Koo JS. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. PLoS One. 2015 Apr 21;10(4):e0122628. doi: 10.1371/journal.pone.0122628.

269. Platt A, Morten J, Ji Q, Elvin P, Womack C, Su X, Donald E, Gray N, Read J, Bigley G, Blockley L, Cresswell C, Dale A, Davies A, Zhang T, Fan S, Fu H, Gladwin A, Harrod G, Stevens J, Williams V, Ye Q, Zheng L, de Boer R, Herbst RS, Lee JS, Vasselli J. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer. 2015 Mar 23;15:171. doi: 10.1186/s12885-015-1146-8.

270. Morgensztern D, Politi K, Herbst RS. EGFR Mutations in Non-Small-Cell Lung Cancer: Find, Divide, and Conquer. JAMA Oncol. 2015 May;1(2):146-8. doi: 10.1001/jamaoncol.2014.278.

271. Ferrarotto R, Redman MW, Gandara DR, Herbst RS, Papadimitrakopoulou VA. Lung-MAP-framework, overview, and design principles. Chin Clin Oncol. 2015 Sep;4(3):36. doi: 10.3978/j.issn.2304-3865.2015.09.02.

272. McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelakanou V, Rehman J, Velcheti V, Herbst R, LoRusso P, Rimm DL. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol. 2015 Nov 12:1-9. doi: 10.1001/jamaoncol.2015.3638.

273. Nilsson M, Giri U, Gudikote J, Tang X, Lu W, Tran HT, Fan YH, Koo A, Diao L, Tong P, Wang J, Herbst RS, Johnson BE, Ryan AJ, Webster A, Rowe P, Wistuba II, Heymach JV. KDR Amplification is Associated with VEGF-induced Activation of MTOR and Invasion Pathways but Does Not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clin Cancer Res. 2015 Nov 17. pii: clincanres.1994.2015.

274. Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and


Page 33 of 103

recurrent head and neck squamous cell carcinoma. J Clin Invest. 2015 E, Perex-Gracia, J, Han, J, Molina, J, Kim, J, Nov 30. pii: 82066. doi: 10.1172/JCI82066.

275. Herbst RS, Bass, P, Kim, DW, Felip, E, Perex-Gracia, J, Han, J, Molina, J, Kim, J, Dubois Arvis, C, Ahn, MJ, Majem, M, Fidler, MJ, Castro, G, Garrido, M., Lubinecki, G, Shentu, Y, Im, E, Dollerd-Filhart,M, Garon, EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-50.

276. Land SR, Toll BA, Moinpour CM, Mitchell SA, Ostroff JS, Hatsukami DK, Duffy SA, Gritz ER, Rigotti NA, Brandon T, Prindiville SA, Sarna L, Schnoll RA, Herbst RS, Cinciripini PM, Leischow S, Dresler CM, Fiore M, Warren GW. Research Priorities, Measures, and Recommendations for Assessment of Tobacco Use in Clinical Cancer Research. Clin Cancer Res. 2016 Feb 17. pii: clincanres.0104.2016.

277. Xia B, Herbst RS. Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy. 2016 Mar;8(3):279-98. doi: 10.2217/imt.15.123. Epub 2016 Feb 9. PMID: 26860624

278. Schalper KA, Kaftan E, Herbst RS. Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clin Cancer Res. 2016 May 1;22(9):2102-4. doi: 10.1158/1078-0432.CCR-16-0169. PMID: 26957559

279. Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, Jänne PA, Mok TS, Wakelee HA, Pirker R, Mazières J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 May;11(5):613-38. doi: 10.1016/j.jtho.2016.03.012. PMID: 27013409

280. Hedberg ML, Goh G, Chiosea SI, Bauman JE, Freilino ML, Zeng Y, Wang L, Diergaarde BB, Gooding WE, Lui VW, Herbst RS, Lifton RP, Grandis JR. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma. J Clin Invest. 2016 Apr 1;126(4):1606. doi: 10.1172/JCI86862. PMID: 27035818

281. Park SA, Lee JW, Herbst RS, Koo JS. GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer. PLoS One. 2016 Apr 6;11(4):e0153075. doi: 10.1371/journal.pone.0153075. PMID: 27049759

282. Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. PMID: 27229180

283. Morgensztern D, Herbst RS. Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer. Clin Cancer Res. 2016 Aug 1;22(15):3713-7. doi: 10.1158/1078-0432.CCR-15-2998. PMID: 27252413

284. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, Yu J, Hegde U, Speaker S, Madura M, Ralabate A, Rivera A, Rowen E, Gerrish H, Yao X, Chiang V, Kluger HM. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016 Jul;17(7):976-83. doi: 10.1016/S1470-2045(16)30053-5. PMID: 27267608

285. Schalper KA, Carvajal-Hausdorf D, McLaughlin J, Altan M, Velcheti V, Gaule P, Sanmamed MF, Chen L, Herbst RS, Rimm DL. Differential expression and significance of PD-L1, IDO-1 and B7-


Page 34 of 103

H4 in human lung cancer. Clin Cancer Res. 2016 Jul 20. pii: clincanres.0150.2016. PMID: 27440266

286. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Aug 1. pii: JCO660084. PMID: 27480147

287. Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, Lee JJ. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. Stat Biosci. 2016 Jun;8(1):99-128. PMID: 27617040

288. Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, Kim AW, Detterbeck FC, Blasberg JD, Boffa DJ. Association of Delayed Adjuvant Chemotherapy with Survival After Lung Cancer Surgery. JAMA Oncol. 2017 Jan 5. PMID: 28056112

289. Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol. 2016 Sep 29. pii: mdw436. PMID: 27687306

290. Shields PG, Herbst RS, Arenberg D, Benowitz NL, Bierut L, Luckart JB, Cinciripini P, Collins B, David S, Davis J, Hitsman B, Hyland A, Lang M, Leischow S, Park ER, Purcell WT, Selzle J, Silber A, Spencer S, Tanvetyanon T, Tiep B, Tindle HA, Tucker-Seeley R, Urbanic J, Hooper MW, Weksler B, Whitlock CW, Wood DE, Burns J, Scavone J. Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Nov;14(11):1430-1468. PMID: 27799513

291. Du L, Herbst RS, Morgensztern D. Immunotherapy in Lung Cancer. Hematol Oncol Clin North Am. 2017 Feb;31(1):131-141. doi: 10.1016/j.hoc.2016.08.004. PMID: 27912829

292. Morgensztern D, Herbst RS. Evolving Treatment Options for Lung Cancer. Hematol Oncol Clin North Am. 2017 Feb;31(1):xiii-xiv. doi: 10.1016/j.hoc.2016.09.001. PMID: 27912837

293. Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger SN. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov;11(11S):S309-S310. doi: 10.1016/j.jtho.2016.09.097. PMID: 27969529

294. Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol. 2017 Jan 1;28(1):83-89. doi: 10.1093/annonc/mdw437. PMID: 28177435

295. Stevens LE, Cheung WK, Adua SJ, Arnal-Estapé A, Zhao M, Liu Z, Brewer K, Herbst RS, Nguyen DX. Extracellular matrix receptor expression in subtypes of lung adenocarcinoma potentiates outgrowth of micrometastases. Cancer Res. 2017 Feb 14. pii: canres.1978.2016. doi: 10.1158/0008-5472.CAN-16-1978. PMID: 28196904

296. Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L.Enhancing Insights into Pulmonary


Page 35 of 103

Vascular Disease (PVD) Through a Precision Medicine Approach. A Joint NHLBI-CMREF Workshop Report. Am J Respir Crit Care Med. 2017 Apr 21. PMID: 28430547

297. Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol. 2017 Mar 27. PMID: 28368511

298. Altan M, Pelekanou V, Schalper KA, Toki MI, Gaule P, Syrigos KN, Herbst RS, Rimm DL. B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and Tumor Infiltrating Lymphocytes. Clin Cancer Res. 2017 May 24. pii: clincanres.3107.2016. doi: 10.1158/1078-0432.CCR-16-3107. PMID: 28539467

299. Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells KJ, Haddad V, Hanrahan EO, Nilsson M, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Juergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach J. The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer. Clin Cancer Res. 2017 May 30. pii: clincanres.3216.2016. doi: 10.1158/1078-0432.CCR-16-3216. PMID: 28559461

300. Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG. JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol Cancer Ther. 2017 Jul 20. pii: molcanther.0148.2016. doi: 10.1158/1535-7163.MCT-17-0148. PMID: 28729401

301. Korde A, Jin L, Zhang JG, Ramaswamy A, Hu B, Kolahian S, Juan Guardela B, Herazo-Maya J, Siegfried JM, Stabile L, Pisani MA, Herbst RS, Kaminski N, Elias JA, Puchalski JT, Takyar SS. Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis. Am J Respir Crit Care Med. 2017 Aug 30. doi: 10.1164/rccm.201610-2157OC. PMID: 28853613

302. Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper KA, Herbst RS, Politi K. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017 Oct 12. pii: CD-17-0593. doi: 10.1158/2159-8290.CD-17-0593. PMID: 29025772

303. Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. Lancet Oncol. 2017 Nov 20. pii: S1470-2045(17)30694-0. doi: 10.1016/S1470-2045(17)30694-0. PMID: 29169877

304. Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers. Sci Transl Med. 2017 Nov 8;9(415). pii: eaao4307. doi: 10.1126/scitranslmed.aao4307. PMID: 29118262

305. Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed MF, Velcheti V, Syrigos KN, Toki MI, Zhao H, Chen L, Herbst RS, Schalper KA. Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res. 2017 Dec 4. pii: clincanres.2542.2017. doi: 10.1158/1078-0432.CCR-17-2542. PMID: 29203588

306. Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, Gettinger S, Wilson LD,


Page 36 of 103

Herbst RS, Patel AA. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin Cancer Res. 2018 Jan 12. pii: clincanres.1341.2017. doi: 10.1158/1078-0432.CCR-17-1341. PMID: 29330207

307. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan 24;553(7689):446-454. doi: 10.1038/nature25183. PMID: 29364287

308. Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 1;4(2):210-216. doi: 10.1001/jamaoncol.2017.4427. PMID: 29270615

309. Doroshow DB, Herbst RS. Treatment of Advanced Non-Small Cell Lung Cancer in 2018. JAMA Oncol. 2018 Apr 1;4(4):569-570. doi: 10.1001/jamaoncol.2017.5190. PubMed PMID: 29494728.

310. Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS. Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30210-7. doi: 10.1016/j.jtho.2018.03.008. PubMed PMID: 29578107.

311. Wu YL, Herbst RS, Mann H, Rukazenkov Y, Marotti M, Tsuboi M. ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection. Clin Lung Cancer. 2018 Jul;19(4):e533-e536. doi: 10.1016/j.cllc.2018.04.004. Epub 2018 May 1. PMID: 29789220

312. Kim TK, Herbst RS, Chen L. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol. 2018 Aug;39(8):624-631. doi: 10.1016/j.it.2018.05.001. Epub 2018 May 22. Review. PMID: 29802087

313. Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I.Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist. 2018 May 31. pii: theoncologist.2018-0044. doi: 10.1634/theoncologist.2018-0044.PMID: 29853658

314. Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Herbst RS, Mok TS, Peled N, Pirker R, Raez LE, Reck M, Riess JW, Sequist LV, Shepherd FA, Sholl LM, Tan DSW, Wakelee HA, Wistuba II, Wynes MW, Carbone DP, Hirsch FR, Gandara DR. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30680-4. doi: 10.1016/j.jtho.2018.05.030. Review. PMID: 29885479

315. Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018 Jul 17;6(1):75. doi: 10.1186/s40425-018-0382-2. PMID: 30012210 Free PMC Article

316. Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018 Aug 1;101:201-209. doi: 10.1016/j.ejca.2018.06.031. PMID: 30077125

317. Presley CJ, Tang D, Soulos PR, Chiang AC, Longtine JA, Adelson KB, Herbst RS, Zhu W, Nussbaum NC, Sorg RA, Agarwala V, Abernethy AP, Gross CP. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung


Page 37 of 103

Cancer in the Community Oncology Setting. JAMA. 2018 Aug 7;320(5):469-477. doi: 10.1001/jama.2018.9824. PMID: 30088010

318. Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget. 2018 Sep 21;9(74):33995-34008. doi: 10.18632/oncotarget.26129. eCollection 2018 Sep 21. PMID: 30338041 Free PMC Article

319. Goldberg SB, Herbst RS. Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer? Cancer. 2018 Dec 15;124(24):4592-4596. doi: 10.1002/cncr.31681. Epub 2018 Nov 1. No abstract available. PMID: 30383887

320. Peled M, Onn A, Herbst RS. Tumor infiltrating lymphocytes - location for prognostic evaluation. Clin Cancer Res. 2018 Dec 19. pii: clincanres.3803.2018. doi: 10.1158/1078-0432.CCR-18-3803. PMID: 30567833

321. Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G Jr, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB.Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: An updated analysis of KEYNOTE-010 trial.Ann Oncol. 2019 Jan 18. doi: 10.1093/annonc/mdy545.

322. Riaz F, Presley CJ, Chiang AC, Longtine JA, Soulos PR, Adelson KB, Herbst RS, Nussbaum NC, Sorg RA, Abernethy AP, Agarwala V, Gross CP. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer. J Geriatr Oncol. 2019 Feb 1. pii: S1879-4068(18)30419-3. doi: 10.1016/j.jgo.2019.01.016. [Epub ahead of print] PMID: 30718180

323. Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G Jr, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS. Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. J Thorac Oncol. 2019 Jan 31. pii: S1556-0864(19)30091-7. doi: 10.1016/j.jtho.2019.01.016. PMID: 30711649

324. Lee JW, Zhang Y, Eoh KJ, Sharma R, Sanmamed MF, Wu J, Choi J, Park HS, Iwasaki A, Kaftan E, Chen L, Papadimitrakopoulou V, Herbst RS, Koo JS. The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30111-X. doi: 10.1016/j.jtho.2019.02.004. PMID: 30771521

325. Codina A, Renauer PA, Wang G, Chow RD, Park JJ, Ye H, Zhang K, Dong MB, Gassaway B, Ye L, Errami Y, Shen L, Chang A, Jain D, Herbst RS, Bosenberg M, Rinehart J, Fan R, Chen S. Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo. Cell Syst. 2019 Feb 27;8(2):136-151.e7. doi: 10.1016/j.cels.2019.01.004. Feb 20. PMID: 30797773

326. Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res. 2019 Mar 1. pii: clincanres.1538.2018. doi: 10.1158/1078-0432.CCR-18-1538. PMID: 30824587

327. Khuri FR, Herbst RS. The fork in the road: Waun Ki Hong, John Mendelsohn, and the reinvigoration of The University of Texas MD Anderson Cancer Center. Cancer. 2019 Mar 2. doi: 10.1002/cncr.32045. PMID: 30825386


Page 38 of 103

328. Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat Med. 2019 Apr;25(4):656-666. doi: 10.1038/s41591-019-0374-x. Mar 4. PMID: 30833750

329. Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). J Immunother Cancer. 2019 Mar 8;7(1):65. doi: 10.1186/s40425-019-0540-1. PMID: 30850021

330. Altan M, Toki MI, Gettinger SN, Carvajal-Hausdorf DE, Zugazagoitia J, Sinard JH, Herbst RS, Rimm DL. BRIEF REPORT: Immune checkpoint inhibitor associated pericarditis. J Thorac Oncol. 2019 Mar 6. pii: S1556-0864(19)30196-0. doi: 10.1016/j.jtho.2019.02.026. PMID: 30851443

331. Wilson FH, Herbst RS. Larotrectinib in NTRK-Rearranged Solid Tumors<sub>Published as part of the Biochemistry series "Biochemistry to Bedside" Biochemistry. 2019 Mar 26;58(12):1555-1557. doi: 10.1021/acs.biochem.9b00126. Mar 13. PMID: 30865435

332. Aggarwal C, Redman MW, Lara PN Jr, Borghaei H, Hoffman P, Bradley JD, Newman AJ 3rd, Feldman MJ, Minichiello K, Miao J, Mack PC, Papadimitrakopoulou VA, Herbst RS, Kelly K, Gandara DR. SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30462-9. doi: 10.1016/j.jtho.2019.05.041.

333. Langer CJ, Redman MW, Wade JL 3rd, Aggarwal C, Bradley JD, Crawford J, Stella PJ, Knapp MH, Miao J, Minichiello K, Herbst RS, Kelly K, Gandara DR, Papadimitrakopoulou VA. SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). J Thorac Oncol. 2019 May 31. pii: S1556-0864(19)30414-9. doi: 10.1016/j.jtho.2019.05.029.

334. Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. Ann Oncol. 2019 May 14. pii: mdz141. doi: 10.1093/annonc/mdz141.

335. Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA. Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. Clin Cancer Res. 2019 May 3. doi: 10.1158/1078-0432.CCR-18-4142.

336. Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I. amucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.Lancet Oncol. 2019 Jul 10. pii: S1470-2045(19)30458-9. doi: 10.1016/S1470-2045(19)30458-9. PMID: 31301962

337. Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP


Page 39 of 103

Sub-study). J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30557-X. doi: 10.1016/j.jtho.2019.06.027. PMID: 31302234

Invited Articles 1. Baselga J, LoRusso P, Herbst RS, Rischin D, Ranson M, Maddox AM, Averbuch S. A

pharmacokinetic/pharmacodynamic trial of ZD1839 (IRESSA™), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with 5 selected tumor types (a phase I/II) trial of continuous once-daily treatment). Clin Cancer Res 5:29, 1999.

2. Mullani N, Herbst R, Abbruzzese J, Charnsangavej C, Kim E, Tran H, Barron B, Lamki L, Gould K. Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors. Clin Positron Imaging 3:151, 7/2000.

3. Mullani N, Herbst R, Abbruzzese J, Barron B, Lamki L, Charnsangavej C, Kim E, Tran H, Jiwani A, Gould K. First Pass FDG Measured Blood Flow in Tumors: A Comparison with O-15 Labeled Water Measured Blood Flow. Clin Positron Imaging 3:153, 7/2000.

4. Herbst RS. Current perspectives and novel strategies in the treatment of patients with lung cancer introduction. Sem Oncol, 2000.

5. Zinner RG, Herbst RS. Trastuzumab (Herceptinâ) enters non-small-cell lung cancer clinical trials. HER2 in Oncology 1(3):2-6&11, 2000.

6. Herbst RS, Arbuckle R, Guerra MS. Special Report--The University of Texas M. D. Anderson Cancer. Oncology:20-21, 3/2002.

7. Kim ES, Tran H, Herbst RS. A phase II study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with docetaxel in relapsed non-small cell lung cancer. Advances in Lung Cancer 4:13-14, 2002.

8. Onn A, Roach JS, Herbst RS. An overview of novel targeted agents in the management of non-small cell lung cancer. Adv Lung Cancer 4(2):7-10, 2002.

9. Herbst RS, Hong WK. Introduction. Semin Oncol 29(5):1-2, 2002.

10. Massarelli E, Onn A, Zinner R, Khuri FR, Kim ES, Herbst RS. New targets for the treatment of advanced non-small cell lung cancer (Review). Cancer Chemother Biol Response Modif 20:717-61, 2002.

11. Herbst RS, Bunn PA, Jr, Johnson DH. Introduction. Sem Oncol 31(1 Suppl 1):1-3, 2/2004.

12. Herbst RS. EGFR inhibition in NSCLC: The emerging role of cetuximab. J Nat'l Comprehensive Cancer Network 2:S1-S11, 2004.

13. Herbst RS, Onn A. Established and promising salvage therapies for patients with advanced non-small cell lung cancer. Pharmacy Practice News:41-46, 2004.

14. Herbst RS. Established and promising salvage therapies: For patients with advanced non-small cell lung cancer. Oncology 7:1-6, 2004.

15. Tsao AS, Herbst RS. Factors that determine response to EGFR inhibitors. Signal 4(4):4-9, 2004.

16. Herbst RS. Introduction. Sem Oncol 32(6 Suppl 10):S1-2, 12/2005.

17. Herbst RS. Role of novel targeted therapies in the clinic. Br J Cancer 92:S21-27, 2005.

18. Herbst RS. Targeting key pathways in tumour growth and development. Br J Cancer 92:S1, 2005.

19. Massarelli E, Herbst RS. Use of novel second-line targeted therapies in non-small cell lung cancer. Semin Oncol 33(1 Suppl 1):S9-16, 2/2006.

20. Herbst RS, Thomas J. Lynch, MD, Alan B. Sandler, MD. New Treatment Paradigms in Non-Small-Cell Lung Cancer: A roundtable discussion presented by CMPMedica in August 2006.


Page 40 of 103

New Treatment Paradigms in Non-Small-Cell Lung Cancer Including a Clinical Discussion on Audio CD, 2006.

21. Herbst RS, Kaelin W, Quinn D. Targeting Angiogenesis Pathways: A Clinical Update. Targeting Tumor Angiogenesis Vol. 1(2) Fall/Winter, 2006.

22. Herbst RS. Therapeutics options to target angiogenesis in human malignancies. Expert Opin Emerging Drugs 11(4):635-650, 2006.

23. Herbst RS. Introduction: Emerging Role of Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer. Clin Lung Cancer 8(Suppl 2):S50-1, 2/2007.

24. Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 6(2):239-49, 2007.

25. William WN, Kim ES, Herbst RS. Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nat Clin Pract Oncol 6(3):132-3, 3/2009.

26. Tsao AS, Roth JA, Herbst RS. Surgery: Future directions in multimodality therapy for NSCLC. Nat Rev Clin Oncol 7(1):10-2, 1/2010.

27. Politi K, Herbst RS. Lung cancer in the era of precision medicine.Clin Cancer Res. 2015 May 15;21(10):2213-20. CCR-14-2748.

28. Du L, Herbst RS, Morgensztern D. Immunotherapy in Lung Cancer. Hematol Oncol Clin North Am. 2017 Feb;31(1):131-141. PMID: 27912829

29. Morgensztern D, Herbst RS. Evolving Treatment Options for Lung Cancer. Hematol Oncol Clin North Am. 2017 Feb;31(1):xiii-xiv. PMID: 27912837

30. Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations - boosting the anticancer immune response. J Immunother Cancer. 2017 Oct 17;5(1):78. doi: 10.1186/s40425-017-0284-8. Review. PMID: 29037259

Editorials 1. Herbst RS, Fidler IJ. Angiogenesis and lung cancer: potential for therapy. Clin Cancer Res

6:4604-6, 12/2000.

2. Onn A, Tseng JE, Herbst RS. Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy. Clin Cancer Res 7:3311-3, 11/2001.

3. Onn A, Herbst RS. The clinical results of EGFR-targeted therapies: An update and future directions. Signal 3:2-3, 2002.

4. Herbst RS. The year 2002 process of care: An evidence-based approach for the treatment of advanced non-small cell lung cancer: Perfecting patient care. Process of Care, 2003.

5. Onn A, Herbst RS. Molecular targeted therapy for lung cancer. Lancet 366 Comment (9496):1507-8, Oct 29-Nov 4, 2005.

6. Herbst RS, Lippman SM. Molecular Signatures of Lung Cancer -- Toward Personalized Therapy. N Engl J Med 356(1):76-78, 1/2007.

7. Onn A, Herbst RS. Angiogenesis and lung cancer: implications for prognosis and treatment. Lancet Oncol 6(6):460-1, 6/2007.

8. Herbst RS. Commentary in “FLEX trial: first-line cetuximab extends overall survival”. The Oncology Report Fall:83, 2008.

9. Herbst RS, Hirsch FR. Patient selection criteria and the FLEX Study. Lancet 373(9674):1497-8, 5/2009.


Page 41 of 103

10. Altshuler JS, Balogh E, Barker AD, Eck SL, Friend SH, Ginsburg GS, Herbst RS, Nass, SJ, Streeter CM, Wagner JA. Policy: Opening Up to Precompetitive Collaboration. Science Translational Medicine 2(52):cm26, 10/2010.

11. Morgensztern D, Herbst RS. Multitargeted Tyrosine kinase Inhibitors in Unselected Patients with Advanced Non-Smll-Cell Lung Cancer (NSCLC): Impressions From the Motesanib NSCLC Efficacy and Tolerability Study, Journal of Clinical Oncology, Vol. 30, 2012.

12. Goldberg SB, Herbst RS. From the Guest Editors: Progress and Future Directions for the Treatment of Advanced Lung Cancer. Cancer J. 2015 Sep-Oct;21(5):365.

13. Herbst RS, Sznol M. Diminished but not dead: chemotherapy for the treatment of NSCLC. Lancet Oncol. 2016 Nov;17(11):1464-1465. PMID: 27819227

Other Articles 1. Herbst RS, Arquette M, Nabell L, Kies M, Needle M, Waksal HW, Hong WK. Efficacy and safety

of the anti-epidermal growth factor antibody, IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Lung Cancer 34(Suppl 1):S14-15, 2001.

2. Kim E, Mauer A, Fossella F, Kies M, Tran H, Purdom M, Gladish G, Needle M, Vokes E, Herbst R. A phase II study of Erbitux (IMC-C225), an Epidermal Growth Factor Receptor (EGFR) blocking ntibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced Non-Small Cell Lung Cancer (NSCLC). Eur J Cancer 38(Suppl 7):153, 11/2002.

3. Tran HT, Herbst RS, Xiong HQ, Madden T, Mulani N, Faria S, Kim K, Charnsangavej C, O'Reilly M, Abbruzzese JL. Phase I trial of recombinant human endostatin (rHu-endo) administered by continuous infusion (CI) intravenously (IV) in patients with solid tumors: a preliminary report. Eur J Cancer 38(Suppl 7):S73-4, 2002.

4. Mullani N, Lee K, Herbst R, Tran H, Xiong H, Hess K, O'Reilly M, Charnsangavej C, Abbruzzese J. The effect of human recombinant endostatin on blood flow and glucose metabolism in normal tissues. Eur J Cancer 38(Suppl 7):S72, 2002.

5. Herbst RS, Heymach JV. Innovative Medicines for Non-Small Cell Lung Cancer. Foundations of Clinical Cancer Research 5(1):26-7, 1/2007.

Abstracts 1. Boral AL, Skarin AT, Lynch CM, Herbst RS, Berman S, Choi NC, Sugarbaker DJ, Mathisen D,

Lynch TJ. A phase I study of carboplatin (Car) and docetaxel (Doc) followed by weekly Car/Doc with concurrent XRT in patients with stage III NSCLC. Amer Assoc Cancer Res:abstr 1864, 1999.

2. Herbst RS, Khuri FR, Jung M, Fossella FV, Lee JS, Glisson B, Shin DM, Pisters K, Papadimitrakopoulou V, Kurie J, Perez-Soler R, Liu D, Munden R, Hong WK. Phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Proc Amer Soc Clin Oncol 18:462a, 1999.

3. Shin DM, Khuri FR, Glisson BS, Reyes J, Ginsberg L, Papadimitrakopoulou V, Herbst R, Lee JJ, Goepfert H, Lippman SM, Hong WK. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent squamous cell carcinoma of the head and neck. Proc Amer Soc Clin Oncol 18:394a, 1999.

4. Herbst RS, Yano S, Khuri F, Kuniyasu H, Guo F, Bucana C, Liu D, Kemp B, Lee JJ, Lee JS, Hong WK, Fidler IJ. Relative expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Proc Amer Assoc Cancer Res (#1959), 1999.

5. Mullani NA, Herbst RS, Abbruzzese JL, Barron B, Lamki L, Charnsangavej C, Kim E, Tran HT, Jiwani A, Gould KL. First-Pass FDG measured blood flow in tumors: A comparison with 0-15 labeled water measured blood flow. Clin Positron Imaging, 7/2000.


Page 42 of 103

6. DeVore R, Fehrenbacher L, Herbst R, Kabbinivar F, Langer C, Kelley K, Gaudreault J, Holmgren E, Novotny W. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel chemotherapy (CP) to CP alone in patients with stage IIIb/IV NSCLC. Proc Amer Soc Clin Oncol 19:485a, 2000.

7. Mullani NA, Herbst RS, Abbruzzese JL, Charnsangavej C, Kim E, Tran HT, Barron BLamki L, Gould KL. Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors. Clin Positron Imaging:July, 2000.

8. Baselga J, Herbst R, LoRusso P, Rischin D, Ranson M, Plummer R, Raymond E, Maddox A-M, Kaye S, Kieback DG, Harris A, Ochs J. Continuous administration of ZD1839 (IressaTM), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types: Evidence of activity and good tolerability. Proc Amer Soc Clin Oncol 19:177a, 2000.

9. Zinner RG, Fossella FV, Komaki R, Jung M, Jhingran A, Glisson BS, Pisters KM, Stevens CW, Khuri FR, Kurie JM, Lee JS, Herbst RS, Liao Z, Hong WK. Gemcitabine with concurrent 3D conformal radiation followed by consolidation gemcitabine plus cisplatin; a phase I trial for patients with stage III non-small cell lung cancer. Proc Amer Soc Clin Oncol 19:510a, 2000.

10. Herbst RS, Zimmerman O, Roach JS, Kripke ML, Strom SS, El-Naggar K, Fidler IJ, Hong WK, Lippman SM. Matrix metalloproteinase/E-cadherin ratio as a molecular predictor of aggressive phenotype in non-melanoma skin cancer. Proc Amer Assoc Cancer Res 41:386, 2000.

11. Lee JS, Pisters KMW, Komaki R, Terry K, Glisson BS, Perez-Soler R, Fossella FV, Shin DM, Herbst RS, Khuri RR, Kurie JM, Hong WK. Paclitaxel and carboplatin chemotherapy as a primary treatment of brain metastases in patients with non-small cell lung cancer. Proc Amer Soc Clin Oncol 19:501a, 2000.

12. Lu C, Shin DM, Jung M, Lee JS, Herbst R, Glisson B. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Proc Amer Soc Clin Oncol 19:523a, 2000.

13. Khuri FR, Glisson BS, Meyers MI, Herbst RS, Thall PF, Munden RF, Bangert S, Cascino M, Blumenschein G, Pisters K, Hong WK. Phase I study of farnesyl transferase inhibitor SCH66336 with paclitaxel in solid tumors: Dose findings, pharmacokinetics, efficacy/safety. Proc Amer Soc Clin Oncol 19:205a, 2000.

14. Herbst RS, Tran HT, Madden T, Khuri F, Meyers C, Shin D, Puduvalli V, Blumenschein G, Hinton L, Lee JS, Fossella F, Pisters K, Zinner R, Terry K, Guerra M, Daliani D, Logothetis C, Fritsche H, Kudelka A, Valero V, Newman R, Irvine C, Dordal M, Hong WK. Phase I study of the angiogenesis inhibitor TNP-470 in combination with paclitaxel in patients with solid tumors: A dose finding, pharmacokinetic, and efficacy analysis. Proc Amer Soc Clin Oncol 19:182a, 2000.

15. Tseng J, Glisson B, Khuri F, Teddy S, Shin D, Gillenwater A, Myers J, Clayman G, El-Naggar A, Fristche H, Lawhorn K, Thall P, Liu D, Abbruzzese J, Hong WK, Herbst RS. Phase II trial of thalidomide in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Proc Amer Soc Clin Oncol 19:417a, 2000.

16. Herbst RS, Hess KR, Mullani NA, Charnsangavej C, Tran HT, Baker C, Lee AT, Roach JS, Davis D, McConkey DJ, O'Reilly M, Ellis LM, Kim EE, Bucana CD, Pluda JM, Fidler IJ, Hong WK, Abbruzzese JL. A phase I clinical trial of recombinant human endostatin in patients with solid tumors: Surrogate analyses to determine a biologically effective dose. Proc Amer Assoc Cancer Res 42:832, 2001.

17. Blumenschein GR Jr, Fossella FV, Pisters KM, Shin DM, Khuri FR, Lu C, Kies MS, Glisson BS, Zinner RG, Schaerer R, Crane E, Tran H, Dordal M, Hong WK, Herbst RS. A phase I study of continuous infusion of TNP-470 alone or in combination with paclitaxel and carboplatin in adult patients with solid tumors. Proc 2001 AACR-NCI-EORTC International Conference:7, 2001.


Page 43 of 103

18. Papadimitrakopoulou V, Lozada JA, Henderson T, Brito R, McGarry W, Glisson BS, Herbst RS, Zinner RG, Lee JS, Valero V, Hong WK, Khuri FR. A phase II study of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer as front-line and second-line therapy. Proc Amer Soc Clin Oncol 20:259b, 2001.

19. Johnson DH, DeVore R, Kabbinavar F, Herbst R, Holmgren E, Novotny W. Carboplatin + Paclitaxel + RhuMab-VEGF may prolong survival in advanced non-squamous lung cancer. Proc Amer Soc Clin Oncol 20:315a, 2001.

20. Zinner RG, Glisson BS, Pisters KM, Khuri FR, Oh YW, Ro JY, Ordonez NG, El-Naggar AK, Tran HT, Terry K, Hong WK, Herbst RS. Cisplatin and gemcitabine combined with herceptin in patients with HER2 overexpressing, untreated, advanced, non-small cell lung cancer, a phase II trial. Proc Amer Soc Clin Oncol 20:328a, 2001.

21. Herbst RS, Arquette MA, Nabell L, Kies M, Needle MN, Waksal HW, Hong WK. Efficacy and safety of the anti-epidermal growth factor antibody IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Proc 2001 AACR-NCI-EORTC International Conference:113, 2001.

22. Hong W K, Arquette M, Nabell L, Needle M, Waksal HW, Herbst RS. Efficacy and safety of the anti-epidermal growth factor antibody IMC-C225, in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Proc Amer Soc Clin Oncol 20:224a, 2001.

23. Blumenschein GR Jr, Khuri FR, Fossella FV, Lee JS, Glisson B, Shin DM, Liu D, Lu C, Munden R, Lu R, Lee JJ, Hong WK, Herbst RS. Final report of the M. D. Anderson phase II study of combination weekly gemcitabine and vinorelbine in patients with untreated or previously treated non-small cell lung cancer. Proc Amer Soc Clin Oncol 20:344a, 2001.

24. Roach JS, Baker CH, Tran HT, Abbruzzese JL, Fidler IJ, Herbst RS. Induction of apoptosis of human endothelial cells by recombinant endostatin: Development of surrogate assay for clinical studies. Proc Amer Assoc Cancer Res 42:206, 2001.

25. Swisher S, Roth J, Komaki R, Hicks M, Ro J, Hong WK, Ahrar K, Correa A, Dolormente M, Dreiling L, Fang B, Fossella F, Francisco R, Blisson B, Herbst R, Huaringa A, Gu J, Kelly J, Kemp B, Khuri F, Kurie J, Lee J, Lee JS, Liao Z, Merritt J, Morice R, Morello F, Mosheim M, Munden R, Papadimitrakopoulou V, Pisters K, Putnam J, Sarabia A, Shelton T, Stevens C, Shin D, Smythe W, Vaporciyan A, Walsh G, Yin M, Yver A. Induction of pro-apoptotic mediators and tumor regression following intratumoral delivery of adenoviral p53 (RPR/INGN 201) and radiation therapy in patients with non-small cell lung cancer. Proc Amer Soc Clin Oncol 20:257a, 2001.

26. Kim KD, Tsang RZT, Hong WK, Herbst RS. In-vitro, effect of the epidermal growth factor receptor inhibitor PKI 166 on human lung cancer cell lines. Proc Amer Assoc Cancer Res 42:802, 2001.

27. Herbst RS, Tran HT, Mullani NA, Charnsangavej C, Madden TL, Hess KR, Davis D, McConkey DJ, Baker CH, O'Reilly M, Ellis LM, Kim E, Bucana CD, Lee AT, Roach J, Terry K, Gravel D, Dourado J, Pluda JM, Fidler IJ, Hong WK, Abbruzzese JL. Phase I clinical trial of recombinant human endostatin in patients with solid tumors: Pharmacokinetic, safety and efficacy analysis using surrogate endpoints of tissue and radiologic response. Proc Amer Soc Clin Oncol 20:3a, 2001.

28. Herbst RS, Thornton DE, Sinha V, Flanagan S, Cassidy C, Teicher B, Carducci MA. Phase I dose escalation and pharmacokinetic study of single-agent protein kinase C beta inhibitor, LY317615. Proc 2001 AACR-NCI-EORTC International Conference:6, 2001.

29. Tran HT, Blumenschein GR Jr, Madden TL, Shin DM, Khuri FR, Fossella FV, Papadimitrakopoulou V, Dordal M, Hong WK, Herbst RS. Phase I study of the angiogenesis inhibitor TNP-470 in combination with paclitaxel and carboplatin in patients with solid tumors. Proc Amer Soc Clin Oncol 20:99a, 2001.


Page 44 of 103

30. Schiller JH, Hammond LA, Carbone DP, Hong WK, Holroyd K, Rowinsky EK, Herbst RS. Phase IIa trial of squalamine for treatment of advanced non-small cell lung cancer. Proc Amer Soc Clin Oncol 20:339a, 2001.

31. Davis DW, Mullani N, Hess KR, Tseng J, O'Reilly M, Herbst RS, Abbruzzese JL, McConkey DJ. Quantitative analysis of tumor vascular targeting: Effects of endostatin in a phase I clinical trial. Proc 2001 AACR-NCI-EORTC International Conference:59, 2001.

32. Fogler W, Song M, Supko J, Eder J, Kufe D, Tran H, Madden T, Herbst R, Abbruzzese J, Tutsch K, Thomas J, Wilding G, Pluda J, Gubish E. Recombinant human endostatin demonstrates consistent and predictable pharmacokinetics following intravenous bolus administration to cancer patients. Proc Amer Soc Clin Oncol 20:69a, 2001.

33. Kim E, Mauer A, Fossella F, Kies M, Tran H, Purdom M, Gladish G, Needle M, Vokes E, Herbst R. A phase II study of erbitux (IMC-C225), an epidermal growth factor receptor blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. 14th EORTC-NCI-AACR Symposium:abstract 510a, 11/2002.

34. Tran HT, Herbst RS, Xiong HQ, Madden T, Mulani N, Faria S, Kim K, Charnsangavej C, O'Reilly M, Abbruzzese JL. Phase I trial of recombinant human endostatin administered by continuous infusion intravenously in patients with solid tumors: A preliminary report. 14th EORTC-NCI-AACR Symposium:abstract 230, 11/2002.

35. Mullani N, Lee K, Herbst R, Tran H, Xiong H, Hess K, O'Reilly M, Charnsangavej C, Abbruzzese J. The effect of human recombinant endostatin on blood flow and glucose metabolism in normal tissues. 14th EORTC-NCI-AACR Symposium:abstract 226, 11/2002.

36. Blumenschein GR, Fossella FV, Pisters KMW, Khuri FR, Lu C, Kies MS, Glisson BS, Zinner R, Crane E, Schaerer R, Dordal M, Goodin T, Hong WK, Herbst RS. A phase I study of TNP-470 continuous infusion alone or in combination with paclitaxel and carboplatin in adult patients with NSCLC and other solid tumors. Proc Amer Soc Clin Oncol 21:314a, 2002.

37. Kim ES, Mauer AM, Fossella FV, Jamison TA, Kies MS, Pisters KM, Glisson BS, Blumenschein GR, Zinner RG, Tran HT, Windt P, Liu D, Khuri F, Dicke K, Needle M, Vokes EE, Hong WK, Herbst RS. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer. Proc Amer Soc Clin Oncol 21:293a, 2002.

38. Lu C, Kies MS, Glisson BS, Khuri FR, Shin DM, Hong WK, Dinney CP, Talpaz M, Gillenwater AM, Zentgraf RE, Ginsberg LE, Herbst RS. A phase II study of SCH54031 (polyethylene glycol (PEG-modified interferon alfa-2b; PEG intron) in previously treated advanced squamous cell cancers of the head and neck. Proc Amer Soc Clin Oncol 21:240a, 2002.

39. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis C, Albain KS, Brahmer JR, Sandler A, Crawford J, Lutzker SG, Lilenbaum R, Helms L, Wolf M, Averbuch S, Ochs J, Kay A. A phase II trial of ZD1939 ('Iressa') in advanced non-small cell lung cancer patients who had failed platinum- and docetaxel-based regimens (IDEAL2). Proc Amer Soc Clin Oncol 21:292a, 2002.

40. Massarelli E, Andre F, Liu DD, Lee J, Fandi A, Ochs J, Le Chevalier T, Fossella FV, Herbst RS. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including a platin and docetaxel for recurrent non-small cell lung cancer. Proc Amer Soc Clin Oncol 21:331a, 2002.

41. Onn A, Killion JJ, O'Reilly M, Corazon DB, Hong WK, Fidler IJ, Herbst RS. Development of an orthotopic model for human lung cancer to evaluate therapeutic efficacy of receptor tyrosine kinase inhibitors. Proc Amer Assoc Cancer Res 43:785, 2002.

42. Kies MS, Arquette MA, Nabell L, Quinn D, Shin D, Needle MN, Waksal H, Hong WK, Herbst RS. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-


Page 45 of 103

C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck refractory to cisplatin containing chemotherapy. Proc Amer Soc Clin Oncol 21:232a, 2002.

43. Tran, HT, Herbst RS, Glisson BS, Pisters KM, Khuri FR, Oh YW, Ordonez NG, Lee P, El-Naggar AK, Hong WK, Zinner RG. Herceptin in combination with cisplatin and gemcitabine in patients with HER2 overexpressing, untreated, advanced, non-small-cell lung cancer: final report of a phase II trial. Proc Amer Soc Clin Oncol 21:307a, 2002.

44. Herbst RS, Thornton DE, Kies MS, Sinha V, Flanagan S, Cassidy CA, Carducci MA. Phase I study of LY317615, a protein kinase Cb inhibitor. Proc Amer Soc Clin Oncol 21:82a, 2002.

45. Khuri F, Gillenwater A, Diaz E, Lewin J, Shin D, Glisson BS, Herbst RS, Steinhaus G, Altamirano E, Taylor S, Clayman G, Myers J, Papadimitrakopoulou V, Lippman S, Garden AS, Hong WK, Geopfert H. Pilot trial of paclitaxel, ifosfamide and cisplatin as induction or exclusive therapy for intermediate to advanced laryngeal cancer. Proc Amer Soc Clin Oncol 21:227a, 2002.

46. Langmuir VK, Cobleigh MA, Herbst RS, Holmgren E, Hurwitz H, Kabbinavar F, Miller K, Novotny W. Successful long-term therapy with bevacizumab (Avastin) in solid tumors. Proc Amer Soc Clin Oncol 21:9a, 2002.

47. Pentz RD, Flamm AL, Sugarman J, Cohen MZ, Herbst RS, Abbruzzese J. The media and potential participants' perception of a phase I trial. Proc Amer Soc Clin Oncol 21:374a, 2002.

48. Xiong HQ, Herbst RS, Faria S, Davis D, Scholz C, Jackson E, Madden T, McConkey D, Hicks M, Hess K, Charnsangavej C, Abbruzzese J. A phase I surrogate endpoint trial of SU6668 in patients with solid tumors. Proc Amer Assoc Cancer Res 44:1224, 2003.

49. Kim ES, Mauer AM, Tran HT, Liu D, Gladish G, Dicke K, Needle MN, Vokes EE, Hong WK, Herbst RS. A phase II study of cetuximab, an epidermal growth factor receptor blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report. Proc Amer Soc Clin Oncol 22:642, 2003.

50. Lu C, Komaki R, Herbst RS, Evans WK, Smith TL, Moore CA, Kolbye SL, Choi NC, Choy H, Bleyer A. A phase III study of Æ-941 with induction chemotherapy and concomitant chemoradiotherapy for stage III non-small cell lung cancer (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim overall toxicity report. Proc Amer Soc Clin Oncol 22:663, 2003.

51. Zinner R, Obasaju CK, Fossella FV, Papadimitrakopoulou VA, Pisters KMW, O'Day MR, Peeples BO, Hatfield AK, Hong WK, Herbst RS. Alimta plus carboplatin in patients with advanced non-small cell lung cancer: A phase II trial. Proc Amer Soc Clin Oncol 22:642, 2003.

52. Onn A, Isobe T, Roach JS, Wu W, Bucana CD, O'Reilly MS, Fidler IJ, Herbst RS. Blockade of EGFR tyrosine kinase does not predict outcome in an orthotopic model of human lung cancer. Proc Amer Assoc Cancer Res 44:1076, 2003.

53. Itasaka S, Komaki R, Herbst RS, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'Reilly MS. Endostatin blocks endothelial repopulation after radiation therapy. Proc Amer Assoc Cancer Res 44:26, 2003.

54. Onn A, Correa AM, Gilcrease M, Moran C, Roach JS, Isobe T, Bucana CD, Hong WK, Putnam JB, Herbst RS. Epidermal growth factor receptor, HER2, and C-KIT as predictors of outcome in stage I non-small cell lung cancer. Proc Amer Soc Clin Oncol 22:635, 2003.

55. Erasmus JJ, Gladish GW, Broemeling LD, Sabloff BS, Truong MT, Herbst RS, Munden RF. Inter-observer and intra-observer variability in measurement of 41 non-small cell carcinoma lung lesions: Implications for assessment of tumor response. Proc Amer Soc Clin Oncol 22:653, 2003.

56. Mininberg ED, Herbst RS, Henderson T, Kim E, Hong WK, Mass R, Novotny W, Garcia B, Johnson D, Sandler A. Phase I/II study of the recombinant humanized monoclonal anti-VEGF


Page 46 of 103

antibody bevacizumab (Avastin™) and the EGFR-tk inhibitor erlotinib (Tarceva™) in patients with recurrent non-small cell lung cancer. Proc Amer Soc Clin Oncol 22:627, 2003.

57. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese, JL, Mcconkey DJ. Quantitative analysis of biomarkers and changes in tumor blood flow define a biological dose for clinical trials of recombinant human endostatin. Proc Amer Assoc Cancer Res 44:678, 2003.

58. Davis DW, Xiong HQ, Stadler W, Herbst RS, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers in tumor biopsies from phase I/II studies with VEGF receptor tyrosine kinase inhibitors. Proc Amer Assoc Cancer Res 44:920, 2003.

59. Herbst RS, Giaccone G, Schiller J, Miller V, Natale R, Rennie P, Ochs J, Fandi A, Grous J, Johnson D. Subset analyses of INTACT results for gefitinib ('Iressa', ZD1839) when combined with platinum-based chemotherapy for advanced non-small cell lung cancer. Proc Amer Soc Clin Oncol 22:627, 2003.

60. Isobe T, Onn A, Wu W, Shintani T, Itasaka S, Shibuya K, Hong WK, O'Reilly MS, Herbst RS. Biology and therapy of human small cell lung cancer in novel orthotopic nude mouse models. Poster Presentation. Proc Amer Assoc Cancer Res 45:1185 (#5136), 3/2004.

61. Shintani T, Komaki R, Itasaka S, Isobe T, Shibuya K, Wu W, Herbst RS, O'Reilly. Clinical tumor dormancy: Biology and regulation of dormant lung metastases in a characterization of the dormant tumor; B16F10 murine melanoma model. 95th AACR Annual Meeting:abstr 4932, 3/2004.

62. Wu W, Isobe T, Itasaka S, Shintani T, Langley RR, Onn A, Hansen JC, O'Reilly MS, Herbst RS. ZD6474, a small molecule targeting VEGF and EGF receptor signaling, inhibits lung angiogenesis and metastasis and improves survival in an orthotopic model of non-small cell lung cancer. 95th AACR Annual Meeting (#4551), 3/2004.

63. Koshy S, Herbst RS, Obasaju CK, Fossella F, Papadimitrakopoulou V, Pisters KMW, Blumenschein G, Peeples BO, Hong WK, Zinner RG. A phase II trial of pemetrexed plus carboplatin in patients with advanced non-small-cell lung cancer. Proc Amer Soc Clin Oncol 23:631, 2004.

64. Herbst RS, Kurzrock R, Parson M, Benjamin R, Chen L, Ng C, Ingram M, Wong S, Chang D, Rosen L. AMG 706 first inhuman, open-label, dose-finding study evaluating the safety and pharmacokinetics in subjects with advanced solid tumors. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics:abstr 151, 2004.

65. Wu W, Shintani T, O'Reilly MS, Herbst RS. Blocking VEGF and EGF receptor signaling with ZD6474 sensitizes human non-small cell lung cancer to chemotherapy with paclitaxel. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics September 28 - October 1, 2004.

66. Rugo H, Herbst RS, Liu G, Park JW, Kies M, Pithavala YK, McShane TM, Steinfeldt HM, Reich SD, Wilding G. Clinical and dynamic imaging results of the first phase I study of AG - 013736, an oral anti-angiogenesis agent, in patients with advanced solid tumors. Proc Amer Soc Clin Oncol 23:163, 2004.

67. Herbst RS, Johnson D, Blumenschein G, Henderson T, Lee J, Truong M, Mass R, Kim E, Garcia B, Sandler AB. Erlotinib in combination with bevacizumab for patients with recurrent non-small-cell lung cancer: A phase I/II trial. 29th European Society for Medical Oncology (ESMO) Congress 2004:abstr 641PD, 2004.

68. Janas M, Bailey LR, Schmidt K, Bindslev N, Wolf M, Fandi A, Askaa J, Herbst R, Giaccone G, Johnson DH. Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment. Proc Amer Soc Clin Oncol 23:619, 2004.

69. Bailey LR, Janas M, Schmidt K, Bindslev N, Wolf M, Grous J, Askaa J, Herbst R, Johnson DH, Giaccone G. Evaluation of epidermal growth factor receptor as a predictive marker in patients


Page 47 of 103

with non-small-cell lung cancer receiving first-line gefitinib combined with platinum-based chemotherapy. Proc Amer Soc Clin Oncol 23:618, 2004.

70. Gaspar LE, Gay GE, Crawford J, Putnam JB, Herbst RS, Bonner JA. Limited small cell lung cancer (stages I-III): Observations from the National Cancer Database. Proc Amer Soc Clin Oncol 23:619, 2004.

71. Miller VA, Herbst R, Prager D, Fehrenbacher L, Hermann R, Hoffman P, Johnson B, Sandler AB, Kris MG, Ramies D. Long survival of never smoking non-small cell lung cancer patients treated with erlotinib HCl (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. Proc Amer Soc Clin Oncol 23:628, 2004.

72. Davis DW, Xiong HQ, Herbst RS, Abbruzzese JL, Heymach JV, Demetri GD, Stadler W, McConkey DJ. Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668. 95th AACR Annual Meeting:abstr 3988, 2004.

73. Tran HT, Zinner R, Blumenschein GR Jr, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum B, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced non-small cell lung cancer. Proc Amer Soc Clin Oncol 23:139, 2004.

74. Sandler AB, Blumenschein G, Henderson T, Lee J, Truong M, Mass R, Kim E, Garcia B, Johnson D, Herbst RS. Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. Proc Amer Soc Clin Oncol 23:127, 2004.

75. Herbst RS, Prager D, Hermann R, Miller V, Fehrenbacher L, Hoffman P, Johnson B, Sandler A, JohnsoFn DH. TRIBUTE - A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. Proc Amer Soc Clin Oncol 23:617, 2004.

76. Heymach JV, Dong RP, Dimery I, Lu C, Wheeler C, Johnson B, Herbst R. ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCSL: Results of the run-in phase of a two-part, randomized phase II study. Proc Amer Soc Clin Oncol 23:207, 2004.

77. Lu C, Komaki R, Herbst RS, Evans WK, Lee JJ, Truong M, Moore CA, Choy H, Bleyer A, Fisch MJ. A phase III study Of Æ941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An interim report of toxicity and response. Proc Amer Soc Clin Oncol 23:656s, 2005.

78. Blumenschein GR, Khuri F, Gatzemeier U, Miller WH, von Pawel J, Rigas JR, Herbst RS, Dziewanowska Z, Negro-Vilar A, Mabry M, SPIRIT II Lung Cancer Study Group. A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer. Proc Amer Soc Clin Oncol 23:621s, 2005.

79. Heymach JV, Johnson BE, Rowbottom JA, Fidias P, Lu C, Prager D, Roubec J, Csada E, Dimery I, Herbst RS. A randomized, placebo-controlled Phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. Proc Amer Soc Clin Oncol 23(16S):197s, 2005.

80. Koshy S, Fossella F, Liu D, Schaerer R, Tsao A, Kies M, Pisters K, Lee J, Herbst R, Zinner R. Asian ethnicity as a predictor of response to gefitinib in non-small cell lung cancer. Lung Cancer 49:S254, 2005.

81. Shibuya K, Komaki R, Shintani T, Wu W, Itasaka S, Isobe T, Ryan AJ, Herbst RS, O'Reilly MS. Combined blockade of VEGFR and EGFR with ZD6474 enhances the antitumor and antivascular effects of radiation therapy in an orthotopic mouse model of human lung cancer. Proc Amer Assoc Cancer Res 46:1371, 2005.


Page 48 of 103

82. Reiling RB, Natale R, Wade J, Herbst R, Hensing T, Belani CP, Kelly K, Ochs J, Govindan R, Wozniak A, Krebs A. Efficacy and safety of gefitinib in chemo-naive Patients with non-small cell lung cancer in an expanded access program. Proc Amer Soc Clin Oncol 23:643s, 2005.

83. Herbst R, Davies A, Johnson B, Natale R, Dang T, Murren J, Schiller J, Garland L, Miller V, Mendelson J, Melenevsky Y, Devries S, Van Den Abbeele A, Eberhard D, Lyons B, Lutzker S. Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in non-small cell lung cancer patients after prior chemotherapy. Lung Cancer 49:S62, 2005.

84. Zinner RG, Lu C, Ji Y, Clarke C, Ando M, Altundag O, Tsavachidis S, Herbst RS, Fung ET, Wu X, Al-Zein R, Spitz MR, Lang W, Coombes KR, Mao L. Identification of serum protein markers to predict outcome of platin-based chemotherapy in patients with advanced non-small cell lung cancer. Proc Amer Assoc Cancer Res 46:855, 2005.

85. Gaspar L, Gay G, Crawford J, Putnam J, Herbst R, Bonner J. Limited small cell lung cancer - observations from the National Cancer Database on the impact of age, gender and treatment on survival. Lung Cancer 49:S319, 2005.

86. Salmon JS, Sandler A, Billheimer D, Herbst RS, Tran HT, Tsao A, Dang TP. MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer. Proc Amer Soc Clin Oncol 23(16S):626s, 2005.

87. Eberhard D, Johnson B, Goddard A, Herbst R, Janne P, Johnson D, Klein P, Ostland M, Seshagiri S, Hillan K. Mutations in EGFR, HER2, KRAS and BRAF in NSCLC: Prevalences and correlations with clinical outcomes in patients treated with carboplatin and paclitaxel with or without erlotinib. Lung Cancer 49:S62, 2005.

88. Komaki R, Allen P, Roth J, Swisher S, Rice D, Fossella F, Herbst R, Oh Y, Munden R, Cox J. Optimal treatment for superior sulcus tumors (SST): Surgery first followed by adjunct RT/ChT improved survival for patients with resectable SST. Lung Cancer 49:S79, 2005.

89. Zinner R, Kortsik C, Dark G, Price A, Manegold C, Rosell R, Paz-Ares L, Herbst R, Crino L, Scagliotti G. Pemetrexed plus carboplatin as 1st treatment for patients with locally advanced or metastatic non-small-cell lung cancer: Results of both a multi-center European and an MD Anderson Cancer Center phase II trials. Lung Cancer 49:S91, 2005.

90. Tsao AS, Herbst R, Sandler A, Seshagiri S, Wistuba I, Henderson T, Ramies D, Goddard A, Johnson D, Eberhard D. Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene. Proc Amer Soc Clin Oncol 23(16S):643s, 2005.

91. Johnson BE, Ma P, West H, Kerr R, Prager D, Sandler A, Herbst RS, Stewart DJ, Dimery IW, Heymach JV. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st line treatment in patients with NSCLC. Proc Amer Soc Clin Oncol 23(16S):645s, 2005.

92. Rosen L, Kurzrock R, Jackson E, Wathen L, Parson M, Eschenberg M, Mulay M, Purdom M, Yan L, Herbst RS. Safety & pharmacokinetics of AMG706 in patients with advanced solid tumors. Proc Amer Soc Clin Oncol 23:195s, 2005.

93. Wu W, Langley R, Baker CH, O'Reilly MS, Fidler IJ, Herbst RS. The anti-vascular and anti-tumor response of human lung cancer growing orthotopically in mice to AEE788, a tyrosine kinase inhibitor of EGFR and VEGFR, is dependent upon EGF/TGFa expression. Proc Amer Assoc Cancer Res 46:713, 2005.

94. Onn A, Herbst R, Massarelli E, Wistuba I, Bekele B, Vaporciyan A, O'Reilly M, Zinner R. The level of EGFR phosphorylation in NSCLC core biopsies from in situ tumor prior to vessel ligation may be more accurate than tissue obtained immediately after lobectomy. Lung Cancer 49:S375, 2005.

95. Massarelli E, Onn A, Herbst RS, Wistuba II, Bucana CD, Bekele BN, Vaporciyan AA, O'Reilly MS, Zinner RG. The time of tissue processing for human surgical specimens influences the


Page 49 of 103

level of epidermal growth factor receptor phosphorylation. Proc Amer Assoc Cancer Res 46:100, 2005.

96. Heymach J, West H, Kerr R, Prager D, Sandler A, Herbst R, Stewart D, Dimery I, Johnson B. ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: Results of the run-in phase of a two-part randomized phase II study. Lung Cancer 49:S247, 2005.

97. Shintani T, Lewis VO, Komaki R, Wu W, Ryan AJ, Herbst RS, O'Reilly MS. ZD6474 inhibits human lung cancer bone metastases in a murine model by targeting both the tumor and its vasculature. Proc Amer Assoc Cancer Res 46:1375, 2005.

98. Herbst R, Johnson B, Rowbottom J, Fidias P, Lu C, Prager D, Roubec J, Csada E, Dimery I, Heymach J. ZD6474 plus docetaxel in patients with previously treated NSCLC: Results of a randomized, placebo-controlled phase II trial. Lung Cancer 49:S35, 2005.

99. Aggarwal S, Ryu S-H, Menter DG, Herbst RS, Hong W-K, Lippman SM, Koo JS. Targeting protein kinase C beta enhances cell death of non-small cell lung cancer cells. Proc Fifth AACR International Conference on Frontiers in Cancer Prevention Research (#A127), 11/2006.

100. Herbst RS, Mendolson DS, Ebbinghaus S, Gordon MS, O'Dwyer P, Lieberman G, Ing J, Kurzrock R, Novotny W, Eckhardt G. A phase I safety and pharmacokinetic (PK) study of recombinant Apo 2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol (2006 ASCO Annual Meeting Proceedings) 24(18s) (Suppl, abstr 3013), Clinical Science Symposium:124s, 2006.

101. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spasova I, Hou J, Kennedy S, Herbst RS. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow up results. J Clin Oncol 18:368s (#7016 ASCO Annual Meeting Oral Presentation), 24, 2006.

102. Fehrenbacher L, O'Neill V, Belani CP, Bonomi P, Hart L, Melnyk O, Sandler A, Ramies D, Herbst RS. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol (2006 ASCO Annual Meeting Proceedings) 24(18s) (Suppl, abstr 7062), Poster Discussion:379s, 2006.

103. Ling J, Herbst RS, Mendelson DS, Eckhardt SG, O'Dwyer P, Ebbinghaus S, Osborne R, Cheu M, Lieberman G, Lum BL. Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. J Clinic Oncol (2006 ASCO Annual Meeting Proceedings) 24(18s) (Suppl, abstr 3047), Poster Discussion:132s, 2006.

104. Kelly K, Herbst RS, Crowley JJ, McCoy J, Atkins JN, Lara Jr PN, Dakhil SR, Albain KS, Kim ES, Gandara DR. Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): A randomized phase II selectional trial SWOG 0342. J Clin Oncol (2006 ASCO Annual Meeting Proceedings) 24(18s) (Suppl, abstr 7015), Oral Presentation, 2006.

105. Miller VA, Zakowski M, Riely GJ, Pao W, Ladanyi M, Tsao AS, Sandler A, Herbst R, Kris MG, Johnson DH. EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell caricinoma (BAC): Results of a prospective phase II trials. J Clin Oncol (2006 ASCO Annual Meeting Proceedings) 24(18s) (Suppl, abstr 7003), Clinical Science Symposium:364s, 2006.

106. Gandara DR, Yoneda K, Shelton D, Beckett LA, Ramies DA, Bloss J, Herbst RS. Independent review of fatal interstitial lung disease (ILD) in TRIBUTE: paclitaxel + carboplatin + erlotinib in advanced non-small cell lung cancer (NSCLC). J Clin Oncol (2006 ASCO Annual Meeting Proceedings) 24(18s) (Suppl, abstr 7071), Poster Discussion:381s, 2006.


Page 50 of 103

107. Garey JS, Burke BJ, Herbst RS, Kim ES. Managing cutaneous side effects associated with erlotinib in head and neck cancer (HNC) and non-mall cell lung cancer (NSCLC) patients (pts). J Clin Oncol (2006 ASCO Annual Meeting Proceedings) 24(18s) (Suppl, abstr 18538):691s, 2006.

108. Boughton D, Rosen L, Van Vugt A, Kurzrock R, Eschenberg M, Wiezorek J, Ingram M, Wang D, Stepan D, Herbst RS. Safety and antitumor activity of AMG 706 in patients (pts) with thyroid cancer (TC): A subset analysis from a phase 1 dose-finding study. J Clin Oncol (2006 ASCO Annual Meeting Proceedings) 24(18s) (Suppl, abstr 3030), Poster Discussion:128s, 2006.

109. Blumenschein Jr G, Sandler A, O'Rourke T, Eschenberg M, Sun Y, Gladish G, Salgia R, Alden C, Herbst RS, Reckamp K. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC) (General Poster Session). J Clin Oncol, 2006 ASCO Annual Meeting 24(18s):393s (#7119), 2006.

110. Massarelli E, Zhou X, Ozburn NC, Wislez M, Bekele BN, Roth JA, O'Reilly M, Hong WK, Kurie JM, Herbst RS, Wituba II. TGF-α and phosphorylated EGFR protein levels impact the survival of patients with stage I-IIIA non small cell lung cancer. Proc Amer Assoc Cancer Res 47:1348 (#5729), 2006.

111. Lu C, Lee JJ, Komaki R, Herbst RS, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong M, Fisch MJ. A phase III study of -Æ941 with induction chemotherapy (IC) and concomitant chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303). ASCO 43rd Annual Meeting, Chicago, IL, June 2007 Poster Discussion (#7527), 2/2007.

112. Massarelli E, Prudkin Silva L, Ozburn N, Feng L, Yin G, O'Reilly M, Hong W, Herbst RS, Wistuba I. Correlation between VEGF/VEGFR2 and EGFR immunohistochemical protein expression in early stage non-small cell lung cancer. Proc Amer Assoc Cancer Res Poster Presentation (#5029), 4/2007.

113. Furutani K, Komaki R, Imagumbai T, Onn A, Jacoby J, Massarelli E, Korshunova M, Ryan A, Jurgensmeier J, Herbst RS, O'Reilly M. Targeted therapy against VEGFR-1, -2, and -3 by AZD2171 blocks tumor growth and angiogenesis, and enhances paclitaxel efficacy in an orthotopic lung cancer model. Proc Amer Assoc Cancer Res Poster Presentation (#2121), 4/2007.

114. Zhou S, Kim ES, Herbst RS, S. Liu S, Wistuba II, Mao L, Lewis J, Lippman SM, Hong WK, Lee JJ. A clinical trial design applying Bayesian adaptive randomization for targeted therapy development in lung cancer: A step toward personalized medicine. ASCO 43rd Annual Meeting, Chicago, IL General Poster Session (#7697), 6/2007.

115. Camidge D, Herbst RS, Gordon M, Eckhardt S, Kurzroc R, Durbin B, Ing J , Ling J, Sager J, Mendelson D. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. J Clin Oncol, 2007 ASCO Annual Meeting 25(18S) (#3582), 6/2007.

116. Herbst RS, Chansky K, Kelly K, Atkins JN, Davies AM, Dakhil SR, Albain KS, Kim ES, Crowley JJ, Gandara DR. A phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC): Final report of SWOG 0342. J Clin Oncol 25(18S) (#7545 ASCO Annual Meeting), 6/2007.

117. Bepler G, Oh Y, Burris H, Cleverly A, Lahn M, Herbst RS. A phase II study of enzastaurin as second- or third-line treatment of non-small lung cancer (NSCLC). J Clin Oncol 25(18S) (#7543), 6/2007.

118. Zinner R, Fossella FV, Kies MS, Herbst RS, Lu C, Johnson FM, Bhat SV, Price JS, Cleeland C, Wang X. A phase II trial of pemetrexed (P) in patients (pts) with performance status (PS) 2 and 3 as first- and second-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2007 ASCO Annual Meeting 25(18S) (#18149), 6/2007.


Page 51 of 103

119. Pan Y, Xu R, Peach M, Huang C, Branstetter D, Durbin B, Herbst RS, Eckhardt G, Mendelson D, Holland P. Application of pharmacodynamic assays in a phase Ia trial of Apo2L/TRAIL in patients with advanced tumors. J Clin Oncol 25(18S) (#3535 ASCO Annual Meeting), 6/2007.

120. Onn A, Martinez CH, Herbst RS, Riddle JR, Blumenschein GR, Jr, Stewart DJ, Marom EM. Clinical implications of tumor cavitation following therapy with angiogenesis inhibitors in non-small cell lung cancer (NSCLC) patients. J Clin Oncol, 2007 ASCO Annual Meeting 25(18S) (#18034), 6/2007.

121. Herbst RS. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). ASCO 43rd Annual Meeting, Chicago, IL, June 2007 Poster Discussion, 6/2007.

122. Kies MS, Ghebremichael MS, Katz TL, Herbst RS, Youssoufian H, Burtness B. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol, 2007 ASCO Annual Meeting 25(18S) (#6024), 6/2007.

123. Rosen LS, Hong D, Chap L, Kurzrock R, Garcia A, Rasmussen E, Nguyen L, Hwang Y, Storgard C, Herbst RS. First-in-human study of AMG 386, a selective angiopoietin ½-neutralizing peptibody, in adult patients with advanced solid tumors. ASCO 43rd Annual Meeting, Chicago, IL (#3522), 6/2007.

124. LoRusso P, Hong D, E. Heath, Kurzrock R, Wang D, Hsu M, Goyal L, Wiezorek J, Storgard C, Herbst R. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol, 2007 ASCO Annual Meeting 25(18S) (#3534), 6/2007.

125. William WN, Jr, Kies MS, Fossella FV, Gladish G, Heymach JV, Glisson BS, Tse WH, Liu D, Herbst RS, Lippman SM. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). J Clin Oncol, 2007 ASCO Annual Meeting 25(18S) (#18098), 6/2007.

126. Massarelli E, Miller VA, Leighl NB, Rosen PJ, Albain KS, Hart LL, Melnyk O, Sternas L, Ackerman J, Herbst RS. Phase II study of the efficacy and safety of intravenous (IV) AVE0005 (VEGF Trap) given every 2 weeks in patients (Pts) with platinum-and erlotinib- resistant adenocarcinoma of the lung (NSCLA). ASCO 43rd Annual Meeting, Chicago, IL General Poster Session (#7627), 6/2007.

127. Heymach J, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt W, Herbst RS, Krebs A, Langmuir P, Johnson BE. Randomized phase II study of Vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO 43rd Annual Meeting, Chicago, IL Poster Discussion (#7544), 6/2007.

128. Craft B S, Kurzrock R, Herbst R, Culotta K, Stewart C, Dorsey V, Lippman S, Gingher D, Bekele N, Karp D. The changing face of phase I protocols: A closer look at study requirements. J Clin Oncol, 2007 ASCO Annual Meeting 25(18s) (#3061), 6/2007.

129. Albain KS, Unger J, Gotay CC, Davies AM, Edleman M, Herbst RS, Kelly K, Williamson S, Wozniak AJ, Gandara DR, for the Southwest Oncology Group Lung Committee. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. ASCO 43rd Annual Meeting, Chicago, IL Poster Discussion (#7549), 6/2007.

130. Hanrahan E, Prudkin L, Lin HY, Behrens C, Massarelli E, Herynk M, Du D, Wislez M, Kurie J, Herbst RS, Lee JJ, Wistuba I, Heymach J. Angiogenesis in non-small cell lung cancer (NSCLC): Gender differences in tumor and circulating angiogenic factors. Proc Amer Assoc Cancer Res Poster Presentation (#A24), 10/2007.


Page 52 of 103

131. Herbst RS, Furutani K, Komaki R, Kuwai T, Isobe T, Korshunova M, Erez B, Ryan A, Jurgensmeier J, O'Reilly M. Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of irinotecan in orthotopic human small cell lung cancer models. Proc Amer Assoc Cancer Res Poster Presentation (#A26), 10/2007.

132. Furutani K, Komaki R, Kuwai T, Jacoby J, Korshunova M, Erez B, Ryan A, Jurgensmeier J, Herbst RS, O'Reilly M. Cediranib, an orally available and highly potent VEGFR signaling inhibitor, inhibits angiogenesis and progression and enhances the effects of paclitaxel in orthotopic human lung adenocarcinoma models. Proc Amer Assoc Cancer Res Poster Presentation (#A25), 10/2007.

133. Jacoby J, Erez B, Furutani K, Korshunova M, Kirkpatrick L, Lippman S, Powis G, O`Reilly M, Herbst RS. HIF1-α antagonism by PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. Proc Amer Assoc Cancer Res Poster Presentation (#1440), 4/2008.

134. Furutani K, Komaki R, Korshunova M, Ryan A, Jurgensmeier J, Herbst RS, Oreilly M. Targeted therapy against VEGFR tyrosine kinase signaling by vandetanib inhibits tumor growth, angiogenesis, and progression in orthotopic human small cell lung cancer models. Proc Amer Assoc Cancer Res Poster Presentation (#2495), 4/2008.

135. Heymach JV, Hanrahan EO, Mann H, Langmuir P, Natale RB, Johnson BE, Herbst RS, Ryan AJ. Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC. J Clin Oncol, 2008 ASCO Annual Meeting 26(15S) (#8009), 5/2008.

136. Infante JR, Spratlin JL, Kurzrock R, Eckhardt SG, Burris HA, III, Puchalski TA, Li J, Wu K, Ochs J, Herbst RS. Clinical, pharmacokinetic (PK), pharmacodynamic findings in a phase I trial of weekly (wkly) intravenous AZD4877 in patients with refractory solid tumors. J Clin Oncol, 2008 ASCO Annual Meeting 26(15S) (#2501), 5/2008.

137. Peng G, Zinner RG, Wang Y, Treat J, Monberg M, Obasaju CK, Herbst RS, Novello S, Scagliotti GV. Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials. J Clin Oncol, 2008 ASCO Annual Meeting 26(15S) (#8096), 5/2008.

138. Tran HT, Kim ES, Lee JJ, Herbst RS, Liu S, Wistuba II, Yan S, Mao L, Hong WK, Heymach JV. Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study. J Clin Oncol, 2008 ASCO Annual Meeting 26(15S) (#8010), 5/2008.

139. Oh Y, Wallace S, Taylor S, Herbst RS, Lippman SM, Karp DD, Stewart DJ. Minimally increased risk of cerebrovascular occlusive disease or intracerebral hemorrhage in patients on bevacizumab treatment and association with intracerebral malignancies. J Clin Oncol, 2008 ASCO Annual Meeting 26(15S) (#14507), 5/2008.

140. Bahleda R, Felip E, Herbst RS, Hanna NH, Laurie SA, Shepherd FA, Armand JP, Sweeney CJ, Calvo-Aller E, Soria JC. Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. J Clin Oncol, 2008 ASCO Annual Meeting 26(15S) (#2564), 5/2008.

141. Xin Y, Tohnya TM, Herbst RS, Mendelson DS, Eckhardt SG, O'Dwyer PJ, Novotny W, Allison DE, Lum BL, Jumbe N. Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a Phase 1a Study in advanced cancer and lymphoma. J Clin Oncol, 2008 ASCO Annual Meeting 26(15S) (#2525), 5/2008.

142. Dang TP, Salmon JS, Chen H, Chen S, Lee JW, Sandler AB, Herbst RS, Brahmer J, Carbone DP, Shyr Y. Predictive value of serum MALDI-TOF proteomic profiling from patients treated with


Page 53 of 103

erlotinib and bevacizumab for survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib alone. J Clin Oncol, 2008 ASCO Annual Meeting 26(15S) (#11014), 5/2008.

143. Salmon JS, Dang TP, Billheimer D, Roder H, Grigorieva J, Tsypin M, Herbst RS, Tsao AS, Tran H, Carbone DP. VeriStrat predicts survival in patients with non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab. J Clin Oncol, 2008 ASCO Annual Meeting 26 (#8008), 5/2008.

144. Herbst RS, Stern H, Amler L, Otterson G, Lin M, O'Connor P, Hainsworth J. Biomarker Evaluation in the Phase III, Placebo (P)-Controlled, Randomized BeTa Trial of Bevacizumab (B) and Erlotinib (E) for Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) after Failure of Standard 1st-Line Chemotherapy: Correlation with treatment outcomes. IASLC 13th World Conference on Lung Cancer (#Session: B2 - Oral Presentation), 8/2009.

145. Saura C, Baselga J, Herbst RS, del Campo J, Marotti M, Tessier J, Collins B, Heymach J. Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study. J Clin Oncol, 2009 ASCO Annual Meeting 27(15s) (#6023), 2009.

146. Mack PC, Holland WS, Redman M, Lara PN, Snyder LJ, Hirsch FR, Franklin WA, Kim ES, Herbst RS, D. R. Gandara. KRAS mutation analysis in cetuximab-treated advanced stage non-small cell lung cancer (NSCLC): SWOG experience with S0342 and S0536. J Clin Oncol 27(15s) (#8022 ASCO Annual Meeting), 2009.

147. Jimeno A, Hong DS, Hecker S, Clement R, Kurzrock R, Pestano LA, Hiscox A, Leos RA, Kirkpatrick DL, Eckhardt SG, Herbst RS. Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor. J Clin Oncol 27(15s) (#3542 ASCO Annual Meeting), 2009.

148. Gold KA, Lee JJ, Rice D, Tse W, Stewart D, Wistuba I, Herbst RS, Lippman SM, Hong WK, Kim ES. Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC). J Clin Oncol 27(15s) (#7566 ASCO Annual Meeting), 2009.

149. Kim ES, Herbst RS, Lee JJ, Blumenschein F, Tsao A, Wistuba I, Alden C, Gupta S, Stewart D, Hong WK. Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. J Clin Oncol 27(15s) (#8024 ASCO Annual Meeting), 2009.

150. Zinner R, Herbst RS, Fossella FV, Johnson FM, Karp DD, Kies MS, Heymach JV, Price JS, Lippman SM, Erasmus J. Results from short-term CT assessments in patients (pts) with advanced poor performance status non-small cell lung cancer (NSCLC) receiving pemetrexed in a phase II trial. J Clin Oncol 27(suppl) (#e19069 ASCO Annual Meeting), 2009.

151. Otterson GA, O’Connor PG, Lin M, Herbst RS. Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy. J Clin Oncol 27(suppl) (#e19025 ASCO Annual Meeting), 2009.

152. Franklin WA, Gandara DR, Kim ES, Herbst RS, Moon J, Redman MW, Olsen C, Hirsch FR, Mack P, Kelly K. SWOG S0342 and S0536: Expression of EGFR protein and markers of epithelial-mesenchymal transformation (EMT) in cetuximab/chemotherapy-treated non-small cell lung cancer (NSCLC). J Clin Oncol 27(15s) (#11076 ASCO Annual Meeting), 2009.

153. Bahleda R, Soria J, Harbison C, Park J, Felip E, Hanna N, Laurie SA, Armand J, Shepherd FA, Herbst R. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. J Clin Oncol 27(15s) (#8098 ASCO Annual Meeting), 2009.


Page 54 of 103

154. Herbst RS, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, Wang J, Langmuir P, Kennedy SJ, Johnson BE. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 27(18s) (#CRA8003 ASCO Annual Meeting), 2009.

155. Saintigny P, Zhang L, Girard L, Xu L, Byers L, Kadara H, Fan Y, Lee J, Coombes K, Lam C, Gerald W, Beer D, Hisayuki S, Tsao M, Shepherd F, Tang X, Herbst R, Kim E, Papadimitrakopoulou V, Lippman S, Mao L, Hong W, Wistuba I, Minna J, Heymach J. An EGFR gene expression signature predicts EGFR mutation status and clinical outcome in early stage lung adenocarcinomas and identifies metastasis associated in colon cancer 1(MACC1) as an EGFR mutant-associated regulator of MET (Oral Presentation and Poster Session). 2010 CPRIT Innovations in Cancer Prevention and Research Conference Abstracts:2 (#8), 11/2010.

156. Herbst R, Mims M, Schiller J, Karnad A, Reynolds C, Hellerstedt B, Campos L, Nemunaitis J, Ruud C, Kim E, Beaudet A, Gibbs R, Ayala G, Berry D, Hilsenbeck S, Buzdar A, Elting L, Poplack D. The Cancer Trials Network of Texas (CTNeT) (Poster Session). 2010 CPRIT Innovations in Cancer Prevention and Research Conference Abstracts:57 (#217), 11/2010.

157. Jacoby JJ, Erez B, Takahashi O, Korshunova MV, Hosho K, Powis G, O'Reilly MS, Herbst RS. Addition of the HIF-1α inhibitor PX-478 enhances the therapeutic efficacy of EGFR inhibitors in an orthotopic human lung adenocarcinoma model (Poster Session). Proc Amer Assoc Cancer Res (#3632), 2010.

158. Jimeno A, Herbst RS, Falchook GS, Messersmith WA, Hecker S, Peterson S, Hausman DF, Kurzrock R, Eckhardt SG, Hong DS. Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase (General Poster Session). J Clin Oncol, 2010 ASCO Annual Meeting 28:7s (#3089), 2010.

159. Burris H, Rodon J, SharmaS, Herbst RS, Tabernero J, Infante JR, Silva A, Demanse D, Hackl W, Baselga J. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol, 2010 ASCO Annual Meeting 28:7s (#3005), 2010.

160. Ihle NT, Kingston J, Gumbiner-Russo L, Byers L, Yordy J, Giri U, Heymach JV, Minna J, Larsen J, Herbst R, Powis G. KRas mediated induction of HIF-1α in normoxia promotes tumorigenesis and identifies HIF-1α as a therapeutic target (Poster Session). Proc Amer Assoc Cancer Res (#306), 2010.

161. Saintigny P, Byers LA, Zhang L, Yordy JS, Tang XM, Girard L, Lang W, Fan YH, Ji L, Lee JJ, Kim ES, Hong WK, Lippman SM, Herbst RS, Minna J, Wistuba II, Heymach JV, Mao L. MYC downregulation and chemoresistance in non-small cell lung cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program (Poster Session). Proc Amer Assoc Cancer Res (#1981), 2010.

162. Tibes R, Falchook GS, Von Hoff DD, Weiss GJ, Iyengar T, Kurzrock R, Pestano L, Lowe AM, Herbst RS. Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1α (General Poster Session). J Clin Oncol, 2010 ASCO Annual Meeting 28:7s (#3076), 2010.

163. Herbst RS, Blumenschein GR, Jr., Kim ES, Lee J, Tsai AS, Alden CM, Liu S, Stewart DJ, Wistuba II, Hong WK. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial (General Poster Session). J Clin Oncol, 2010 ASCO Annual Meeting 28:7s (#7609), 2010.

164. Yan W, Shih JH, Raso MG, Rodriguez-Canales J, Behrens C, Papadimitrakopoulou VA, Herbst RS, Emmert-Buck MR, Wistuba II, Erickson HS. Targeted-therapy related molecular biomarker characterization in NSCLC smokers and never-smokers by a novel qRT-PCR for microdissected tissues methodology (Poster Session). Proc Amer Assoc Cancer Res (#794), 2010.

165. Kim ES, Herbst RS, Lee JJ, Blumenschein GR, Jr., Tsao A, Alden CM, Tang X, Liu S, Stewart DJ, Heymach JV, Tran HT, Hicks ME, Erasmus J, Jr., Gupta S, Powis G, Lippman SM, Wistuba II, Hong WK. The BATTLE trial (Biomarker -integrated Approaches of Targeted Therapy for


Page 55 of 103

Lung Cancer Elimination): personalizing therapy for lung cancer (Plenary Session). Proc Amer Assoc Cancer Res (#LB-1), 2010.

166. Johnson BE, Ryan AJ, Heumach J, Stephens C, Kennedy SJ, Langmuir PB, Herbst RS. Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. J Clin Oncol, 2010 ASCO Annual Meeting 28:7s (#7516), 2010.

167. Hosho K, Komaki R, Tailor R, Ryan A, Jürgensmeier JM, Smith PD, Jacoby JJ, Takahashi O, Korshunova MV, Erez B, Herbst RS, O'Reilly MS. VEGF or VEGF and EGF receptor signaling inhibition by cediranib or vandetanib enhances the therapeutic effects of chemoradiation in an orthotopic small cell lung cancer model (Poster Session). Proc Amer Assoc Cancer Res (#3435), 2010.

168. Takahashi O, Komaki R, Tailor R, Jürgensmeier JM, Ryan A, Smith PD, Jacoby JJ, Hosho K, Korshunova MV, Erez B, Herbst RS, O'Reilly MS. VEGFR signaling inhibition by cediranib enhances the antitumor and anti-metastatic effects of chemotherapy and radiation in an orthotopic human lung cancer model (Poster Session). Proc Amer Assoc Cancer Res (#1397), 2010.

169. R.S. Herbst. Novel molecular studies to inform the conduct of oncology clinical trials: From Battle to Master Protocols. Annals of Oncology (2014) 25 (suppl_4): iv41-iv42. 10.1093/annonc/mdu317

170. Herbst RS, de Marinis F, Jassem J, Spigel DR, Shankar G, Mocci S, Sandler A, Lopez-Chavez A, Li S, Giaccone G. Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1–selected chemotherapy-naÃ¯ve patients with advanced NSCLC. Annals of Oncology (2015) 26 (suppl_9): 103-106. 10.1093/annonc/mdv528

171. Roy S. Herbst, Johanna C. Bendell, Nicolas Isambert, Emiliano Calvo, Rafael Santana-Davila, Philippe Cassier, Jose Luis Perez-Gracia, Jing Yang, Jessicca Rege, David Ferry, Gu Mi, Ian Chau. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. J Clin Oncol 34, 2016 (suppl; abstr 3056)

172. Roy S. Herbst, Paul Baas, Jose Luis Perez-Gracia, Enriqueta Felip, Dong-Wan Kim, Ji-Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler, Veerle Surmont, Gilberto Castro, Marcelo Garrido, Yue Shentu, Marisa Dolled-Filhart, Ellie Im, Edward B. Garon. Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC. J Clin Oncol 34, 2016 (suppl; abstr 3030)

173. Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, Surmont V, De Castro G Jr, Garrido M, Shentu Y, Dolled-Filhart M, Im E, Garon EB. P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy. J Thorac Oncol. 2016 Oct;11(10S): S242-S243. PMID: 27676575

174. Gordon MS, Herbst RS, Horn L, Soria JC, Gandhi L, Felip E, Sequist L, Spigel DR, Antonia SJ, Balmanoukian A, Cassier P, Liu B, Kowanetz M, O'Hear C, Fassò M, Sandler A, Gettinger SN. PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov;11(11S): S309-S310. PMID: 27969529

175. Herbst RS, De Marinis F, Jassem J, Lam S, Mocci S, Sandler A, Lopez-Chavez A, Deng Y, Giaccone G, Spigel DR. IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy-Naive NSCLC Patients: Topic: Medical


Page 56 of 103

Oncology.J Thorac Oncol. 2016 Nov;11(11S):S304-S305. doi: 10.1016/j.jtho.2016.09.091. PMID: 27969523

Book Chapters 1. Herbst RS, Babiss LE. Regulation of liver gene expression during development and

regeneration. In: Mechanisms of Differentiation. CRC Press, 15-48, 1990.

2. Herbst RS, Babiss LE. The state of cellular differentiation determines the activity of the adenovirus E1A enhancer element: Negative regulation of the E1A enhancer in undifferentiated rodent cells and its effect on adenovirus transformation. In: Genetic Mechanisms in Carcinogenesis and Tumor Progression. J. Wiley and Sons, 213-215, 1990.

3. Herbst RS, Kantoff P. Chemotherapy for testicular cancer. In: Advances in Urology. 9, 6th. Mosby: Chicago, 25-38, 1996.

4. Herbst RS, Teicher BA. Potential of antiangiogenic agents in systemic therapy for non-small cell lung cancer. In: Infusion Chemotherapy-Irradiation Interactions. Elsevier Science, 305-330, 1998.

5. Dang NH, Herbst RS, Skarin AT. Chemotherapy of advanced non-small cell lung cancer. In: Multimodality Treatment of Lung Cancer. Marcel Dekker, 235-280, 1999.

6. Herbst RS, Khuri FR, Hong WK. Chemoprevention: scientific rationale and clinical studies. In: Lung Cancer: Principles and Practice. Lippincott Williams & Wilkins, 438-450, 2000.

7. Onn A, Herbst RS. Angiogenesis, metastasis, and lung cancer: An overview. In: Molecular Pathology Methods and Review. 1. Humana Press, 329-348, 2002.

8. Massarelli E, Onn A, Zinner R, Khuri FR, Kim ES, Herbst RS. New targets for the treatment of advanced non-small cell lung cancer. In: Cancer Chemotherapy and Biological Response Modifiers. Annual 20, Chapter 35. Ed(s) Giaccone G, Schilsky R, Sondel P. Elsevier Science: Amsterdam, The Netherlands, 717-61, 2002.

9. Herbst RS, Onn A, Mendelsohn J. The role of growth factor signaling in malignancy. In: Signal Transduction in Cancer. Kluwer Academic Publishers, 19-72, 2003.

10. Herbst RS, LoRusso P, Isobe T, Hurwitz HI. Angiogenesis pathway inhibitors. In: Cancer Chemother Biol Response Modif. 22. Elsevier Science, in press, 2005.

11. Onn A, Herbst RS. Changing the landscape of non-small-cell lung cancer therapy. In: Cancer Principles & Practice Oncology. 19. Wolters Kluwer Health-Lippincott Williams & Wilkins Healthcare, 1-8, 2005.

12. Onn A, Vaporciyan AA, Chang JY, Komaki R, Roth JA, Herbst RS. Cancer of the lung. In: Holland Frei Cancer Medicine, 7. Ed(s) Bast RC, Jr., Hait W, Hong WK, Pollock RE, Weichselbaum RR, Holland JF, Frei E, III. BC Decker Inc.: Ontario, Canada, 1179-1224, 2006.

13. LoRusso PM, Bekele BN, Boerner SA, Davis DW, Evelhoch JL, Herbst RS. Phase 1 Trials Today. In: Molecular Basis of Cancer Therapy, 3. Ed(s) Mendelsohn J, Howley PM, Israel MA, Gray J, Thompson CB. Saunders: U.S., 2008.

14. LoRusso PM, Ryan AJ, Boerner SA, Herbst RS. Small-Molecule Tyrosine Kinase Inhibitors. In: CANCER: Principles & Practice of Oncology. 1, 8. Ed(s) DeVita VT, Jr, Lawrence TS, Rosenberg SA. Lippincott Williams & Wilkins: U.S., 457-468, 2008.

15. Bar J, Onn A, Herbst RS. Molecular events surrounding the angiogenic switch of lung cancer. In: Lung Cancer: Principles and Practice, Fourth. Ed(s) Pass HI, Carbone DP, Johnson DH, Minna JD, Turrisi AT, Scagliotti GV. Lippincott Williams & Wilkins: U.S., 113-34, 2010.

16. Lu C, Onn A, Vaporciyan AA, Chang JY, Glisson BS, Komaki R, Wistuba II, Roth JA, Herbst RS. Cancer of the Lung. In: Eighth Edition Holland - Frei Cancer Medicine, Eighth Edition. Ed(s) Hong WK, Bast RC, Hait WN, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E. People's Medical Publishing House-USA: Shelton, CT, 999-1043, 2010.


Page 57 of 103

17. Morgensztern D, Herbst RS. Evolving Treatment Options for Lung Cancer(Editorial). In: Hematology/Oncology Clinics of North America, Volume 31, Issue 1. Ed(s) Herbst RS, Morgensztern D. Elsevier, Philadelphia, PA. xiii-xiv. 2017

18. Du L, Herbst RS, Morgensztern D. Immunotherapy in Lung Cancer(Review). In: Hematology/Oncology Clinics of North America, Volume 31, Issue 1. Ed(s) Herbst RS, Morgensztern D. Elsevier, Philadelphia, PA. 131-141. 2017

19. Morgensztern D., Herbst R.S. (2018) Immune Checkpoint Inhibition in Lung Cancer. In: Zitvogel L., Kroemer G. (eds) Oncoimmunology. Springer, Cham

Books (edited and written) 1. Ed(s) Davis DW, Herbst RS, Abbruzzese JL. Antiagiogenic Cancer Therapy. CRC Press:

Atlanta, GA, 2007.

2. Editor-In-Chief, Maurie Markman. Ed(s) Jaffer A. Ajani, Richard R. Barakat, Elihu H. Estey, Mark R. Gilbert, Roy S. Herbst, Paulo M. Hoff, Douglas A. Levine, Ashfaq A. Marghoob, Barbara A. Murphy, Shreyaskumar Patel, Edith A. Perez, Daniel P. Petrylak, Anas Younes. Atlas of Cancer, Second. Springer: Philadelphia, 2008.

3. Ed(s) Herbst RS, Morgensztern D. Hematology/Oncology Clinics of North America, Volume 31, Issue 1. Elsevier, Philadelphia, PA. 2017

Letters to the Editor 1. Herbst RS, Giaccone G. Letter in response to: Gefitinib and cisplatin-based chemotherapy in

non-small-cell lung cancer: simply a bad combination? J Clin Oncol 23(4):930-1, 2/2005.

2. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Valerra-Garcia M, Gandara DR. In Reply to "Can EGFR-FISH predict clinical benefit from cetuximab treatment in patients with non-small-cell lung cancer?" by Toshimi Takano, et.al. J Clin Oncol 27(3):465-7, 1/2009.

Manuals, Teaching Aids, Other Teaching Publications 1. Kies MS, Herbst RS. Head and neck cancer. Cambridge University Press, 207-216, 2003.

2. Herbst RS. BCEI.org. e-Pub 2006.

3. Herbst RS. BCEI.org. e-Pub 2007.

4. Herbst RS. CME PeerView Initiative on Lung Cancer. e-Pub 2007.

5. Herbst RS. Lung Cancer eJournal Club. e-Pub 2007.

6. Herbst RS. Lung Cancer eJournal Club. e-Pub 2008.

7. Herbst RS, Perez-Soler R, Riely GJ, Clinical Updates in Non-Small Cell Lung Cancer: New Management Strategies to Improve Patient Outcomes, CME/CE released online: 3/18/2015

8. Govindan R, Herbst RS, Unleashing the Immune System in Advanced NSCLC, CME released rnline: 9/12/2014

9. Herbst RS, Socinski MA, Stinchcombe TE, Tsao AS, Wakelee GA, Immunotherapy in Non-Small Cell Lung Cancer, Peer Exchange released online 3/27/2015

Other Publications Herbst R, Rubin E, LaVange L, Abrams J, Wholley D, Arscott K, Malik S. Design of a Disease-Specific Master Protocol. Whitepaper from Conference on Clinical Cancer REsearch. 11/2012. Available online http://www.focr.org/sites/default/files/pdf/CCCR12MasterProtocol.pdf

EDITORIAL AND REVIEW ACTIVITIES Editor/Service on Editorial Board(s)

Associate Editor, Clinical Lung Cancer, 2007−present


Page 58 of 103

Senior Editor, Clinical Cancer Research, AACR, 2009−present

Editorial Board, AACR Molecular Cancer Therapeutics, 2001−present

Editorial Board, Clinical Cancer Research, 2001−present

Editorial Board, Clinical Lung Cancer, 2002−present

Editorial Board, Investigational New Drugs, 2002−present

Editorial Board, Signal, 2003−2008

Editorial Board, Clinical Advances in Hematology & Oncology, 2003−present

Associate Editor, American Journal of Clinical Oncology, 2004

Editorial Board, Cancer Investigation, 2004

Editorial Board, Journal of Clinical Oncology, Phase I and Clinical Pharmacology, 2004−2009

Associate Editor, Seminars in Oncology, 2006

Associate Editor, The Oncology Report, International Medical News Group division of Elsevier, 2007−2010

Editorial Board, The Cancer Journal: The Journal of Principles and Practice of Oncology, 2007

Editorial Board, Cancer Research, 2010−2012

Editorial Board, Journal of the National Cancer Institute (JNCI) and JNCI Cancer Spectrum, 2017-

Editorial Board Member, Shanghai Chest Journal, 2018-

Member of Editorial Review Board N/A

Journal Reviewer Reviewer, Annals of Oncology, Oxford University Press, 2008

Reviewer, Cancer Chemotherapy and Pharmacology

Reviewer, Cancer Discovery

Reviewer, Cancer Research

Reviewer, Clinical Cancer Research

Reviewer, Journal of Clinical Oncology

Reviewer, Lancet Oncology

Reviewer, Molecular Cancer Therapeutics

Reviewer, Nature Reviews-Oncology

Reviewer, New England Journal of Medicine

Reviewer, Science

Other Editorial and Review Activities N/A


Page 59 of 103

TEACHING Teaching Outside Institution - The University of Texas MD Anderson Cancer Center Formal Teaching

Courses Taught Lecturer, Molecular Mechanisms of Disease: Angiogenesis inhibitors, 1997

Lecturer, Small Cell Lung Cancer, 10/1998

Lecturer, Angiogenesis as a Therapeutic Target in a Metastatic Disease, 1998

Lecturer, Angiogenesis in Head and Neck Cancer, 1998

Lecturer, Emerging Therapies for NSCLC, 1999

Lecturer, New Drugs for NSCLC, 2000

Lecturer, Lung Cancer, 2001−2003

Lecturer, Translational Research, 3/2004

Lecturer, Targeted Therapies, Human Biology and Patient Based Research, 11/2004

Course Director, Angiogenesis Inhibitors in NSCLC: Applying Clinical Data to Clinical Practice (Course Hours: 1) 11/2006−11/2007

Co-Course Director, Clinical Update on Antiangiogenic Therapy in NSCLC, 4/2007−4/2008

Instructor, Mechanisms in Cancer Therapeutics, Course Number: GS04-0213 (Course Hours: 1), Spring, 2008

Instructor, The Biology of Cancer Metastasis, Course Number: GS040093, Spring, 3/2010

Faculty, 2010 NSCLC Curriculum, 2010

Training Programs Faculty, Methods in Clinical Cancer Research, AACR/ASCO Workshop, 1998−2000, 2006−2008

Faculty, Cases Cubed: 3 Cases, 3 Expert Opinions in Non-Small-Cell Lung Cancer, 12/2009−12/2010

Faculty, Clinical Insight: Implications of Recent Data in NSCLC on Clinical Practice, 12/2009−12/2010

Program Director, Practice in Evolution: Optimal Management of NSCLC, 12/2009−12/2010

Other Formal Teaching Lecturer, M. D. Anderson Cancer Center - Oncology Board Review, 1999

Lecturer, Meet the Professor - ASCO Clinical Practice Forum, 2000−2004

Lecturer, Meet the Professor - M. D. Anderson Cancer Center Cancer Course, 2000

Co-Program Director, Targeted Therapy for Lung Cancer, 2002−2009

Program Faculty, Novel Agents in the Treatment of Lung Cancer: Advances in EGFR Inhibitors, 2009−2010

Supervisory Teaching Committees Advisory Committees NA

Supervisory Committees N/A


Page 60 of 103

Examining Committees N/A

Direct Supervision Undergraduate and Allied Health Students N/A

Medical Students N/A

Graduate Students N/A

Postdoctoral Research Fellows Mentor, Dr. Amir Onn, Medical Oncology Fellow, 2001−2007

Mentor, Dr. Wenjuan Wu, Postdoctoral Fellow, 2002−2007

Mentor, Laboratory Projects, Dr. Erminia Massarelli, 5/2004−4/2007

Clinical Residents and Fellows Preceptor, Dr. Clarissa Geyer, Medical Oncology Fellow, 1/1998−6/1998

Mentor, Dr. Ralph Zinner, Medical Oncology Fellow, 6/1998−7/1999

Mentor, Dr. George R. Blumenschein, Jr., Medical Oncology Fellow, 6/1998−7/2000

Mentor, Dr. Jennifer Tseng, Medical Oncology Fellow, 1999

Co-Mentor, Dr. Edward S. Kim, Medical Oncology Fellow, 2000−2002

Mentor and Preceptor, Dr. Quinghu Henry Xiong, Medical Oncology Fellow, 2000−2002

Mentor, Dr. Eric Mininberg, Medical Oncology Fellow, 2001−2003

Mentor, Clinical Projects, Dr. Erminia Massarelli, 4/2001−12/2001

Mentor, Dr. Anne Tsao, Medical Oncology Fellow, 2003−2004

Mentor, Dr. Balvindar Johal, 2008

Mentor, Dr. Pierre Saintigny, 7/2010−present

Preceptor, Dr. George R. Blumenschein, Jr., Medical Oncology Fellow

Mentor, Dr. Krishna Gunturu, Medical Oncology Fellow, 2009 - 2011

Other Supervisory Teaching Mentor, Dr. Takeshi Isobe, Assistant Professor, 2002−2006

Mentor, Dr. James W. Welsh, Assistant Professor, Clinical Faculty, 2009−present

Teaching Inside of Current Institution Formal Teaching

Courses Taught Personalized Therapy for Cancer: Tumor Profiling, Genes and Novel Drugs, Davenport College Masters Tea, Yale University, School of Medicine, 3/2012

Translation for Lung Cancer, Yale University, School of Medicine, 4/2012

Molecular Pharmacology of Lung Cancer, 4/2015


Page 61 of 103

Lecturer: Principles of Pharmacology: Biological and Targeted Therapy for Cancer (PHAR 504a). 2015 – present

Lecturer: Science and Politics of Cancer (MCDB 040b). 4/25/2017

Training Programs N/A

Other Formal Teaching Lecturer, Personalized Therapy for Advanced non-Small Cell Lung Cancer, Yale Cancer Center Evening Oncology Series: Lung Cancer, Yale Cancer Center Smilow Cancer Hospital, May 10, 2012

Faculty, Lung Cancer Update/Conversations with Oncology Investigators: Bridging the Gap between Research and Patient Care, 2009

Lecturer, Davenport Master’s Tea, 2013

Supervisory Teaching Committees Advisory Committees Yale University, New Haven, CT, Freshmen Advisor, 2011-present

Medical Student Teaching, Yale University, 5/30/2012 (M. DiGiovanna)

Supervisory Committees N/A

Examining Committees N/A

Direct Supervision Undergraduate and Allied Health Students Marina Horiates, Yale University, Davenport College, 2012-13

Mark Forsborg, Yale University, Davenport College, 2012-13

Medical Students N/A

Graduate Students N/A

Postdoctoral Research Fellows N/A

Clinical Residents and Fellows Mentor, Dr. Vamsidhar Velchetti, Medical Oncology Fellow, 2010 - 2013

Mentor, Dr. Joseph McLaughlin, Medical Oncology Fellow, 2011 – 2014

Mentor, Dr. Mehmet Altan, Medical Oncology Fellow, 2012 – 2015

Mentor, Dr. Bing Xia, Medical Oncology Fellow, 2014 - present

Mentor, Dr. Carolyn Presley, Medical Oncology Fellow, 2015 – present

Mentor, Dr. Brian Henick, Medical Oncology Fellow, 2016 – present

Mentor, Dr. Debbie Doroshow, Medical Oncology Fellow, 2016-present

Other Supervisory Teaching Mentor, Dr. Scott Gettinger, Associate Professor, 2011 – present


Page 62 of 103

Mentor, Dr. Sarah Goldberg, Assistant Professor, 2012 – present

Mentor, Dr. Joseph McLaughlin, Clinical Instructor, 2014 – present

Mentor, Dr. Mehmet Altan, Clinical Instructor, 2015 – present

Mentor, Dr. Anne Chiang, Assistant Professor, 2016 – present

Mentor, Dr. Kurt Schalper, Assistant Professor, 2016 – present

Mentor, Dr. Frederick Wilson, Assistant Professor, 2017 – present

CONFERENCES AND SYMPOSIA Organization of Conferences/Symposia (Include chairing session)

NCI Head and Neck Workshop, Bethesda, MD, Section Leader - Section on Antiangiogenic, 2/1999

4th Annual Taiwan Oncology Conference, Taipei, Taiwan, Keynote Speaker, 4/1999

Piedmont Oncology Association Spring Meeting, Winston-Salem, NC, Keynote Speaker, 4/1999

Southwest Oncology Group Conference, Phoenix, AZ, Keynote Speaker, 4/1999

First Tokyo International Seminar on Lung Cancer Therapy, Tokyo, Japan, Keynote Speaker, 7/1999

36th ASCO 2000 Annual Meeting, New Orleans, LA, Education Session Speaker, 5/2000

Fifth Annual Advances in Solid Tumors Meeting, Amelia Island, FL, Faculty Member, 10/2000

First Annual Opinion Leader Roundtable-Targeted Therapies in the Treatment of Lung Cancer, Aspen, CO, Session Chairman, 1/2001

26th International Congress of Internal Medicine-Molecular Target-based Therapy for Neoplasma, Kyoto, Japan, Keynote Speaker, 5/2002

2002 Genentech Solid Tumor Investigators' Meeting, Avastin, Tarceva, 2C4, and Herceptin for a Scientific Exploration of the Respective Roles of these Agents in the Treatment of Solid Tumors, Scottsdale, AZ, Scientific Exploration, 9/2002

NOCR Annual Oncology Fellows Meeting, Career Opportunities in the Practice of Oncology, Atlanta, GA, 10/2002

IRESSA Opinion Leader Summit Meeting for Non-Small Cell Lung Cancer, Washington, D.C., Chair, 11/2002

ASCO Molecular Therapeutics Symposium, San Diego, CA, Faculty Member, 11/2002

Third Annual Opinion Leader Summit Meeting for Targeted Therapies for the Treatment of Lung Cancer, Aspen, CO, Co-Chairman, 1/2003

NCCN 8th Annual Conference, Hollywood, FL, Keynote Speaker, 3/2003

NCCN Annual Investigators Meeting, New York, NY, Keynote Speaker, 11/2003

Chemotherapy Foundation Symposium XXI on Innovative Cancer Therapy for Tomorrow, New York, NY, 11/2003

IRESSA (gefitinib, ZD1839): Opinion Leader Summit Meeting, Boston, MA, Chair, 11/2003

Radiation Therapy Oncology Group (RTOG) Conference, New Orleans, LA, Vice-Chairman-Lung Committee, 1/2004

2004 Targeted Therapies for the Treatment of Lung Cancer Investigators' Meeting, San Diego, CA, Chair, 2/2004


Page 63 of 103

RTOG Semi-Annual Meeting, Washington, D.C., Vice-Chairman-Lung Committee, 6/2004

Fifth International Lung Cancer Congress, Kauai, HI, Co-chairman, Moderator, 6/2004

Fourth Annual EGFR Summit 2005, Boca Raton, FL, 4/2005

Southwest Oncology Group, Fall 2005 Group Meeting, Dallas, TX, 10/2005

Scientific Leadership Council in Lung Cancer-Coalition of Cancer Cooperative Groups, Scientific Dialogue with Associated Constituencies, Santa Monica, CA, 1/2006

International Lung Cancer Congress, Eighth International Lung Cancer Congress, Maui, HI, Co-Chairman, Lecturer, Moderator, Speaker, 6/2007

100th AACR 2009 Annual Meeting, Denver, CO, Co-Chairperson, Program Committee, 2008

2008 ASCO 44th Annual Meeting, Chicago, IL, Faculty Member, 2008

International Association for the Study of Lung Cancer (IASLC), 8th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA, Chair: "Proapoptotic Agents," and Presenter, 2/2008

AACR, Clinical Plenary Session 1: Breakthroughs in Phase I, II, and III Clinical Trials, San Diego, CA, Moderator, 4/2008

International Lung Cancer Congress, Ninth International Lung Cancer Congress, Maui, HI, Lecturer, Program Director, 6/2008

AACR Cancer Biostatistics Workshop Developing Targeted Agents, Sonoma, CA, Member, Scientific Program Committee; Faculty Member, 7/2008

2008 AACR/ASCO Workshop on Methods in Clinical Cancer, Vail, CO, Representative, Workshop Program Committee, 8/2008

Personalized Therapies for Lung Cancer and Head and Neck Cancer, First Annual Symposium on Personalized Therapies for Lung Cancer and Head and Neck Cancer, Chicago, IL, Chair, CME Symposium Member, Organizing Committee, Presenter, 9/2008

Southwest Oncology Group, Fall 2008 Group Meeting, Chicago, IL, Member, Lung Cancer Committee, 10/2008

Center for Biomedical Continuing Education, Oncology Unplugged: Using Molecular and Histological Markers to Select Chemotherapy regimens for Patients With NSCLC, Chicago, IL, Chair, Oncology Unplugged-Molecular Predictive Markers for Lung Cancer: How Close Are We to Fulfilling the Promise of Personalized Medicine?, 11/2008

The Center for Biomedical Continuing Education (CBCE), Oncology Unplugged interview entitled "Using Molecular Markers to Select Chemotherapy Regimens for Patients With NSCLC," Chicago, IL, Program Chair, 11/2008

AACR-IASLC Joint Conference, Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy, Coronado, CA, Co-Chairperson, Program Committee, 2009

IASLC, 13th World Conference on Lung Cancer 2009, San Francisco, CA, Member, Medical Oncology Section of the Core Program Committee, 2009

Current Issues in the Management of Non-Small Cell Lung Cancer, Annenberg Center for Health Sciences, Santa Monica, CA, Chair/Moderator, 2/2009

AACR "Molecular Biology in Early Phase Clinical Trials" forum, Denver, CO, Moderator, 4/2009

Vandetanib Advisory Board Meeting, AstraZeneca, Saint Paul de Vence, France, Chair, 4/2009


Page 64 of 103

10th International Lung Cancer Congress, Kohala Coast, HI, Faculty, 6/2009

IOM National Cancer Policy Forum Workshop on Policy Issues in the Development of Personalized Medicine in Oncology, Planning Committee Co-chair, 6/8-9/2009

New & Emerging Strategies for Targeting Non-Small Cell Lung Cancer, 13th World Congress on Lung Cancer, San Francisco, CA, Program Chair/Moderator, 7/2009

Pazopanib Lung Cancer Advisory Board Meeting, GlaxoSmithKline Oncology, San Francisco, CA, Chair, 7/2009

Hoffman-LaRoche Advisory Board Meeting, San Francisco, CA, Advisor, 8/2009

Novartis Pipeline in Lung Cancer Advisory Board Meeting, San Francisco, CA, Advisor, 8/2009

Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer, Philadelphia, PA, Chair, 8/2009

Summit Task Force, Summit Series on Clinical Trials, Alexandria, VA, Partner with Distinction, 11/2009

AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy, Coronado, CA, Chair, 1/2010

10th Annual Targeted Therapies of The Treatment of Lung Cancer, International Association For The Study of Lung Cancer, Santa Monica, CA, Chair, 2/2010

IOM National Cancer Policy Forum Workshop: Extending the Spectrum of Precompetitive Collaboration in Oncology Research, Planning Committee Member, Washington, DC, 2/9-10/2010

Current Trends in Lung and Head & Neck Cancer, Chicago, IL, Program Director, 3/2010

Molecular Cancer Therapeutics, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain, Organiser, 3/2010

Molecular Cancer Therapeutics, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain, Chair, 3/2010

Integrating Science and Policy to Combat the Global Tobacco Epidemic, AACR 101st Annual Meeting 2010, Washington, D.C., Moderator, 4/2010

Personalized Therapy of Advanced Non-small Cell Lung Cancer, AACR 101st Annual Meeting 2010, Washington, D.C., Chair, 4/2010

AACR Translational Cancer Medicine, AACR, San Francisco, CA, Chair, 7/2010

Physicians' Education Resource, 11th International Lung Cancer Congress, Rancho Palos Verdes, CA, Program Director, 7/2010

Physicians' Education Resource - Maintenance and Second-Line Therapy in Advanced NSCLC, 11th International Lung Cancer Congress, Rancho Palos Verdes, CA, Chair, 7/2010

Physicians' Education Resource - State-of-the-Art Treatment of Advanced Lung Cancer (Part 1), 11th International Lung Cancer Congress, Rancho Palos Verdes, CA, Chair, 7/2010

Physicians' Education Resource - Third Annual Addario Foundation Keynote lecture, 11th International Lung Cancer Congress, Rancho Palos Verdes, CA, Chair, 7/2010

University of Nebraska Medical Center, Lung Cancer Summit, Houston, TX, Chair, 8/2010

AACR Molecular Diagnostics in Cancer Therapeutics Development: Challenges and New Horizons, AACR, Denver, CO, Chair, 9/2010


Page 65 of 103

UT-MDACC 2010 Symposia on Cancer Research, Personalized Cancer Therapy and Prevention, Houston, TX, Session Co-chair, 10/2010

IOM National Cancer Policy Forum National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care, National Cancer Policy Forum Member, Washington, DC, 10/25/2010

2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, Faculty Member, 12/2010

11th Annual Targeted Therapies of the Treatment of Lung Cancer, International Association For The Study of Lung Cancer, Santa Monica, CA, Chair, 2/2011

IOM National Cancer Policy Forum Facilitating Collaborations to Develop Combination Investigational Cancer Therapies, Workshop Planning Committee Member, Session Presenter and Moderator, Washington, DC, 6/13-14/2011

IOM National Cancer Policy Forum Workshop on Delivering Affordable Cancer Care in the 21st Century, National Cancer Policy Forum Member, Washington, DC, 1/8-9/2012

2012 ASCO Annual Meeting. Symposium chair: “Targeting Histology & Oncogenic Drivers of NSCLC: Guidelines & Evidence – an Interactive Tumor Board.” 6/3/2012

Questions and Answers, Progress on the Treatment of Lung Cancer, Cancer Care Teleconference, 4/20/2012

Moderator, 2nd Annual Yale Talks About Drug Discovery & Translational Medicine, Yale University, New Haven, CT 5/12/2012

American Thoracic Society, Pulmonary Personalized Medicine Challenge, San Francisco, CA, 5/2012

Cancer Research is Saving Lives, Reserve Officers Association, Washington, D.C., 5/2012

Course Director, Yale ASCO Review 2012, Highlights of the Annual Meeting, Yale Cancer Center, Yale New Haven, 6/22/2012

IOM National Cancer Policy Forum Workshop on Reducing Tobacco-Related Cancer Incidence and Mortality, Workshop Planning Committee Chair, Washington, DC, 6/11-12/2012

Co-Program Director of the “13th International Lung Cancer Congress,” Huntington Beach, CA. 7/19-22/2012

Co-Chair of the “5th Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer.’ Los Angeles, CA. 9/29/2012

IOM National Cancer Policy Forum Sharing Clinical Research Data: A Workshop, National Cancer Policy Forum Member, Washington, DC, 10/4-5/2012

Chair of Panel Two - Design of a Disease-Specific Master Protocol, Friends-Brookings Conference on Clinical Cancer Research, Washington, D.C., 11/14/2012

Co-Chair of the 13th Annual Targeted Therapies of Lung Cancer Meeting sponsored by the IASLC. Santa Monica, CA. 2/20-23/2013

2013 International Lung Cancer Congress, Program Director, Huntington Beach, CA, 7/25-27/2013

Co-Chair of the 14th Annual Targeted Therapies of Lung Cancer Meeting, sponsored by the IASLC. Santa Monica, CA, 2/19-2/22/2014

IOM National Cancer Policy Forum 2013 National Cancer Policy Summit, Planning Group Member, Washington, DC, 11/4/2013


Page 66 of 103

IOM National Cancer Policy Forum Workshop on Contemporary Issues in Human Subjects Protections, Workshop Planning Committee Member, Washington, DC, 2/24-25/2014

Invited Speaker, TOP Seminar “Alvin Slotnick Lecture”, Boston, MA, 6/24/2014

Innovation in Cancer Science & Therapy Symposium, Cambridge, MA, 6/11-12/ 2014

LEAD Summit XII, Montreal, Canada, 6/28/2014

Healthcare Insights Conference at Harvard Medical School, Boston, MA, 7/7-8/2014

2014 International Lung Cancer Congress, Chair, Huntington Beach, CA, 7/31-8/2/2014

IOM National Cancer Policy Forum Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer: A Workshop, Workshop Planning Committee Member, Session Moderator, and Session Presenter, Washington, DC, 11/10-11/2014

Co-Chair of the 15th Annual Targeted Therapies of Lung Cancer Meeting, sponsored by the IASLC. Santa Monica, CA, 2/18-21/2015

ASCO representative to the Program Committee for the 2017 Multidisciplinary Thoracic Cancers Symposium, 9/2015 –


Chair, Oncology at the Limits VII. The Royal College of Physicians, London, UK. March 15-17, 2017.

ASCO-SITC Clinical Immuno-Oncology Symposium Program Committee Member. 2017



AACR Annual Meeting. Scientific Program Committee. 2018

Presentations at National or International Conferences Invited Angiogenesis Inhibitors: Preclinical Studies and Ongoing Clinical Trials, Third Annual Oncology Conference, Missouri Cancer Society, Lake Ozark, MO, 4/1/1998

Medical Management of Non-small Cell Lung Cancer: Combined Modalities, Induction versus Adjuvant Therapy, Facing the Challenges of Non-Small-Cell Lung Cancer Symposium, Oklahoma City, OK, 6/25/1998

Emerging Clinical Trials with Angiogenesis Inhibitors, 5th Research Workshop-Biology, Prevention, and Treatment of Head and Neck Cancer, McLean, VA, 8/26/1998

Research and Current Clinical Experiences and Planned Clinical Trials with Gemzar Doublets in the Treatment of Lung Cancer, Eli Lilly Lung Cancer Consultants' Meeting, Montreal, Canada, 9/12/1998

Therapy for Advanced Non-small Cell Lung Cancer: New Cytotoxic Drugs and Antiangiogenesis Approaches, American Oncology Resources, 1998 Fall Conference, West Palm Beach, FL, 10/16/1998

Antiangiogenesis: Current Studies and Future Trials, Clinical Community Oncology Program, Grand Rapids, MI, 12/10/1998

Gemcitabine in Non-small Cell Lung Cancer, Antimetabolites in Lung Cancer Advisory Board Meeting, Minneapolis, MN, 12/12/1998


Page 67 of 103

Non-small Cell Lung Cancer, US Oncology Community Advisory Board Annual Meeting, Palm Springs, CA, 1/22/1999

TNP-470: Preclinical Data and Current Clinical Studies, First International Symposium on Antiangiogenic Agents, Irving, TX, 1/29/1999

Gemcitabine and Vinorelbine Combinations in Patients with Untreated or Previously Treated Non-small Cell Lung Cancer, Symposium on Non-platin Based Therapy, Philadelphia, PA, 4/8/1999

Platinum-based Regimens for Advanced Non-small Cell Lung Cancer, Effective Management of Advanced NSCLC Symposium, Philadelphia, PA, 4/10/1999

Combinations of Chemotherapy with Biologic Agents in the Treatment of Advanced Solid Tumors and A New Paradigm: Biologic Therapy Plus Cytotoxic Chemotherapy, 14th Annual Scientific Meeting of the Society for Biological Therapy, Cambridge, MA, 10/1/1999

Current Status of First Line Platinum- based Combinations and Biotherapy in Non-small Cell Lung Cancer, 4th Annual Perspectives in Thoracic Cancer, Dallas, TX, 10/1/1999

Herceptin in Lung Cancer, 3rd Annual Fall Oncology Conference, Advances in Solid Tumors, Amelia Island, FL, 10/2/1999

Gemzar and Navelbine Combinations in NSCLC, Eli Lilly Oncology Lung Cancer Consultants' Meeting, St. Julians, Malta, 10/14/1999

Angiogenesis as a Therapeutic Target in Solid Tumors, New Drugs in GI Malignancies: A Look to the Next Century, Paris, France, 1/1/2000

Phase I Trial of Human Endostatin, NCI CTEP Drug Development and Phase I Meeting, Bethesda, MD, 2/29/2000

Lung Cancer Session, 2000 US Gemzar Investigators Meeting, San Antonio, TX, 3/4/2000

Antiangiogenesis, Optimizing Pharmacotherapy of the Oncology Patient: Making a Difference, Savannah, GA, 3/24/2000

Angiogenesis as a Therapeutic Target in Solid Tumors, 8th Annual Radiation Workshop: the Biology Based Combined Modality Radiotherapy, Round Top, TX, 4/14/2000

Angiogenesis Inhibitors: Where Do We Stand Now? National Surgical Adjuvant Breast and Bowel Project Annual Meeting, New Orleans, LA, 6/12/2000

Clinical Update of Complete and Ongoing Studies of IMC-C225 in Cisplatin-refractory Head and Neck Cancer, 5th International Head and Neck Conference-Satellite Symposium, San Francisco, CA, 7/1/2000

Antiangiogenesis, US Oncology Breakthroughs in Cancer Care, Marina del Rey, CA, 7/29/2000

Phase II Study of Combination Weekly Gemcitabine and Vinorelbine in Patients with Untreated or Previously Treated Non-small Cell Lung Cancer, IASLC-9th World Conference on Lung Cancer, Tokyo, Japan, 9/11/2000

Antiangiogenesis and Other Novel Therapies in Cancer: Are They Ready for Prime Time? 5th Annual National VA Oncology Symposium, Alexandria, VA, 10/4/2000

Biotherapy Options in Non-small Cell Lung Cancer, 5th Annual Perspectives in Thoracic Cancer, Charleston, SC, 10/20/2000

Lung Cancer, Network for Oncology Communication and Research-Midwest Regional Practice Guidelines Retreat, Chicago, IL, 10/28/2000


Page 68 of 103

A Phase I Clinical Trial of Recombinant Human Endostatin in Patients with Solid Tumors: Surrogate Analyses to Determine a Biologically Effective Dose, NIC-EORTC-AACR Symposium, Amsterdam, 11/8/2000

New Drugs for Solid Tumors, Antiangiogenesis and Anti-EGFR Agents, M. D. Anderson International-Espana, Madrid, Spain, 11/11/2000

Phase II Trial of IMC-225 plus Cisplatin in Refractory Head and Neck Cancer, IMC-225 Monoclonal Antibody Opinion Leader Summit Meeting, Cancun, Mexico, 1/5/2001

Clinical Trials with Non-specific Antiangiogenic Agents (TNP-470, Squalamine, Interferon), 3rd International Symposium on Anti-Angiogenic Agents, Irving, TX, 1/18/2001

Anti-EGFR Monoclonal Antibody Therapy (IMC-225) for the Treatment of Head and Neck and Colon Cancer and Clinical Studies of the Anti-EGFR Tyrosine Kinase Inhibitor ZD-1839 in Non-small Cell Lung Cancer and Other Solid Tumors, 11th International Congress on Anti-Cancer Treatment-Novel targeted Biological Therapies for Cancer-Satellite Symposium, Paris, France, 2/1/2001

Clinical Development of Epidermal Growth Factor Receptor Inhibitors: Activity as Single Agents or in Combination with Chemotherapy, Beyond Chemotherapy-Emerging Targeted Therapies for the Treatment of Cancer Conference, San Francisco, CA, 5/1/2001

Epidermal Growth Factor Receptor-Targeted Therapies for Colorectal, Head and Neck and Pancreatic Cancer, Targeted Therapies Plus Chemotherapy for Advanced Solid Tumors Conference, San Francisco, CA, 5/1/2001

Angiostatin and Endostatin in NSCLC, 2nd International Lung Cancer Congress, Kauai, HI, 7/18/2001

Preclinical Angiogenesis Imaging Models, Biomedical Imaging Program of the National Cancer Institute, Washington, D.C., 7/24/2001

Future Developments in the Therapy of Lung Cancer, The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Colorado Springs, CO, 7/25/2001

Clinical Trial Design Issues for Trials Using Antiangiogenesis Agents: How to Employ Surrogate Methods of Response in Clinical Practice, 3rd Annual Angiogenesis: Innovative Science and New Applications, Boston, MA, 7/30/2001

Trials with Trastuzumab in Lung Cancer and Cetuximab (C225) in Pancreatic, Head and Neck and Other Cancers, Congress on Monoclonal Antibodies in Cancer Conference, Banff, Canada, 8/1/2001

Molecular Targeted Therapy for Advanced Non-small Cell Lung Cancer, The First Princess Margaret Hospital Conference-New Developments in Cancer Management, Toronto, Canada, 9/20/2001

Efficacy and Safety of the Anti-epidermal Growth Factor Antibody IMC-C225 in Combination with Cisplatin in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck Refractory to Cisplatin Containing Chemotherapy, Second International Chicago Symposium on Malignancies of the Chest and Head and Neck, Chicago, IL, 10/4/2001

The Impact of EGFR-TK Inhibition on the Most Common Solid Tumors, Chicago, IL, 10/11/2001

Molecular Targeted Therapy in NSCLC, Perspectives in Thoracic Cancer, New York, NY, 10/27/2001

Clinical Phase I Studies on Surrogate Endpoints: the Endostatin Experience, Banbury Workshop on New Concepts for Clinical Cancer Trials, Cold Spring Harbor, NY, 11/1/2001

Molecular Targeting Therapy in NSCLC, The 42nd Annual Meeting of the Japan Lung Cancer Society, Osaka, Japan, 11/1/2001

Novel Therapy for Advanced NSCLC, Current Perspectives in the Management of Advanced NSCLC symposium, Osaka, Japan, 11/1/2001


Page 69 of 103

Biology and Target-based Therapy, IASLC Workshop for Small Cell Lung Cancer-Biology and New Treatment, Osaka, Japan, 11/3/2001

IRESSA Data Board Meeting, New York, NY, 11/6/2001

TNP-470 in Solid Tumors, EGFR: IMC-C225 in Solid Tumors, Taxotere and C225 in Lung Cancer, Chemotherapy Foundation Symposium XIX on Innovative Cancer Therapy for Tomorrow, New York, NY, 11/7/2001

Where Are We with Antiangiogenesis, 12th International Congress on Anti-Cancer Treatment, Paris, France, 2/1/2002

The Impact of EGFR-TK Inhibition on the Most Common Solid Tumors, Coronado, CA, 2/21/2002

Target Therapies in the Treatment of Lung Cancer, The Second Annual Opinion Leader Summit, Scottsdale, AZ, 2/27/2002

EGFR Blockers Used in Combination with Cytotoxic Agents for the Treatment of Head and Neck Cancer, Mount Sinai/University of Iowa Multidisciplinary Course on Contemporary Management of Head and Neck Tumors, New York, NY, 3/7/2002

Antiangiogenesis-Is It Effective, AACR 93rd Annual Meeting 2002, San Francisco, CA, 4/1/2002

The Best Targets in Lung Cancer, AACR 93rd Annual Meeting 2002, San Francisco, CA, 4/1/2002

Antiangiogenesis: Current Status of Clinical Trials, AACR 93rd Annual Meeting 2002, San Francisco, CA, 4/6/2002

ASCO Abstracts-NSCLC Session, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

ASCO Education Sessions on Targeted Therapy for Lung Cancer, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

ASCO Highlights-Fellow Meet the Professor Session, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

AstraZeneca Press Briefing, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

Aventis Taxotere/Docetaxel Investigator's Meeting, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

Fellows Program Angiogenesis in Cancer Therapy, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

Lung Carcinoma Advisory Board meeting, AstraZeneca US Lung Carcinoma Advisory Board meeting, New York, NY, 5/1/2002

AstraZeneca Iressa ASCO Virtual Symposium Netcast, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/18/2002

Current Management and Approaches to Lung Cancer, Korea University Hospital, Seoul, 6/4/2002

Gemzar as First Line Treatment for NSCLC, Xian Symposium, Shanghai, China, 6/6/2002

Advance for Gemzar in Treatment of NSCLC, Shanghai Symposium, Shanghai, China, 6/7/2002

Surrogate Markers in Anti-angiogenesis Trials, 1st international symposium on Signal Transduction Modulators in Cancer Therapy, Amsterdam, 9/23/2002

Career Opportunities in the Practice of Oncology, NOCR Annual Oncology Fellows Meeting, Atlanta, GA, 10/3/2002


Page 70 of 103

INTACT (IRESSA Non-Small Cell Lung Cancer Trial Combination Treatment) Investigator Meeting, Orlando, FL, 10/12/2002

Angiogenesis Monitoring in Clinical Cancer Trials, Society of Biologic Therapy Annual Meeting, San Diego, CA, 11/7/2002

EGFR Therapy in NSCLC: Innovative Cancer Therapy for Tomorrow, Chemotherapy Foundation Symposium XX, New York, NY, 11/15/2002

The Impact of EGFR-TK Inhibition on NSCLC, Lung Cancer-Scientific and Clinical Symposium, Philadelphia, PA, 2/21/2003

Epidermal Growth Factor Receptor, HER2, and c-KIT as Predictors of Outcome in Stage I Non-small Cell Lung Cancer, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

Subset Analyses of INTACT Results for Gefitinib (ZD1839) when Combined with Platinum-based Chemotherapy for Advanced Non-small Cell Lung Cancer, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

Targeting Receptor Tyrosine Kinases in Oncology, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

Understanding Targeted Therapies in Clinical Practice--Evolving Roles in Solid Tumors, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

Second-Line Treatment and Beyond for Lung Cancer, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/30/2003

Molecular Targeted Lung Cancer Therapeutics and New Targets for Lung Cancer-What's Hot, What's Not, IASLC-10th World Conference on Lung Cancer, Vancouver, Canada, 8/1/2003

Status of Erb-B Targeted Therapies in Thoracic Malignancies, Second International Congress on Targeted Therapies in Cancer, Washington, D.C., 8/29/2003

Tarceva for NSCLC, Genentech BioOncology 2003 Solid Tumor Investigator's Meeting, Dana Point, CA, 11/6/2003

Antiangiogenic Therapy-What Can We Learn from Success and Failures? Princess Margaret Hospital/National Cancer Institute of Canada - Strategic Directions in Cancer Therapy, Nassau, Bahamas, 2/13/2004

Agouron AG013736 End-of-Study Investigator's Meeting, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

EGFR Inhibition: How Can We Maximize Clinical Benefit in Non-small Cell Lung Cancer at the conference entitled EGFR Inhibition: Unanswered Questions and Strategies for Patient Care, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

Tarceva Clinical Data Review, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

Targeted Therapies News Briefing, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

Targeting Multiple Pathways in Solid Tumors at the conference entitled Targeting Growth and Angiogenic Pathways: From Bench to Bedside, 46th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

TRIBUTE-A Phase II Trial of Erlotinib HCI (OSI-774) Combined with Carboplatin and Paclitaxel Chemotherapy in Advanced Non-small Cell Lung Cancer, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004


Page 71 of 103

Treatment of Non-small Cell Lung Cancer in the Second Line, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/4/2004

Update on Trials of Gefitinib and Analyses of Fraction of Patients with Benefit, IASLC-Update on Clinical Trials of EGFR Inhibitors, Baltimore, MD, 7/9/2004

Molecularly Targeted Therapies, The Best of ASCO, Denver, CO, 8/27/2004

AEE 788 and Genasense, Priorities for Trials of CT+Targeted RX in Advanced NSCLC, Treatment of Advanced NSCLC: Does the Future Lie with Molecular Targeted Agents? A Head-to-Head Debate, IASLC/ASCO/ESMO 2004 Meeting-Targeted Therapy for Lung Cancer, Algarve, Portugal, 9/1/2004

Phase I Data for the AMG706 Trial and Preclinical Studies Using a Mouse Orthotopic Model, 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, 9/1/2004

Molecular Targeted Therapy for Non-small Cell Lung Cancer, The 43rd Annual Meeting of the Japan Lung Cancer Society, Osaka, Japan, 10/26/2004

Avastin & Tarceva in NSCLC, Chemotherapy Foundation Symposium XXII-Innovative Cancer Therapy for Tomorrow, New York, NY, 11/10/2004

BCI-2 Antisense New Development in Lung Cancer, Chemotherapy Foundation Symposium XXII-Innovative Cancer Therapy for Tomorrow, New York, NY, 11/10/2004

Biomarkers & Genetic Mutations, Chemotherapy Foundation Symposium XXII-Innovative Cancer Therapy for Tomorrow, New York, NY, 11/10/2004

Update on EGFR Inhibitors in NSCLC, Chemotherapy Foundation Symposium XXII-Innovative Cancer Therapy for Tomorrow, New York, NY, 11/10/2004

Recent Advances with HER1/EGFR-Targeting Therapies for NSCLC, Human Epidermal Growth Factor Receptor (HER) Education Network, New York, NY, 11/14/2004

Role of Anti-angiogenic Agents, Evolving Paradigms in the Treatment of Thoracic Malignancies, New York, NY, 12/2/2004

Careers in Clinical and Translational Cancer Research, AACR 96th Annual Meeting 2005, Anaheim, CA, 4/1/2005

New Concepts in Organ Site Research and lectured on Clinical/Translational Studies with EGFR Inhibitors in Non-small Cell Lung Cancer, AACR 96th Annual Meeting 2005, Anaheim, CA, 4/1/2005

Recent Advances with HER1/EGFR-Targeted Therapies in NSCLC and Other Solid Tumors, Anaheim, CA, 4/1/2005

Breast Cancer & Targeted Therapies, 2005 ASCO Annual Meeting, Orlando, FL, 5/1/2005

Developmental Therapeutics: Molecular Therapeutics, 2005 ASCO Annual Meeting, Orlando, FL, 5/1/2005

Recent Advances with HER1/EGFR-Targeted Therapies in NSCLC, Orlando, FL, 5/1/2005

Monoclonal Antibodies, International Oncology Network-Lung Cancer Symposium, Scottsdale, AZ, 5/6/2005

Clinical Translational Studies, 2005 ASCO Annual Meeting, Orlando, FL, 5/13/2005

Anti-angiogenesis Strategies, Targeted and Tailored Therapies in Hematology/Oncology, Chicago, IL, 5/17/2005


Page 72 of 103

Personalized Medicine, Health Journalism 2006-National Conference of the Association of Health Care Journalists (AHCJ), Houston, TX, 3/17/2006

Careers in Clinical and Translational Cancer Research, 97th Annual Meeting 2006, Washington, D.C., 4/1/2006

Novel Agents and New Technologies, AACR 97th Annual Meeting 2006, Washington, D.C., 4/1/2006

Update on EGFR Therapy for NSCLC, Merck-Expert Input Forum, New York, NY, 4/7/2006

Lung Cancer, Roche-HORIZONs 1st Annual Lung Cancer Expert Forum, Hamburg, Germany, 4/8/2006

Future of Tarceva (Erlotinib) in Lung Cancer, MD Anderson International Tarceva Launch Meeting, Madrid, Spain, 4/19/2006

Targeted Agents in Lung Cancer, Current Trends in Lung Cancer and Head and Neck Cancer, New York, NY, 4/29/2006

Targeted Therapy: Clinical Applications, ONS 31st Annual Congress, Boston, MA, 5/4/2006

A Phase I Safety and Pharmacokinetic (PK) Study of Recombinant APO2L/Trail, an Apoptois-Inducing Protein in Patients with Advanced Cancer, 2006 ASCO Annual Meeting, Atlanta, GA, 6/2006

Sequestering VEGF with Novel Decoy Receptors (Including VEGF-TRAP), 7th International Lung Cancer Congress, Maui, HI, 6/28/2006

Clinical Discussions in Non-Small Lung Cancer, Hematology/Oncology Conference, Denver, CO, 12/14/2006

Therapy for Aerodigestive Cancer, AACR Special Conference in Cancer Research, Charleston, SC, 2/6/2007

Chat with the Experts, 13th Annual NOCR Meeting, Las Vegas, NV, 2/16/2007

Discovery of the Epidermal Growth Factor Receptor and Its Therapeutic Implications, 13th Annual NOCR Meeting, Las Vegas, NV, 2/16/2007

Careers in Clinical and Translational Cancer Research, AACR 98th Annual Meeting 2007, Los Angeles, CA, 4/14/2007

Targeted therapy for non-small cell lung cancer: first steps towards personalized medicine, The 3rd Severance-MD Anderson Cancer Center Joint Symposium, Yonsei University Health System, Korea, Republic of, 5/19/2007

Personalized Therapy Options for Advanced Non-Small Cell Lung Cancer, The Second Annual AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment, Atlanta, GA, 9/18/2007

Combinations: TEB, BeTa, Chemo Intercalation, EGFR Summit, Genentech, New York, NY, 2/9/2008

"BevBeta/Atlas"; "AMG 386"; TRAIL Ligand," 8th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA, 2/22/2008

Issues in the Modulation of Angiogenesis Pathways, 2008 ASCO 44th Annual Meeting, Meet the Professor Session, Chicago, IL, 5/30/2008

Toward Personalized Therapy for Lung Cancer, First Annual Symposium on Personalized Therapies for Lung Cancer and Head and Neck Cancer, The Oncology Learning Center, Chicago, IL, 9/19/2008

Personalized Therapy for Advanced Non-Small Cell Lung Cancer, 7th Arizona Biosciences Leadership Symposium on Translational Medicine, Tucson, AZ, 10/7/2008


Page 73 of 103

Personalized Therapy Approaches for Advanced NSCLC, Chemotherapy Foundation Symposium XXVI, Mount Sinai School of Medicine, New York, NY, 11/7/2008

Patient Selection for EGFR Inhibitors Using Clinical Characteristics, Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Integrating Molecular Biomarkers Into the Clinic, Chicago, IL, 11/12/2008

Optimizing Targeted Therapy in Patients with NSCLC, Systemic Therapy for Metastatic Non-Small Cell Lung Cancer: Ingegrating Clinical, Pathologic, and Molecular Data, Chicago, IL, 11/14/2008

Will cetuximab eclipse the oral EGFR small molecule inhibitors? Does "FLEX" offer us more flexibility?" 13th Annual Perspectives in Thoracic Oncology, New York, NY, 11/22/2008

Personalized Therapy for Advanced Non-Small Cell Lung Cancer: The M. D. Anderson Battle Program, 2008 Alliance Symposium Matching Drugs to Patients, Waltham, MA, 12/3/2008

Phase I Experience with PX-478, The 11th International Symposium on Anti-Antiogenic Agents: Recent Advances and Future Directions in Basic and Clinical Cancer Research, San Diego, CA, 2/6/2009

Presented ZODIAC results at Vandetanib (ZACTIMA/ZD6474, Principal Investigator: Roy S Herbst MD, PhD) Phase III Programme Results Meeting, AstraZeneca, Dallas, TX, 3/20/2009

Presented results from the ZODIAC Phase III trial, AstraZeneca, Vandetanib Advisory Board, St. Paul de Vence, France, 4/1/2009

Presented results from ZODIAC Phase III trial, AstraZeneca Press Briefing, 13th World Conference on Lung Cancer, San Francisco, CA, 7/31/2009

Established Targets for NSCLC - Multi-Targeted Agents and Drug Combinations, 13th World Conference on Lung Cancer, IASCLC, San Francisco, CA, 8/1/2009

Targeting the Epidermanl Growth Factor Receptor - Disscussant II, 13th World Conference on Lung Cancer, IASCLC, San Francisco, CA, 8/1/2009

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced NSCLC: a randomized, double-blind phase III trial (ZODIAC), 13th World Conference on Lung Cancer Press Program, IASLC, San Francisco, CA, 8/1/2009

Biomarker Evaluation in the Phase III, Placebo (P)-Controlled, Randomized BeTa Trial of Bevacizumab (B) and Erlotinib (E) for Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) after Failure of Standard 1st-Line Chemotherapy: Correlation with treatment outcomes, 13th World Conference on Lung Cancer, IASCLC, San Francisco, CA, 8/2/2009

Individualizing Treatment, 13th World Conference on Lung Cancer, IASCLC, San Francisco, CA, 8/2/2009

Maintenance with VEGF Agent, 13th World Conference on Lung Cancer, IASCLC, San Francisco, CA, 8/2/2009

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced NSCLC: a randomized, double-blind phase III trial (ZODIAC), 13th World Conference on Lung Cancer, IASLC, San Francisco, CA, 8/3/2009

Personalizing therapies for thoracic malignancies with anti-angiogenesis small molecules, Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer, Philadelphia, PA, 9/26/2009

Personalized therapeutic approaches for advanced NSCLC: The MDACC BATTLE program, AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy, Coronado, CA, 1/14/2010


Page 74 of 103

The M. D. Anderson BATTLE Program: Therapy for Non-Small Cell Lung Cancer, Chancellor's Council Executive Committee Winter Meeting, Houston, TX, 1/22/2010

Personalized Medicine, Graduate Medical Education Core Curriculum Lecture Series (GME), GME Curriculum Subcommittee, Houston, TX, 2/22/2010

Phase II randomized study of biomarker-directed treatment for non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain, 3/10/2010

Adaptive Trial Design, Twenty-First Annual Cancer Progress Conference, Communitech, New York, NY, 3/17/2010

Emerging Targeted Agents in NSCLC, Current Trends in Lung and Head & Neck Cancer, Chicago, IL, 3/20/2010

Toward personalized therapy of lung cancer: The MD Anderson BATTLE programs, AACR 101st Annual Meeting 2010, Washington, D.C., 4/18/2010

Tobacco and cancer: Biology and pathoogenesis, AACR 101st Annual Meeting 2010, Washington, D.C., 4/20/2010

Personalized Therapy for Advanced NSCLC: The MD Anderson BATTLE Programs, Annual Phase II Symposium, University of Chicago, Chicago, IL, 4/23/2010

AZD6244 combination with MK2206 clinical trials, AstraZeneca/MedI 2010 Cross-Alliance Scientific Symposia, AstraZeneca/MedImmune, Manchester, United Kingdom, 6/17/2010

State of the Art: Advanced Lung Cancer, 11th International Lung Cancer Congress, Physicians Education Resource, Rancho Palos Verdes, CA, 7/10/2010

Targeted Therapies in Lung Cancer (Part I), University of Nebraska Medical Center, Houston, TX, 8/20/2010

Personalized Approaches for Advanced Non-Small Cell Lung Cancer: The M. D. Anderson BATTLE Programs, AACR Molecular Diagnostics in Cancer Therapeutic Development: Challenges and New Horizons, AACR, Denver, CO, 9/30/2010

Current Status of Prognostic and Predictive Molecular Markers in Lung and Colorectal Cancers, 2010 ASCO-NCI-EORTC Annual Meeting on Molecular Markers, ASCO, Hollywood, FL, 10/19/2010

Conducting genome-guided prospective RCTs to identify and validate PGx markers of treatment response: “The example of the BATTLE lung cancer trail”, Cancer Pharmacogenomics: Integrating Discoveries in Basic, Clinical and Population Sciences to Advance Predictive Cancer Care, PPWG, Bethesda, MD, 10/28/2010

Clinical Aspects in the Treatment of Lung Cancer (NSCLC), A Review of the Most Recent Developments in Cancer Therapy, EXCEL Continuing Education, Houston, TX, 11/6/2010

Clinical Trials Update, Association of Cancer Executives, New Orleans, LA, 1/29/2011

Personalized therapy for Advanced Non-Small Cell Lung Cancer, Pittsburgh Cancer Conference 2011, Pittsburgh, PA, 5/5/11

EGFR Inhibitors in the Treatment of Lung Cancer, Pathology of the 21st Century From Molecular Diagnostics to personal Cancer Therapy, The University of Texas, M.D. Anderson Cancer, Houston, TX, 5/6-7/2011

NSCLC: Toward Personalized Therapy, NSCLC Experts in Residence program, Luci Curci Cancer Center, Rancho Mirage, CA, 5/19/2011


Page 75 of 103

Approaches to Inhibiting bFGFR, 12th International Lung Cancer Congress, Carlsbad, CA, 8/11-14, 2011

Personalized therapy for advanced non-small lung cancer: Lessons learned from the BATTLE Trial, Challenges in Cancer – Answering the Difficult Questions, Queens’s University, 9/6-9/2011

Personalized Therapy for Advanced Non-small cell lung cancer: Lessons Learned from the BATTLE Trial. 2nd Annual 2011 Meeting of the Society for Translational Oncology

3rd International Cancer Symposium of the Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Challenges in Cancer: Answering the Difficult Questions, Belfast, Northern Ireland, 9/7-8/2011

Tobacco: Still the Dominant Global Health and Disparities Threat, 4th AACR Conference on The Science of Cancer Health Disparities, Washington, D.C. 9/18-21/2011

Personalized Therapy for Advanced Non-small Lung Cancer: Lessons Learned from the BATTLE trial, UCL, 10/12/2011

Personalized Therapy for Lung Cancer, Oncology at the Limits II, 2011, Stockholm, 10/13-16, 2011

Personalized Therapy for Advanced Non-small cell lung cancer: Lessons Learned from the BATTLE Trial, Belfast, Northern Ireland, 10/24-25/2011

AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine Meeting, Meeting Chair, San Diego, CA, 1/18-11/2012

From Bench to Bedside, 2nd Lung Cancer Network 2012, Oncology Unit GPP, Athens School of Medicine, Athens, Greece, 2/3-4/2012

Downstream Signal, MTOR PI3K, 12th Annual Targeted Therapies of Lung Cancer meeting, Chair, IASLC, Santa Monica, CA, 2/22-25/2012

Challenging Conventional Cancer Care: The Untold Story of Tobacco’s Effect on Cancer Biology, Treatment Response, and Survival, AACR, Chicago, IL 3/31-4/4/2012

From Molecular Mechanisms to Targeted Cancer Therapy Program, Lessons Learned from the BATTLE Trials: Personalized Therapy for Advanced Non-small Cell Lung Cancer, Cadenabbia, Italy, 4/26-29/2012

State-of-the-art Clinical Trials in 2012, UK Lung Cancer Symposium, Manchester, England, 4/29-05/02/2012

Molecular and Mutational Testing in the NSCLC Setting, Personalized Therapy for NSCLC: Lessons Learned From The Battle Team, The Pulmonary Personalized Medicine Challenge, American Thoracic Society 2012 International Conference, San Francisco, CA, 5/18-23/2012

2nd Yale Cancer Center Symposium at UCL Cancer Institute, London, England, 6/24-28/2012

Lung Cancer in Never-Smokers: Implications for Treatment, 5th Latin American Conference on Lung Cancer, Rio de Janeiro, Brazil, 7/25-27/2012

Diatech Oncology Medical Advisory Meeting, Montreal, Canada, 8/03/2012

2012 Best of ASCO Meeting, Boston, MA, 8/3-4/2012

National Engineering Laboratory for Anti-Tumor Protein Therapeutics, Beijing, China, 8/5-12/2013

AACR Science Policy and Legislative Affairs Committee Meeting, Washington, D.C., 9/12/2012

Cancer Research Committee Meeting (ASCO), Clinically Meaningful Outcomes, Washington, D.C., 9/13/2012


Page 76 of 103

Local Insights; Expert Perspectives on Optimizing Molecular Testing in NSCLS (Pfizer), New York, NY, 10/06/2012

Delivering Afforadable Cancer Care in the 21st Century, IOM’s National Cancer Policy Forum, Washington, D.C., 10/7-8/2012

Biothera Clinical Advisory Panel Meeting, New York, NY, 10/8/2012

Personalized Therapy for Advanced Non-Small Cell Lung Cancer, Molecular Pathology: Focusing on Patients, The Beaumont Estate Hotel and Conference Center, Old Windsor, UK, 10/12-14/2012

EGFR WT Advisory Board Meeting, Roche Pharmaceuticals, Miami, FL, 10/13/2012

Lung Cancer Drugs in Development, 13th Annual Retreat of the Medical and Scientific Advisory Board of MPM Capital, LP, Boston, MA, 10/17/2012

SWOG Conference, Chicago, IL, 10/19-20/2012

Pushing the Envelope Forward: Novel Trial Designs and New Dimensions for Treatment of Advanced Disease, Oncology at the Limits, London, England, 10/24-27/2012

Lilly Global Thoracic Advisory Board, New York, NY, 11/10/2012

Workshop on Reducing Tobacco-Related Cancer Incidence and Mortality, IOM’s National Cancer Policy Forum Meeting, Washington, D.C., 2/10/2013

Oncology: Targeting the Next Breakthrough in Lung Cancer, Leerink Swann Global Healthcare Conference 2013, New York, NY, 2/13/2013

Mind the Gap, Oncology Scientific Advisory Board Meeting, Chicago, IL, 2/18-19/2013

Friends of Cancer Research workshop on the Design of a Lung Cancer Master Protocol, Washington, DC, 3/ 12/2013.

Israel Cancer Research Fund Scientific Review Panel, New York, NY, 3/18/2013

Targeting Immunotherapy, 6th International Conference on Molecular Targeted Therapies in Lung Cancer, Sorrento, Italy, 4/17-20/2013

Spring SWOG Meeting, San Francisco, CA, 05/01-04/2013

2013 AACI/AACR/ASCO/FOCR Capitol Hill Day, Washington, D.C., 05/16/2013

Novel Mechanisms of Targeting Tumors: It’s Not Just the TKI’s Anymore!, 2013 ASCO Annual Meeting, Chicago, IL, 05/30 – 06/04/2013

A Study of MPDL3280A, An Engineered PD-L1 Antibody in Patients with Locally Advanced or Metastatic Tumors, 2013 ASCO Annual Meeting, Chicago, IL, 05/30 - 06/04/2013

MK3475 Protocol 010 Investigators’ Meeting, Scientific Background, Baltimore, MD, 06/14/2013

Personalized Therapy for Advanced Non-Small Cell Lung Cancer, Dartmouth College Grand Rounds, Hanover, NH, 06/20/2013

The Academy for Continued Healthcare Learning LLC, NSCLC VPP presentation, Victoria, TX, 7/2/2013

NCI Workshop on Small Cell Lung Cancer: Seizing on Opportunities to Translate Recent Research into the Clinic for New Diagnostics and Interventions, Special Session: Attracting Investigators to the Field of SCLC, Bethesda, MD, 7/8-9/2013

Roche/Genentech Lung Advisory Board Meeting, New York, NY, 7/9-10/2013


Page 77 of 103

Reducing Tobacco-Related Cancer Incidence and Mortality, 2013 Lung Cancer SPORE Workshop, Rockville, MD, 7/10-12/2013

Second National Cancer Policy Summit, Rockville, MD, 7/10-12/2013

2013 Lung Cancer SPORE Workshop, 2013 Lung Cancer SPORE Workshop, Contemporary and Future Human Subjects Protections in Cancer Research, Rockville, MD, 7/10-12/2013

IOM’s National Cancer Policy Forum, Washington, D.C. 7/14-15/2013

Foundation Medicine Tumor Board, Boston, MA, 7/17/2013

Personalized Therapy for Advance Non-small Cell Lung Cancer: From the Battle Trial to Master Protocol, 2013 Japanese Society for Medical Oncology, Sendai, Japan, 8/23-9/1/2013

NCI/AACR Joint Meeting, Rockville, MD, 9/16/2013

AACR Tobacco and Cancer Subcommittee Meeting, Rockville, MD, 9/17/2013.

AACR Science Policy and Government Affairs Committee Meeting, Washington, D.C., 9/17/2013

MS 13-Statistics of Personalized Medicine, 15th Annual World Conference on Lung Cancer, Sydney, Australia, 10/27-30/2013.

Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow. The Greenspan Meeting XXXI, PD-1 and PD-L1 Inhibitors for NSCLC, New York, NY, 11/6-8/2013

Friends-Brookings Conference on Clinical Cancer Research, Washington, D.C., 11/7/2013

Targeting c-MET and Additional Novel Targets in Late-stage Clinical Development, and Anti-PD-1, anti-PDL-1, anti-CTLA-4 Blockade: Applications of Immune-checkpoint Inhibition for Lung Cancer, 6th Annual Symposium Personalized Therapy Meeting, Los Angeles, CA, 11/16/2013

The Biologic Rationale for Targeting the Immune Checkpoint in Lung Cancer, 1st Annual Summit on Practical and Emerging Approaches for Lung Cancer, Dallas, TX, 12/14-15/2013

AACR-IASLC Joint Conference on the Molecular Origins of Lung Cancer, Opening Keynote Session, San Diego, CA, 1/6-9/2014

Oncology at the Limits IV, Innovation in Clinical Trial Design in the Era of Genomic Medicine, Heidelberg, Germany, 2/13-15/2014

The Histological and Pathological Underpinnings of Non-Small Cell Lung Cancer, NSCLC Grand Rounds, Middletown, CT, 2/19/2014

Pathophysiology of Tobacco-Induced Cancers, 165th Meeting of the National Cancer Advisory Board, Bethesda, MD, 2/27/2014

Histological and Pathological Underpinnings of Non-Small Cell Lung Cancer, Good Samaritan Medical Center, West Palm Beach, FL, 02/28/2014

Clinical Trial Component: Bucket and Baskets Protocols, Precision Oncology Planning Meeting, Boston, MA, 3/4-5/2014

Targeting the EGFR in Lung Cancer, Israeli Lung Cancer Conference, Tel Aviv, Israel, 3/9-12/2014

National Comprehensive Cancer Network 19th Annual Conference: Advancing the Standard of Cancer Care, Hollywood, FL, 3/13-15/2014

Personalized Therapy for Advanced Non-Small Cell Lung Cancer; From the Battle Trial to Master Protocols, New York Academy of Sciences Lung Cancer Symposium, New York, NY, 3/25/2014


Page 78 of 103

Immunologic Approach to Lung Cancer, European Lung Cancer Conference, Geneva, Switzerland, 3/25-29/2014

Cancer Treatment: How Far Have We Come? 2014 Global Health and the Arts Conference, New Haven, CT, 4/3-4/2014

Fostering Evidence-based Tobacco Control; AACR Research and Policy Initiatives, and Novel Clinical Trial Designs in the Whole-Exome Era, AACR, San Diego, CA, 4/5-8/2014

Cancer Center Experience with Genomic Tumor Board, 2014 ASCO-AMP-CAP Genomics Roundtable, Alexandria, VA, 4/1-11/2014

A Phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer, American Society of Clinical Oncology Annual Meeting, Chicago IL, 5/30-6/3/2014

LEAD Summit, Participation as Oncology lead expert advisor on Development at Summit XII, Montreal, Canada, 6/20-21/2014

TOP Seminar Alvin Slotnick Lecture, Boston, MA, 6/24/2014

Novel Therapies in Lung Cancer: Leaping Forward or Incremental Progress? Healthcare Insights Conference, Harvard Medical School, Boston, MA, 7/7-8/2014

Present and Future, Medscape Oncology, New York, NY, 7/11-12/2014

Lung Cancer – Present and Future, Great Debates and Updates in Thoracic Malignancies, New York, NY, 7/12/2014

The Future of Immunotherapy, and Biology of the Immune System in Lung Cancer, 2014 ILCC Congress, Panel Discussion, Huntington Beach, CA, 7/27-8/3/2014

Meet the expert: Innovative Clinical Trial Designs for NSCLC: From Battle to Master, & Clinical Trials with Anti PLD-1 and PD-1, Latin America Lung Cancer Conference (LALCA), Lima, Peru, 8/21-23/2014

Novel Molecular Studies to Inform the Conduct of Oncology Clinical Trials: From Battle to Master Protocols, European Society for Medical Oncology (ESMO) 2014 Congress, Madrid, Spain, 9/29/2014

Immune Checkpoint Therapy for Non-Small Cell Lung Cancer: Clinical Results, Biomarker Development and Combination Therapy, Cancer Research Institute International Immunotherapy Symposium, New York, NY, 10/6/2014

Patient-Centered Clinical Development Models, Turning the Tide against Cancer Conference, Washington, D.C., 10/9/2014

Targeted Therapies in Lung Cancer PD-1/PD-L1, 12th Annual Targeted Therapies Congress, New York, NY, 10/11/2014

Immunotherapy: Integrating a New Approach to Lung Cancer Therapy into Community Practice, 7th Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer, Session Chair, San Francisco, CA, 10/18/2014

Master Protocols: Innovative Statistical Designs and Lessons Learned from Lung-MAP, SWOG Fall 2014 Group Meeting, Discussion Panelist, Chicago, IL, 10/25/2014

Incorporating Molecular Biomarkers into the Therapy of Solid Tumors—Case Studies on ‘How I Treat’, Third Annual PMO Live: A Global Biomarkers Consortium, San Francisco, CA, 10/31/2014

What Is Next for Immune Therapies?, 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, 11/1/2014


Page 79 of 103

Personalized Immunotherapy for Non-Small Cell Lung Cancer, Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting, National Harbor, MD, 11/7/2014

Incorporation of Immunotherapy in Lung Cancers: How Far Have We Come in 2014?, 9th Annual New York Lung Cancer Symposium, New York, NY, 11/8/2014

“Generating Evidence: Clinical Trail Designs – Lung MAP,” IOM’s National Cancer Policy Forum, Washington, D.C., 11/10/2014

10th Annual Personalized Medicine Conference, Panel Discussion, “Oncology,” Boston, MA, 11/12/2014

The Protocol of S1400 and its Background, and Immunotherapy for Non-Small Cell Lung Cancer: Clinical Studies, Predictive Markers and Combination Therapies, 55th Annual Meeting of the Japan Lung Cancer Society, Kyoto Japan, 11/16/2014

PD-1 Pathway Blockade, Stand Up to Cancer (SU2C) Meeting, New York, NY, Moderator, 12/4/2014

The Future of Individualized Treatment for Advance Lung Cancer, Were Should We Go? and EGFR-TKI and Beyond: Past, Present, and Future Targeted Therapy for NSCLC, 4th International Symposium on Respiratory Endoscope and Lung Cancer (ISRELC), Shanghai, China, 12/13/ 2014

“Unique challenges of community-based research; raising the bar for clinical trials” and “Importance of EGFR mutation variant in the selection of front-line therapy; emerging data on bevacizumab in EGFR mutation-positive disease” and “New clinical trials and treatment concepts: Combinations and sequences of checkpoint inhibitors and other agents, 12 Annual Winter Lung Cancer Conference, Miami, FL, 2/6-8/2015

Updates on MPDL3280 early phase, cetuximab, and GDC 0032 P13K, and Should tumor PD-L1 status be used to select treatment?, 15th Annual Targeted Therapies of the Treatment of Lung Cancer, sponsored by the IASLC, Santa Monica, CA, Debate Moderator, 2/18-21/2015

Emerging Therapy for Non-Small Lung Cancer: From Angiogenesis to Immunotherapy, 17th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer, San Diego, CA, 2/21/2015

Accelerating Translation: Personalized Immunotherapy for Advance Non-Small Cell Lung Cancer; Translational Science 2015, sponsored by the Association for Clinical and Translational Science (ACTS), Washington, D.C., 4/18/2015

The New Standard of Care for the Treatment of Previously Treated Non-Squamous Cell Non-Small Cell Lung Cancer? Where do we go from here?, and Small Cell Lung Cancer: A Glimpse of Light, 51st Annual ASCO Meeting, Chicago, IL, 5/30/2015

Distinguishing Immuno-Oncology from a Chemotherapy and Targeted Therapy Model: The New Paradigm for NSCLC, 2015 ASCO CME/CE Satellite Symposium, Chicago, IL, 5/31/2015

Lung-MAP (SWOG S1400): A Biomarker-Driven Protocol Accelerating Development of Squamous Cell Lung Cancer Therapies, and Immuno Checkpoint Inhibitors-Current Status and Future Prospects, and Personalized Immunotherapy for Advanced Non-Small Cell Lung Cancer; 2015 Japanese Society for Medical Oncology, Sapporo, Japan; 7/16-17/2015

Lung Cancer: First-Line Therapy, Combination vs. Sequential, and Biomarkers of PD-L1 Inhibition to Predict Response to Anti–PD-L1 Therapy; Global Summit on Harnessing the Immune System in Cancer, West Palm Beach; 7/24-25/2015

Overview of Immunotherapy in Lung Cancer in 2015, and Case-Based Panel Discussion: The Future of Immunotherapy (moderator), 2015 International Lung Cancer Congress (ILCC), Huntington Beach, 7/30-31/2015


Page 80 of 103

Lung Cancer Pathogenesis - Novel Biomarkers and Approaches to Targeting These Pathways; Harnessing the Full Potential of the Immune System: PD1/PDL1 Studies; The New Frontier in NSCLC - Beyond EGFR, VEGF and ALK: Expanding the Paradigm to Include Patients Without Actionable mutations; A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): SWOG S0819; Immune Biology, Microenvironment and Novel Targets: Biology, Pathology, and Molecular Testing (Discussant); 16th Annual World Conference on Lung Cancer, Denver, CO, 9/6-9/2015

Why is Immune Therapy Different from Targeted and Chemotherapy for Lung Cancer? 8th Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer, San Francisco, 10/17/2015

The Promise of Immunotherapy for the Treatment of Lung Cancer. 33rd Annual Chemotherapy Foundation Symposium, New York, 11/5/2015

Immunotherapy for Lung Cancer 2015: Drugs, Biomarker and Combinations and Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From BATTLE to Master Protocols to Immunotherapy. 56th Annual Meeting of the Japan Lung Cancer Society, Yokohama Japan, 11/28/2015

Personalized Therapy for Advanced NSCLC. Association for Molecular Pathology (AMP) 2015 Annual Meeting. Austin, TX, 11/7/2016

Our changing understanding of the biology of cancer. ECRI Annual Health Policy Conference. Washington, DC, 11/17/2015

Immunotherapy for Lung Cancer 2015: Drugs, Biomarker and Combinations; Personalized Therapy for Advanced Non-Small Cell Lung Cancer : From BATTLE to Master Protocols to Immunotherapy. The 56th Annual Meeting of the Japan Lung Cancer Society. Yokohama, Japan.

KEYNOTE-010: Phase 2/3 Study of Pembrolizumab (MK-3475) vs Docetaxel for PD-L1–Positive NSCLC After Platinum-Based Therapy. Presidential Symposium, European Society for Medical Oncology (ESMO)-Asia 2015. Singapore. 12/20/2015

Targeting PD1 and PDL1 in lung cancer treatment- Where are we now?; How Advocacy is Driving Science (speaker). Fourth AACR-IASLC International Joint Conference. San Diego, CA. 1/6/2016

Lung Cancer: Today and Tomorrow. Canadian Lung Cancer Conference 2016. Vancouver, Canada. 2/12/2016

Science of checkpoint inhibitors; Keynote 10; Effects of checkpoint inhibitors on brain mets; Cetuxumab 0819. 16th Annual Targeted Therapies of Lung Cancer Meeting. Santa Monica, CA. 2/17-20/2016

Tobacco Control Policy Session -The Need for ENDS Regulations: Public Health Concerns and Opportunities (panelist). AACR Annual Meeting 2016. New Orleans, LA. 4/17/2016

Immunotherapy Grand Rounds: Nursing and Physician Investigators Discuss Cases from Their Practices (panelist). 41st Annual Oncology Nursing Society Congress, San Antonio, TX. 4/27/2016.

Drug Development: How Far We’ve Come—Post-Treatment Biopsies in Phase I Clinical Trials: Point; Practical Tips for Academic, Private, and Industry Career Tracks: Negotiating Contracts and Education Debt Management: Academic Perspective; ASCO Annual Meeting 2016. Chicago, IL. 6/2-6/2016.

Dissecting the Decision: Investigators Discuss the Available Data and Clinical Factors that Shape the Management of Non-Small Cell Lung Cancer (faculty). Research to Practice Satellite Symposium at ASCO Annual Meeting 2016. Chicago, IL. 6/3/2016.


Page 81 of 103

Emerging Resistance to Targeted and Immunotherapy in the Treatment of Cancer: Response and Resistance to Lung Cancer Therapies. American Molecular Satellite Symposium at ASCO Annual Meeting 2016. Chicago, IL. 6/4/2016

Immunotherapy in Non-Small Cell Lung Cancer: Answering Clinically Relevant Questions (chair). prIME Oncology and the Society for Immuno-Therapy in Cancer (SITC) Satellite Symposium at ASCO Annual Meeting 2016. Chicago, IL. 6/5/2016.

The Master Protocol in Oncology: Lessons Learned. NHLBI Workshop on Enhancing Treatments for Pulmonary Vascular Diseases. Rosemont, IL. 6/7/2016.

Picking Patients for Immunotherapy: How Far Have We Come? TRM Oncology Emerging Paradigms In Care (EPIC) Lung Cancer Expert Roundtable. Chicago, IL. 6/7/2016

The Next Generation of Agents for Lung Cancer: Overview; Biomarker Development for Immune Checkpoint Inhibitor Therapy: Beyond Tumor PD-L1 Testing; Case-Based Panel Discussion: Optimizing Current Tools for Lung Cancer Translational Research in 2016 (panelist). 2016 International Lung Cancer Congress (ILCC), Huntington Beach, 8/4-6/201

Innovative Clinical Trial Designs for NSCLC; Innovative Clinical Trial Designs for NSCLC. IASLC 7th Latin American Conference on Lung Cancer. Panama City, Panama. 8/25-27/2016

Looking Forward: Immunology Approach in 2020. IASLC 2016 Chicago Multidisciplinary Symposium in Thoracic Oncology. Chicago. 9/22/2016

The Crossroads of Targeted Therapy and Immunotherapy. Lung Satellite Symposium at ESMO 2016 Congress. 10/09/2016

Initial Treatment of Patients with Lung Cancers with Immunotherapy. 11th Annual New York Lung Cancer Symposium. New York, NY. 11/12/2016

Perspectives on the Value of Cancer Immunotherapy: Predictive and Companion Biomarkers. ASCO-SITC 2016. Value of Cancer Immunotherapy Summit. 11/13/2016

Novel Drugs in Thoracic Cancers: KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab; Immunotherapy of NSCLC: Immunotherapy in the First-Line Setting of Advanced NSCLC. IASLC 17th World Conference on Lung Cancer. Vienna, Austria. 12/05-6/2016

Medical Crossfire: PD-L1 Testing Is Standard of Care in NSCLC. International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application, New York, NY. 12/10/2016

Emerging Research Information with The Use of Anti-PD-1/PD-L1 Antibodies in Patients with Previously Untreated Metastatic NSCLC; Available Efficacy and Safety Data with Osimertinib; Ongoing Evaluation in the First-Line Setting; Effectiveness in Patients with CNS Metastases. 14th Annual Winter Lung Cancer Conference. Aventura, FL. 02/11/2017

Immune Checkpoint Inhibitors in NSCLC- SU2C. 17th Annual Targeted Therapies of Lung Cancer Meeting. Santa Monica, CA. 02/23/2017

Evolving Treatment Paradigms with Use of Immuno-Oncology Strategies for the Management of Non-Small Cell Lung Cancer; What Have We Learned about the Biomarkers and Resistance? Satellite Symposium: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder Cancers. ASCO-SITC Clinical Immuno-Oncology Symposium. Orlando, FL. 02/24/2017.

The Most Promising Combinations with Immune Checkpoints; ASCO-SITC Clinical Immuno-Oncology Symposium. Orlando, FL. 02/24/2017.


Page 82 of 103

Lung Master Protocol (Lung-MAP): A Biomarker-Driven Protocol for Accelerating Therapeutic Development for Squamous Cell Lung Cancer. National Academies of Sciences, Engineering, and Medicine Workshop: Enabling Precision Medicine: The Role of Genetics in Clinical Drug Development. Washington, DC. 03/08/2017

Rationale and Design of Immune Checkpoint Combination Therapy: Novel Biologically Based Clinical Trials Using Immune Phenotyping: BATTLE Immunotherapy; Lung Cancer Outcomes: Clinical Implications for Smoking: Smoking and Lung Cancer: Implications for Pathogenesis, Prevention, and Treatment, and E-cigarettes: Are they a Public Health Threat or a Useful Cessation Tool? 2017 Annual Meeting of the American Association for Cancer Research. Washington, DC. 04/01-02/2017.

Molecular Tumor Board: Integrating Biomarker Analyses into Clinical Decision Making Regarding the use of Immune Checkpoint Inhibitors in Cancer Treatment? Research to Practice Satellite Symposium at the 2017 AACR Annual Meeting. Washington, DC. 04/03/2017

Beyond Checkpoint Inhibitors: New Approaches to Altering the Tumor Environment. 2017 Accelerating Anticancer Agent Development and Validation Workshop. Bethesda, MD. 5/05/2017

Is there a role for second-line immunotherapy in patients with PD-L1 negative NSCLC? (Controversy session). 7th European Lung Cancer Conference. Geneva, Switzerland. 5/05-08/2017

Future Strategies for Personalized Immunotherapy Session: Biomarkers for Immunotherapy: An Illusion or a Reality? 2017 ASCO Annual Meeting. Chicago, IL. 6/02-06/2017

Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder Cancers (Program Chair). Physicians’ Education Resourse Satellite at the 2017 ASCO Annual Meeting. Chicago, IL 6/03/2017

Therapeutic Paradigms in NSCLC for 2020 (keynote); Workshop 1: Molecular Tumor Board (chair); The Next Generation of Agents for Lung Cancer: Overview; Immunotherapy in NSCLC; Case-Based Panel Discussion: State-of-the-Art/Challenges and Opportunities in Lung Cancer (chair); Paradigm-Changing Phase 3 Trials in Lung Cancer (chair). 18th Annual International Lung Cancer Congress. Huntington Beach, CA. 7/26/29/2017

Bringing Clarity to Immunotherapy in Lung Cancer: Translating Data into Clinical Decisions. Roche-sponsored Special Symposium at ESMO Congress 2017. Madrid. 9/9/2017

Immuno-oncology: Current Status and Future Perspectives; Immuno-Therapy for Lung Cancer: Therapies, Biomarkers, and Combinations. 58th Annual Meeting of the Japan Lung Cancer Society. Yokohama, Japan. 10/14/2017

The Science of Immunotherapy; Mechanisms of Resistance in IO. 18th IASLC World Conference on Lung Cancer. Yokohama, Japan. 10/15-17/2017

KEYNOTE-021G, 024 and CM026 and the Latest Trials. MSD-sponsored program at 18th IASLC World Conference on Lung Cancer. Yokohama, Japan. 10/17/2017

Immunotherapy in NSCLC: The Takeover. EPIC (Emerging Paradigms in Care) Expert Panel Discussion at 18th IASLC World Conference on Lung Cancer. Yokohama, Japan. 10/18/2017

Lung-MAP: Opportunities for Longitudinal Follow-Up of Patients with Liquid Biopsy. Biomarkers Consortium Cancer Steering Committee Annual Scientific Symposium. Washington, DC. 11/6/2017

The Evolving Development of Biomarkers for Immunotherapy. 35th Annual Chemotherapy Foundation Symposium. New York, NY. 11/9/2017

Immunotherapy's Second Act: New Combinations (including CTLA-4 and IDO inhibition). 12th Annual New York Lung Cancer Symposium. New York, NY. 11/11/2017


Page 83 of 103

Role of Monoclonal Antibodies: Can EGFR mABs be Resuscitated? Imedex 22nd Annual Perspectives in Thoracic Oncology. New York, NY. 11/18/2017

Emerging Technologies to Monitor Complex Immune Interplay in the Tumor Microenvironment. Cancer Research Institute’s Cancer Immunotherapy Consortium. New York, NY. 1/24/2018

Using Combinations of Immunotherapy in Non-Small Cell Lung Cancer. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium. San Francisco, CA. 1/26/2018

The Science of Immune Checkpoint Inhibitors + Other Immune Combination Co-stimulatory and Co--Inhibitor molecules. 18th Annual Targeted Therapies of Lung Cancer Meeting. Santa Monica, CA. 02/22/2018

Tom Grogan Honorary Keynote Lecture: Novel Biologically Based Clinical Trials using Immune Phenotyping: Battle Immunotherapy. Tucson Symposium 2018. Tucson, AZ. 03/13/2018

Personalized Immunotherapy for NSCLC. 8th Annual Cancer Immunotherapy Conference. New York, NY. 04/05/2018

Clinical Trials Plenary, CTPL03 Immunotherapy Combinations: The New Frontier in Lung Cancer (discussant); A Town Hall Discussion of AACR’s Priorities in Tobacco Policy (chair); SU2C Scientific Session: Harnessing the Whole Immunotherapy Arsenal. AACR 2018 Annual Meeting. Chicago, IL, 04/14-18/2018

New Frontiers in Cancer Care: Challenges of Combination Therapies. 2018 Oncology Nursing Society (ONS) Annual Congress. Washington, DC. 05/19/2018

IO in the Age of Precision Medicine: How Precise Is It? World Conference on Interventional Oncology (WCIO) 2018. Boston, MA 06/07/2018

KN-010 Trial Design; The Roles of Immune Checkpoint Inhibitors for PD-L1 positive NSCLC; Primary and Acquired Mechanisms of Resistance to Immunotherapies. 6th Japanese Cancer Association (JCA) -AACR Special Joint Conference on Lung Cancer. Kyoto, Japan. 07/12/2018

Limits of Monotherapy, and the State of PD-1 and PD-L1 Combination Therapies in Clinical Trials; Regulatory Challenges with Developing PD-1/PD-L1 Combination Therapies (moderator); Stakeholder Perspectives on the Path Forward (panelist). National Cancer Polity Forum: Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors. Washington, DC. 07/16-17/2018

Translational Research in Lung Cancer: Improving Medicine Through Science (moderator); Strategies for Overcoming KRAS Mutations; Combination Immunotherapies: What's Hot and What's Not (panelist). 18th Annual International Lung Cancer Congress. Huntington Beach, CA. 07/26-28/2018

Planning a Career in Lung Cancer - Clinical Trials. 18th IASLC World Conference on Lung Cancer. Toronto, Canada. 10/18/2017

Personalizing Immmunotherapy for Cancer: Clinical Trials, Biomarkers, and Combinations. National Academy of Medicine Interest Group Meeting. Washington, DC. 10/14/2018

Pragmatic and Adaptive Trials: Defining Their Role in Evidence Generation. Conquer Cancer Corporate Conquerors Circle Annual Meeting. Alexandria, VA. 10/16/2018

Total Mutation Burden is a Necessary Clinical Tool for Managing NSCLC Patients Today (Debate: Yes). Should We Use the Most Effective Anti-ALK-Directed Therapy or Anti-EGFR Therapy "Up Front" or Save it for Relapse? (Debate: Save it for Relapse). 11th Annual Symposium on Personalized Therapies and Best Practices for Lung Cancer and H&N Cancer. San Francisco, CA. 10/27/2018.


Page 84 of 103

Consensus rr Controversy: Clinical Investigators Provide Perspectives on the Current and Future Application of Immune Checkpoint Inhibition in the Management of Metastatic Lung Cancer (faculty member). Research to Practice Satellite Symposium at the 2018 SITC Annual Meeting. Washington, DC. 11/8/2018

Which Biomarker Is Best to Guide Clinical Decision Making with IO Therapy? PD-L1, TMB, or Nothing at All? (panelist). Advances In Biomarkers: How Can I Utilize Tumor Mutational Burden in my Practice? 36th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow. New York, NY. 11/9/2018

System Therapies. 13th Annual New York Lung Cancers Symposium. New York, NY. 11/10/2018.

Lessons from Recent Immuno-Oncology Trials - When Activity Estimation Diverges from Therapeutic Confirmation: Biomarker Selection Considerations. SITC 33rd Annual Meeting. Washington, DC. 11/11/2018.

Long-term Results with Single Agents (pembroplizumab, nivolumab, atezolizumab, durvalumab). IASLC 19th Lung Cancer Targeted Therapies Meeting. Santa Monica, California. 2/21/2019

Immunotherapy in Lung Cancer—Sensitivity-Resistance and New Indications (chair). ASCO-SITC Clinical Immuno-Oncology Symposium. San Francisco. 2/28/2019

Current Landscape in NSCLC. 9th Annual Cancer Immunotherapy Conference. New York, NY. 03/21/2019

Clinical Trials Plenary, CTPL02 Can the Challenge of NSCLC Resistance be MET or Will We Not MEK It? (Discussant). A Discussion of the U.S. Youth E-cigarette Epidemic: Using Science to Inform Policy to Prevent Another Generation from the Dangers of Nicotine Addiction (chair). AACR Annual Meeting 2019. Atlanta, GA. 3/31/2019.

New Combinations for Personalizing Immunotherapy and Targeting Resistance (chair). Using Science to Guide Rational Combinations for Immunotherapy. Tucson Symposium 2019. Tucson, AZ. 04/09/2019

Personalized immunotherapy for Non-Small Cell Lung Cancer: Sensitivity, Resistance, and Combinations (Keynote). 2019 China Cancer Immunotherapy Workshop. Tianjin, China. 06/30/2019.

Cancer Immunotherapy; A Paradigm Shift in the First-Line Treatment of Lung Cancer. 17th Annual Meeting of JSMO. Kyoto, Japan. 07/18/2019.

Other, Including Scientific Exhibitions Pneumocystis Carinii Pneumonia in Non-small Cell Lung Cancer Patients Treated with Combination Gemcitabine and Vinorelbine Therapy, US Gemzar Investigators Meeting, New Orleans, LA, 3/1/1999

Phase II Study of Combination Weekly Gemcitabine and Vinorelbine in Patients with Untreated or Previously Treated Non-small Cell Lung Cancer, 35th ASCO 1999 Annual Meeting, Atlanta, GA, 5/1/1999

Phase II Study of Paclitaxel, Ifosfamide, and Carboplatin in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck, 35th ASCO 1999 Annual Meeting, Atlanta, GA, 5/1/1999

Continuous Administration of ZD1839 (IressaTM), a Novel Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Patients with Five Selected Tumor Types: Evidence of Activity and Good Tolerability, AACR-NCI-EORTC International Conference, Washington, D.C., 11/1/1999

Matrix Metalloproteinase/E-cadherin Ratio as a Molecular Predictor of Aggressive Phenotype in Non-melanoma Skin Cancer, AACR 91st Annual Meeting 2000, San Francisco, CA, 4/1/2000


Page 85 of 103

Gemcitabine with Concurrent 3D Conformal Radiation Followed by Consolidation Gemcitabine plus Cisplatin; a Phase I Trial for Patients with Stage III Non-small Cell Lung Cancer, 396th ASCO 2000 Annual Meeting, New Orleans, LA, 5/1/2000

Paclitaxel and Carboplatin Chemotherapy as a Primary Treatment of Brain Metastases in Patients with Non-small Cell Lung Cancer, 36th ASCO 2000 Annual Meeting, New Orleans, LA, 5/1/2000

Phase I Study of the Angiogenesis Inhibitor TNP-470 in Combination with Paclitaxel in Patients with Solid Tumors: A Dose Finding, Pharmacokinetic, and Efficacy Analysis, 36th ASCO 2000 Annual Meeting, New Orleans, LA, 5/1/2000

Phase II Trial of Thalidomide in The Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck, 36th ASCO 2000 Annual Meeting, New Orleans, LA, 5/1/2000

A Phase I Clinical Trial of Recombinant Human Endostatin in Patients with Solid Tumors: Pharmacokinetic, Safety and Efficacy Analysis, 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, 11/1/2000

Patients' Perceptions of a High-profile Phase I Trial, 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, 11/1/2000

In-vitro, Effect of the Epidermal Growth Factor Receptor Inhibitor PKI 166 on Human Lung Cancer Cell Lines, AACR 92nd Annual Meeting 2001, New Orleans, LA, 3/1/2001

Induction of Apoptosis of Human Endothelial Cells by Recombinant Endostatin: Development of Surrogate Assay for Clinical Studies, AACR 92nd Annual Meeting 2001, New Orleans, LA, 3/1/2001

Carboplatin + Paclitaxel + rhuMab-VEGF may prolong survival in advanced non-squamous lung cancer, 37th ASCO 2001 Annual Meeting, San Francisco, CA, 5/1/2001

Cisplatin and Gemcitabine Combined with Herceptin in Patients with HER2 Overexpressing, Untreated, Advanced, Non-small Cell Lung Cancer, A Phase II Trial, 37th ASCO 2001 Annual Meeting, San Francisco, CA, 5/1/2001

Final report of the M. D. Anderson Phase II Study of Combination Weekly Gemcitabine and Vinorelbine in Patients with Untreated or Previously Treated Non-small Cell Lung Cancer, 37th ASCO 2001 Annual Meeting, San Francisco, CA, 5/1/2001

Induction of Pro-apoptotic Mediators and Tumor Regression Following Intratumoral Delivery of Adenoviral p53 (RPR/INGN 201) and Radiation Therapy in Patients with Non-small Cell Lung Cancer, 37th ASCO 2001 Annual Meeting, San Francisco, CA, 5/1/2001

Phase I Clinical Trial of Recombinant Human Endostatin in Patients with Solid Tumors: Pharmacokinetic, Safety and Efficacy Analysis Using Surrogate Endpoints of Tissue and Radiologic Response, 37th ASCO 2001 Annual Meeting, San Francisco, CA, 5/1/2001

Phase I Study of the Angiogenesis Inhibitor TNP-470 in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors, 37th ASCO 2001 Annual Meeting, San Francisco, CA, 5/1/2001

Phase IIa Trial of Squalamine for Treatment of Advanced Non-small Cell Lung Cancer, 37th ASCO 2001 Annual Meeting, San Francisco, CA, 5/1/2001

Efficacy and Safety of the Anti-epidermal Growth Factor Antibody, IMC-C225, in Combination with Cisplatin in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck Refractory to Cisplatin Containing Chemotherapy, 2nd International Chicago Symposium on Malignancies of the Chest and Head & Neck, Chicago, IL, 10/1/2001

A phase I Study of Continuous Infusion of TNP-470 Alone or in Combination with Paclitaxel and Carboplatin in Adult Patients with Solid Tumors, 2001 AACR-NCI-EORTC International Conference, Miami Beach, FL, 11/1/2001


Page 86 of 103

Development of an Orthotopic Model for Human Lung Cancer to Evaluate Therapeutic Efficacy of Receptor Tyrosine Kinase Inhibitors, AACR 93rd Annual Meeting 2002, San Francisco, CA, 4/1/2002

A Phase I Study of TNP-470 Continuous Infusion Alone or In Combination with Paclitaxel and Carboplatin in Adult Patients with NSCLC and Other Solid Tumors, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

A Phase II Study of SCH54031 (polyethylene glycol (PEG-modified interferon alfa-2b; PEG intron) in Previously Treated Advanced Squamous Cell Cancers of the Head and Neck, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

A Retrospective Analysis of the Outcome of Patients Who Have Received Two Prior Chemotherapy Regimens Including a Platin and Docetaxel for Recurrent Non-small Cell Lung Cancer, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

Herceptin in Combination with Cisplatin and Gemcitabine in Patients with HER2 Overexpressing, Untreated, Advanced, Non-small-cell Lung Cancer: Final Report of a Phase II Trial, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

Successful Long-term Therapy with Bevacizumab (Avastin) in Solid Tumors, 38th ASCO 2002 Annual Meeting, Orlando, FL, 5/1/2002

A Phase III Study of Æ-941 with Induction Chemotherapy and Concomitant Chemoradiotherapy for Stage III Non-small Cell Lung Cancer (NCI T99-0046, RTOG 02-70, MDA 99-303): An Interim Overall Toxicity Report, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

Alimta plus Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer: A Phase II Trial, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

Epidermal Growth Factor Receptor, HER2, and C-KIT as Predictors of Outcome in Stage I Non-small Cell Lung Cancer, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

Inter-observer and Intra-observer Variability in Measurement of 41 Non-small Cell Carcinoma Lung Lesions Implications for Assessment of Tumor Response, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

Phase I/II Study of the Recombinant Humanized Monoclonal Anti-VEGF Antibody Bevacizumab (Avastin™) and the EGFR-tk Inhibitor Erlotinib (Tarceva™) in Patients with Recurrent Non-small Cell Lung Cancer, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

Phase II Study of Cetuximab, an Epidermal Growth Factor Receptor Blocking Antibody, in Combination with Docetaxel in Chemotherapy Refractory/Resistant Patients with Advanced Non-small Cell Lung Cancer: Final Report, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

Subset Analyses of INTACT Results for Gefitinib (ZD1839) when Combined with Platinum-based Chemotherapy for Advanced Non-small Cell Lung Cancer, 39th ASCO 2003 Annual Meeting, Chicago, IL, 5/1/2003

A Phase I Surrogate Endpoint Trial of SU6668 in Patients with Solid Tumors, AACR 94th Annual Meeting 2003, Washington, D.C., 7/1/2003

Blockade of EGFR Tyrosine Kinase Does not Predict Outcome in an Orthotopic Model of Human Lung Cancer, AACR 94th Annual Meeting 2003, Washington, D.C., 7/1/2003

Endostatin Blocks Endothelial Repopulation after Radiation Therapy, AACR 94th Annual Meeting 2003, Washington, D.C., 7/1/2003

Quantitative Analysis of Biomarkers and Changes in Tumor Blood Flow Define a Biological Dose for Clinical Trials of Recombinant Human Endostatin, AACR 94th Annual Meeting 2003, Washington, D.C., 7/1/2003


Page 87 of 103

Quantitative Analysis of Biomarkers in Tumor Biopsies from Phase I/II Studies with VEGF Receptor Tyrosine Kinase Inhibitor, AACR 94th Annual Meeting 2003, Washington, D.C., 7/1/2003

A phase I study of the VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in patients with advanced solid tumors: safety, pharmacokinetics, and dceMRI, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, 11/1/2003

Biology and Therapy of Human Small Cell Lung Cancer in Novel Orthotopic Nude Mouse Models, AACR 95th Annual Meeting 2004, Orlando, FL, 3/1/2004

Clinical tumor dormancy: Biology and Regulation of Dormant Lung Metastases in a Characterization of the Dormant Tumor; B16F10 Murine Melanoma Model, AACR 95th Annual Meeting 2004, Orlando, FL, 3/1/2004

Pharmacodynamic Analysis of Target Inhibition and Tumor Endothelial Cell Death in Biopsies Obtained from Patients Treated with the VEGF Receptor Antagonists SU5416 or SU6668, AACR 95th Annual Meeting 2004, Orlando, FL, 3/1/2004

ZD6474, a Small Molecule Targeting VEGF and EGF Receptor Signaling, Inhibits Lung Angiogenesis and Metastasis and Improves Survival in an Orthotopic Model of Non-small Cell Lung Cancer, AACR 95th Annual Meeting 2004, Orlando, FL, 3/1/2004

A Phase II Trial of Pemetrexed plus Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

Clinical and Dynamic Imaging Results of the First Phase I Study of AG-013736, an Oral Anti-angiogenesis Agent, in Patients with Advanced Solid Tumors, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

Evaluation of Epidermal Growth Factor Receptor as a Predictive Marker in Patients with Non-small-cell Lung Cancer Receiving First-line Gefitinib Combined with Platinum-based Chemotherapy, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

Evaluation of Epidermal Growth Factor Receptor as a Prognostic Factor for Survival in Non-small-cell Lung Cancer Patients Treated with Platinum-based Chemotherapy as First-line Treatment, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

Limited Small Cell Lung Cancer (Stages I-III): Observations from the National Cancer Database, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

Long Survival of Never Smoking Non-small Cell Lung Cancer Patients Treated with Erlotinib HCl (OSI-774) and Chemotherapy: Sub-group Analysis of TRIBUTE, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

Pharmacokinetic Study of the Phase III, Randomized, Double-blind, Multicenter Trial of Paclitaxel and Carboplatin Combined with Erlotinib or Placebo in Patients with Advanced Non-small Cell Lung Cancer, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

Phase I/II Trial Evaluating the Anti-VEGF MAb Bevacizumab In Combination with Erlotinib, a HER1/EGFR-TK Inhibitor, for Patients with Recurrent Non-small Cell Lung Cancer, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

TRIBUTE - A Phase III Trial of Erlotinib HCI (OSI-774) Combined with Carboplatin and Paclitaxel Chemotherapy in Advanced Non-small Cell Lung Cancer, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004

ZD6474, a Novel Antiangiogenic Agent, in Combination with Docetaxel in Patients with NSCSL: Results of the Run-in Phase of a Two-part, Randomized Phase II Study, 40th ASCO 2004 Annual Meeting, New Orleans, LA, 6/1/2004


Page 88 of 103

AMG 706 First in Human, Open-label, Dose-finding Study Evaluating the Safety and Pharmacokinetics in Subjects with Advanced Solid Tumors, 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, 9/1/2004

Blocking VEGF and EGF Receptor Signaling with ZD6474 Sensitizes Human Non-small Cell Lung Cancer to Chemotherapy with Paclitaxel, 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, 9/1/2004

Erlotinib in Combination with Bevacizumab for Patients with Recurrent Non-small-cell Lung Cancer: A Phase I/II Trial, 29th ESMO Congress 2004, Vienna, Austria, 11/1/2004

Combined Blockade of VEGFR and EGFR with ZD6474 Enhances the Antitumor and Antivascular Effects of Radiation Therapy in an Orthotopic Mouse Model of Human Lung Cancer, AACR 96th Annual Meeting 2005, Anaheim, CA, 4/1/2005

Identification of Serum Protein Markers to Predict Outcome of Platin-based Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer, AACR 96th Annual Meeting 2005, Anaheim, CA, 4/1/2005

The Anti-vascular and Anti-tumor Response of Human Lung Cancer Growing Orthotopically in Mice to AEE788, a Tyrosine Kinase Inhibitor of EGFR and VEGFR, is Dependent upon EGF/TGF? Expression, AACR 96th Annual Meeting 2005, Anaheim, CA, 4/1/2005

The Time of Tissue Processing for Human Surgical Specimens Influences the Level of Epidermal Growth Factor Receptor Phosphorylation, AACR 96th Annual Meeting 2005, Anaheim, CA, 4/1/2005

ZD6474 Inhibits Human Lung Cancer Bone Metastases in a Murine Model by Targeting Both the Tumor and its Vasculature, AACR 96th Annual Meeting 2005, Anaheim, CA, 4/1/2005

A Phase III Study of Æ941 with Induction Chemotherapy (IC) and Concomitant Chemoradiotherapy (CRT) for Stage III Non-small Cell Lung Cancer (NSCLC) (NCI T99-0046, RTOG 02-70, MDA 99-303): An Interim Report of Toxicity and Response, 2005 ASCO Annual Meeting, Orlando, FL, 5/1/2005

A Randomized Phase III Trial Comparing Bexarotene/Carboplatin/Paclitaxel versus Carboplatin/Paclitaxel in Chemotherapy-naive Patients with Advanced or Metastatic Non-small Cell Lung Cancer, 2005 ASCO Annual Meeting, Orlando, FL, 5/1/2005

A Randomized, Placebo-controlled Phase II Trial of ZD6474 Plus Docetaxel, in Patients with NSCLC, 2005 ASCO Annual Meeting, Orlando, FL, 5/1/2005

Efficacy and Safety of Gefitinib in Chemo-naive Patients with Non-small Cell Lung Cancer in an Expanded Access Program, 2005 ASCO Annual Meeting, Orlando, FL, 5/1/2005

MALDI-TOF Mass Spectrometry Proteomic Profiling to Discriminate Response to the Combination of Bevacizumab and Erlotinib in Non-small Cell Lung Cancer, 2005 ASCO Annual Meeting, Orlando, FL, 5/1/2005

Phase I/II Trial of Bevacizumab Plus Erlotinib for Patients with Recurrent Non-small Cell Lung Cancer: Correlation of Treatment Response with Mutations of the EGFR Tyrosine Kinase Gene, 2005 ASCO Annual Meeting, Orlando, FL, 5/1/2005

Preliminary Phase II Safety Evaluation of ZD6474, in Combination with Carboplatin and Paclitaxel, as 1st Line Treatment in Patients with NSCLC, 2005 ASCO Annual Meeting, Orlando, FL, 5/1/2005

Safety & Pharmacokinetics of AMG706 in Patients with Advanced Solid Tumors, 2005 ASCO Annual Meeting, Orlando, FL, 5/1/2005

TGF-α and Phosphorylated EGFR Protein Levels Impact the Survival of Patients with Stage I-IIIA Non small Cell Lung Cancer, AACR 97th Annual Meeting 2006, Washington, D.C., 4/2006


Page 89 of 103

A Phase II, Multicenter, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab in Combination with Either Chemotherapy (docetaxel or pemetrexed) or Erlotinib Hydrochloride Compared With Chemotherapy Alone for Treatment of Recurrent, 2006 42nd ASCO Annual Meeting, Atlanta, GA, 6/2006

Apo2L/TRAIL Pharmacokinetics in a Phase 1a Trial in Advanced Cancer and Lymphoma, Poster Discussion, 2006 42nd ASCO Annual Meeting, Atlanta, GA, 6/2006

Independent Review of Fatal Interstitial Lung Disease (ILD) in TRIBUTE: Paclitaxel + Carboplatin + Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC), Poster Discussion, 2006 42nd ASCO Annual Meeting, Atlanta, GA, 6/2006

Safety and Antitumor Activity of AMG 706 in Patients (pts) with Thyroid Cancer (TC): A Subset Analysis from a Phase 1 Dose-Finding Study, Poster Discussion, 2006 42nd ASCO Annual Meeting, Atlanta, GA, 6/2006

Safety and Pharmacokinetics (PK) of AMG 706, Panitumumab, and Carboplatin/paclitaxel (CP) for the Treatment of Patients (pts) with Advanced Non-Small Cell Lung Cancer (NScLC), General Poster Session, 2006 42nd ASCO Annual Meeting, Atlanta, GA, 6/2006

Served as Mentor at the Professional Advancement Series Roundtable Session entitled, "Careers in Clinical and Translational Cancer Research," AACR 98th Annual Meeting 2007, Los Angeles, CA, 4/14/2007

A Phase II randomized selection trial evaluating concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in patients with advanced non-small cell lung cancer (NSCLC) : Final report of SWOG 0342, Poster Discussion, 2007 43rd ASCO Annual Meeting, Chicago, IL, 6/2007

Served as Mentor at the ASCO Patient Advocate Mentor Program, 2007 43rd ASCO Annual Meeting, Chicago, IL, 6/2007

Served as Moderator of the Lung/Head and Neck Cancers News Briefing, 2007 43rd ASCO Annual Meeting, Chicago, IL, 6/2007

Served as Moderator of the Late Breaking Clinical Trials press briefing, AACR 99th Annual Meeting 2008, San Diego, CA, 4/2008

A Phase III, Multicenter, Placebo-controlled, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab (Avastin) in Combination with Erlotinib (Tarceva) Compared with Erlotinib Alone for Treatment of Advanced Non-small cell Lung Cancer After Failure of Standard First-line Chemotherapy (BETA), ISALC News Briefing, Chicago, IL, 11/13/2008

Served as Moderator of Educational Session titled "Pairing Chemotherapy with Radiation: Treating Stage III Lung Cancer from Multiple Angels," Multidisciplinary Symposium on Thoracic Oncology, Chicago, IL, 11/14/2008

Served as Moderator of Forum titled "Molecular Biology in Early Phase Clinical Trials," AACR 100th Annual Meeting 2009, Denver, CO, 4/20/2009

Vandetanib plus docetaxel versus docetaxel as 2nd-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC), Lung Cancer Press Briefing, 2009 45th ASCO Annual Meeting, Orlando, FL, 5/30/2009

Customizing Therapy for Localized NSCLC, Poster Discussion, 2009 45th ASCO Annual Meeting, Orlando, FL, 5/30/2009

New Agents for Lung Cancer: A Tailored Approach, M. D. Anderson Physicians Network Fifth Annual Symposium, sponsored by UT-MDACC, Boston, MA, 7/13/2009


Page 90 of 103

Targeted Agents for the Treatment of NSCLC: Mechanisms of Action and Efficacy, New & Emerging Strategies for Targeting Non-Small Cell Lung Cancer, 13th World Congress on Lung Cancer, San Francisco, CA, 7/31/2009

Investigational Drugs in Late Stage Development for Lung Cancer, Second Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer and Head and Neck Cancer, Philadelphia, PA, 9/26/2009

Toward Personalized Therapy of Advanced Non-Small Cell Lung Cancer, Yale Cancer Center Grand Rounds, New Haven, CT, 12/8/2009

Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial, 2010 ASCO Annual Meeting, Chicago, IL, 6/6/2010

Toward Personalized Therapy for Advanced Non-Small Cell Lung Cancer: The MD Anderson BATTLE Program, AACR Translational Cancer Medicine 2010 (USA), AACR, San Francisco, CA, 7/11/2010

Toward Personalized Therapy for Advanced Non-Small Cell Lung Cancer: The MD Anderson BATTLE Program, AACR Translational Cancer Medicine 2010 (USA), AACR, San Francisco, CA, 7/12/2010

EGFR Inhibitors, 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL, 12/9/2010

Antibodies Targeting Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor In Advanced Non-Small Cell Lung Cancer, Keystone Symposia, Keystone, CO, 2/10/2011

Lung Cancer: Analysis of Primary/Metastatic Samples, Yale-Gilead Joint Steering Committee Meeting, Fourth Quarter 2011, Foster City, CA, 1/26/2012

Personalized Therapy for Advanced Non-Small Cell Lung Cancer; Lessons Learned from the Battle Trials, Flight Attendants Medical Research Institute Center of Excellence at Johns Hopkins, Flight Attendants Medical Research Institute Seminar Series, Johns Hopkins, Baltimore, MD, 2/27/2012

Challenging Conventional Cancer Care: The Untold Story of Tobacco’s Effect on Cancer Biology, Treatment Response and Survival, AACR Committee Service Charlotte Friend Memorial Lectureship Meeting, Chicago, IL 4/1/2012

Early Phase Testing of Two Drugs: Practical Challenges, AACR, Chicago, IL, 4/3/2012

Lessons Learned from the BATTLE Trials: Personalized Therapy for Advanced Non-small Cell Lung Cancer, From Molecular Mechanisms to Targeted Cancer Therapy, DFG German Research Foundation, Cadenabbia (Co), Italy, 4/26-29/2012

State-of-the-art Clinical Trials in 2012, Opportunities and Challenges in Lung, Cancer Symposium, Cancer Research UK, United Kingdom Lung Cancer Symposium, Manchester, United Kingdom, 4/30 – 5/1/2012

Targeting Histology & Oncogenic Drivers of NSCLC: Review of Late Breaking Data, Letters & Sciences and the University of Nebraska Medical Center, Chicago, IL, 6/3/2012

Bringing Battle to Yale – The Developmental Therapeutics Program, UCL Cancer Institute 5th Annual Conference and the 3rd Annual UCL Cancer Research UK Centre Conference, England, 6/27/2012

VEGR Signaling Inhibition by Cediranib Enhances the Antitumor and Anti-metastatic Effects of Radiation Theory More Substantially Than Chemotherapy in Orthotopic Lung Cancer Models, 15th Annual World Conference on Lung Cancer, Poster Session, Sydney, Australia, 10/28/2013


Page 91 of 103

Modernizing Clinical Trials Hearing, Testimony before the Energy and Commerce Committee, United States House of Representatives, Washington D.C., 7/8-9/2014

Personalized Therapy for Lung Cancer: Past Present and Future, Pfizer Oncology Year Beginning Meeting, San Diego, CA, 1/27/2015

The Evolving Role of Immuno Oncology in Lung Cancer, Merck Oncology CBL Leadership Meeting, Bridgewater, NJ, 2/26/2015

Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010. Discussion Session: ESMO 2016 Congress. Copenhagen. 10/09/2016

Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). Poster Discussion Session: ESMO 2016 Congress. Copenhagen. 10/10/2016

Novel Therapy for Lung Cancer: From Targeted Therapy to Immuno-Therapy and Back Again. US Oncology Research held its 15th Annual Science Forum. Dallas, TX. 10/10/2016

Clinical Applications and Next Steps to Apply Biomarkers with the Use of Immunotherapies. Annual Chemotherapy Foundation Symposium. New York, NY. 11/09/2016

143TiP - IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC (poster session): Immunotherapies and targeted therapies in advanced NSCLC: 83O - A phase II study of Durvalumab (MEDI4736) for previously treated patients with stage IV squamous NSCLC (SqNSCLC): Lung-MAP Sub-study SWOG S1400A (proffered paper); Targeted therapies and immunotherapies 90PD - Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): efficacy and safety data (poster session). 7th European Lung Cancer Conference. Geneva, Switzerland. 5/05-08/2017

Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010. (poster session); Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. (poster session); Phase II study of the FGFR inhibitor AZD4547 in previously treated patients with FGF pathway-activated stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400D. (poster session); Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. (poster session); A phase II study of palbociclib (P) for previously treated cell cycle gene alteration positive patients (pts) with stage IV squamous cell lung cancer (SCC): Lung-MAP sub-study SWOG S1400C. (poster session); A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B. (poster session); Disparities in next generation sequencing in a population-based community cohort of patients with advanced non-small cell lung cancer. (poster session). 2017 ASCO Annual Meeting. Chicago, IL. 6/02-06/2017

ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection (poster presentation). Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D. (oral presentation). 18th IASLC World Conference on Lung Cancer. Yokohama, Japan. 10/15-17/2017

American Association for Cancer Research to Host Congressional Briefing on E-Cigarettes, Russell Senate Office Building, Washington D.C., Moderator, 7/18/2018

Immune System: Adaptive vs. Innate, role of T cell, B cell, dendritic cells. Training program for AbbVie Liaisons. 18th IASLC World Conference on Lung Cancer.Toronto, Canada. 9/23/2018


Page 92 of 103

Long-Term Survival in Patients (Pts) With Advanced NSCLC In The KEYNOTE-010 Study Overall and in Pts Who Completed 2 Years of Pembrolizumab. (Proferred Paper Session) European Society for Medical Oncology (ESMO) Congress. Munich, Germany. 10/21/2018

Long-Term Follow-Up in The KEYNOTE-010 Study of Pembrolizumab (Pembro) for Advanced NSCLC, Including in Patients Who Completed 2 Years of Pembro and Pts Who Received a Second Course of Pembro. (Proffered Paper Session). ESMO Immuno-Oncology Congress 2018. Geneva, Switzerland. 12/15/2018

Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non–small-cell lung cancer (NSCLC): LEAP-006, Abstract TPS9118 (poster). Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non–small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT study Abstract TPS9117 (poster). A Phase III Randomized Study of Nivolumab Plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study S1400I, NCT02785952) Abstract 9014 (poster). Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). Abstract 9075. American Society of Clinical Oncology (ASCO) Annual Meeting 2019. Chicago, IL. 06/02/2019.

Seminar Invitations from Other Institutions Therapy for Advanced Stage Non-small Cell Lung Cancer, University of Louisville, Louisville, KY, 3/1/1997

Update 1997-Non-small Cell Lung Cancer, St. Elizabeth's Hospital, Beaumont, TX, 8/1/1997

Novel Treatment Approaches for Breast Cancer: New Cytotoxic Agents and Antiangiogenesis Therapy, Children's Hospital Medical Center, Cincinnati, OH, 10/1/1997

Multimodality Therapy for Non-small Cell Lung Cancer, University of Texas A&M, Bryan, TX, 1/14/1998

New Chemotherapeutic Agents for Non-small Cell Lung Cancer: Novel Cytotoxic Agents and Antiangiogenesis Therapy, The University of Texas Medical Branch-Galveston, Galveston, TX, 2/4/1998

Current Therapy for Advanced Non-small Cell Lung Cancer-New Cytotoxic Drugs and Antiangiogenic Agents, The University of California-Davis Medical Center, Sacramento, CA, 2/27/1998

Therapy for Non-small Cell Lung Cancer, Bentaub Hospital, Houston, TX, 3/11/1998

Therapy for Advanced Non-small Cell Lung Cancer: Cytotoxic Agents, Antiangiogenesis Therapy, The University of Texas Health Science Center, Her, Houston, TX, 6/9/1998

Antiangiogenic Therapy-Truth versus Myth, Marshall University School of Medicine, Huntington, WV, 9/15/1998

Therapeutic Strategies for Advanced Non-small Cell Lung Cancer: New Cytotoxic Agents and Antiangiogenic Strategies, St. Paul University Hospital, Dallas, TX, 10/14/1998

Antiangiogenesis: Preclinical Studies and Clinical Trial, Henry Ford Hospital, Detroit, MI, 12/11/1998

Current Approaches to the Treatment of Advanced Non-small Cell Lung Cancer: New Cytotoxic Drugs and Antiangiogenic Agents, University of Washington Cancer Center, Seattle, WA, 3/5/1999

Targeted Drug Therapy for Advanced Non-small Cell Lung Cancer: Angiogenesis and Signal Transduction Inhibitors, Wayne State Medical Center, Detroit, MI, 10/28/1999

Molecular Therapy of Non-small Cell Lung Cancer, University of Maryland Greenebaum Cancer Center, Baltimore, MD, 11/8/1999


Page 93 of 103

Emerging Therapies for Advanced Non-small Cell Lung Cancer, University of Texas Southwestern Medical Center, Dallas, TX, 11/12/1999

Angiogenesis Inhibitors in Lung Cancer, Weill College of Medicine of Cornell University, New York, NY, 2/25/2000

Biologic Therapy of Lung Cancer, Henry Ford Hospital, Detroit, MI, 6/16/2000

Clinical Trial Designs Using New Biological Agents: Bridging the Gap Between the Laboratory and Clinic, M. D. Anderson Cancer Center-Orlando, Orlando, FL, 11/3/2000

Advances in Second Line Treatment of Lung Cancer, Midland Regional Hospital, Midland, TX, 11/29/2000

Angiogenesis and Epidermal Growth Factor Receptors as New Targets in Cancer Therapy, University of Cincinnati, Cincinnati, OH, 12/15/2000

Angiogenesis and Epidermal Growth Factor Receptors as New Targets in Cancer Therapy, Miami Valley Hospital, Dayton, OH, 12/15/2000

Novel Therapeutic Approaches for Advanced NSCLC: Antiangiogenic Agents and EGFR Inhibitors, Dana-Farber/Partners and Best Israel Hospital Thoracic, Boston, MA, 2/12/2001

New Treatment Trends in NSCLC, University of Chicago Grand Rounds, Chicago, IL, 2/26/2001

Novel Therapy for Advanced NSCLC: EGFR Inhibitors and Antiangiogenic Agents, Memorial Sloan Kettering Cancer Center Medical Gra, New York, NY, 11/20/2001

Novel Therapeutic Options for Advanced NSCLC: Antiangiogenesis Agents and EGFR, Mount Sinai School of Medicine-Division of Medical, New York, NY, 3/8/2002

Innovative Treatments for Small, Early Lung Cancer, Cornell University, New York, NY, 10/18/2002

Targeted Therapies for Lung Cancer, Memorial Sloan Kettering Cancer Center, New York, NY, 11/14/2002

Targeted Therapy for NSCLC, Mayo Clinic, Rochester, MN, 2/25/2003

Management of Advanced Lung Cancer, Dana Farber Cancer Institute, Boston, MA, 3/18/2003

Grand Rounds, Yale Cancer Center, New Haven, CT, 10/14/2003

Molecular Targeted Therapy for Advanced NSCLC, Indiana Cancer Center, Indianapolis, IN, 4/16/2004

Grand Rounds-Clinical Oncology, University of Pittsburgh Cancer Institute-Clinical, Pittsburgh, PA, 4/28/2004

Novel Therapeutic Strategies for Advanced Non-small Cell Lung Cancer, University of Chicago, Chicago, IL, 6/21/2004

From Prevention to Proteomics and Beyond, Mayo Clinic, Rochester, MN, 8/20/2004

Lung Cancer: The EGFR Family and EGFR Inhibitors as Treatment for NSCLC, Baylor College of Medicine, Houston, TX, 9/18/2004

Evolving Evidence Impacting Patient Outcomes in Non-Small-Cell Lung Cancer, Emory University, Atlanta, GA, 10/13/2004

Update on Novel Targeted Therapies for NSCLC, Martin Luther King Jr./Drew Medical Center, Los Angeles, CA, 4/14/2005


Page 94 of 103

The Role of Tarceva (erlotinib) in the Treatment of Locally Advanced or metastatic NSCLC After Chemotherapy Failure, The University of Texas M. D. Anderson Cancer Center, Orlando, FL, 5/12/2005

Novel Therapeutic Approaches for Advanced Non-small Cell Lung Cancer: Antiangiogenic Drugs and Epidermal Growth Factor Receptor Inhibitors, Christus St. Elizabeth Hospital/Mamie McFadden War, Beaumont, TX, 5/31/2005

The Role of Tarceva (erlotinib) in the Treatment of Locally Advanced or Metastatic NSCLC After Chemotherapy Failure, The University of Texas Medical School, Houston, TX, 6/7/2005

Antiangiogenic Therapy for Cancer: Biologic Principles and Clinical Outcomes, Grand Rounds, Medical Center of Plano, Plano, TX, 8/25/2005

Recent Advances with HER1/EGFR-Targeting Therapies for Non-small Cell Lung Cancer, Grand Rounds, Scott and White Memorial Hospital and Clinic, Temple, TX, 1/12/2006

Therapies for Treating Non-small Cell Lung Cancer, Grand Rounds, Texas A&M University System-Health Science Center, Coastal Bend Health Education Center, Corpus Christi, TX, 2/22/2006

New Approaches to Lung Cancer: Translating Clinical Research into Clinical Practice, Grand Rounds, University of Wisconsin Medical School, Madison, WI, 5/10/2006

Antivascular Therapy for NSCLC, Grand Rounds, UT-MDACC, Division of Cancer Medicine, Houston, TX, 7/11/2006

Oncologic Interventional Radiology Seminar Series: Lung Cancer, Didactic Sessions, Case Presentations and Practice Development Components with a Specific Focus on RF Ablation Techniques, Society of Interventional Radiology, Houston, TX, 1/18/2007

MD Anderson Battle Program: A New Paradigm for Personalized Medicine, Sanford-Burnham Institute, San Diego, CA, 7/30/2010

Grand Rounds, Winship Cancer Institute of Emory University, Atlanta, GA, 1/26/2011

Beth Israel Hematology/Oncology Grand Rounds, Boston, MA, 4/27/2011

Personalized Therapy of Lung Cancer Cancer. Presentation at Pittsburgh Conference on 5/5/2011

Progress on the Treatment of Lung Cancer, CancerCare, 4/20/2012

From Iressa to Battle: The Evolution of Personalized Therapy for Advanced Non-Small Cell Lung Cancer. Institute for Translational Medicine and Therapeutics (ITMAT) Seminar Series, University of Pennsylvania, PA, 6/28/2012.

Personalized Therapy for Advanced Non-Small Cell Lung Cancer, Grand Rounds, University of Florida Shands Cancer Center, Gainesville, FL, 1/9/2013

Personalized Immuno-therapy for Advanced Non-Small Cell Lung Cancer, Grand Rounds, Monter Cancer Center, North Shore-Long Island Jewish Health System, Lake Success, NY, 3/15/2015

T Cell Immune Checkpoint Blockade: Beyond PD-1: What’s next?; Lung Cancer 2015: New Discoveries, New Directions CME-accredited course, Weill Cornell Medical College | Columbia University Medical Center, New York, NY, 6/11/2015

Clinical Debate and Consensus Recommendation on the Use of Antiangiogenic Agents in Long Cancer: A Focus on the Elderly Patient. John H. Stroger Hospital of Cook County, Chicago, IL. 6/2/2016

Keynote Lecture: Discovery and Development of Anti-PDL1 Therapy; IO Therapies and The Paradigm Shift in Cancer Treatment: What Does It Mean for Oncology Clinical Trials? and


Page 95 of 103

Immunotherapy in NSCLC: Where are We Now and Where are We Going?. 21st Annual Scientific Symposium “Immuno-Oncology Hong Kong 2016”. Chinese University of Hong Kong (CUHK). Hong Kong. 11/16/2016

Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From BATTLE to Master Protocols. Ohio State University Comprehensive Cancer Center Translational Therapeutics Program Seminar. Columbus, OH. 2/14/2018

Personalized Immunotherapy for NSCLC: From Battle to Keynote. MDACC Translational Molecular Pathology (TMP) Annual Retreat. Houston, TX. 06/09/2018

Harnessing the Immune System in Lung Cancer: A Look to the Future. University of Messina International Symposium: Pattern of Therapeutic Challenges in Pulmonology: A Template for the Next Decade. Taormina, Italy. 10/18/2018

Personalized Immunotherapy for Lung Cancer: Understanding Mechanisms of Sensitivity and Resistance. 13th Dana-Farber/Harvard Cancer Center Lung Cancer Symposium. Boston, MA. 04/29/2019.

Personalized Immunotherapy for Lung Cancer: The Yale Cancer Center for Immuno-Oncology. China National Cancer Center. Beijing, China. 07/02/2019.

Lectureships and Visiting Professorships Chemotherapy XV Symposium Lectureship, TNP-470 and Taxol Chemotherapy, Mount Sinai Hospital, New York, NY, 11/1/1997

Methods Clinical in Cancer Research, AACR/ASCO, Vail, CO, 7/25/1998

Solid Tumor Update 1999, Emerging Therapy for Solid Tumors, New Drugs, AACR/ASCO, Vail, CO, 3/21/1999

Methods in Clinical Cancer Research, AACR/ASCO, Vail, CO, 8/1/2000

The Biology of Metastases: New Therapeutic Targets and Their Relevance for Current Clinical Practice, ASCO, Orlando, FL, 11/4/2000

Program Committee Meeting, ASCO, San Diego, CA, 1/26/2001

Cancer Communications Committee, ASCO, Scottsdale, AZ, 2/4/2004

Cancer Communication Committee, ASCO, Boston, MA, 8/1/2004

Methods in Clinical Cancer Research, AACR/ASCO, Vail, CO, 7/28/2007

Methods in Clinical Cancer Research, AACR/ASCO, Vail, CO, 8/2008

Challenging Conventional Cancer Care: The Untold Story of Tobacco’s Effect on Cancer Biology, Treatment Response, and Survival, AACR Committee Service, Charlotte Friend Memorial Lectureship, Chicago, IL 3/31 – 4/3/2012

UT-MDACC Department of Cancer Medicine Grand Rounds. From Iressa to Battle: The Evolution of Personalized Treatment for Lung Cancer. Houston, TX, 4/23/2012

Dartmouth College Grand Rounds, Personalized Therapy for Advanced Non-Small Cell Lung Cancer. Hanover, New Hampshire, 06/20/2013

Oncology Visiting Professorship CME/CE Program sponsored by the Academy for Continued Healthcare Learning, LLC, New Rochelle, NY, 1/4/2013

Dean’s Distinguished Lecture Series, Weill Cornell Medical College, “Personalized Therapy for Non-Small Cell Lung Cancer: From the BATTLE Trails to the Master Protocol,” New York, NY, 7/16/2014


Page 96 of 103

Paul Calabresi Visiting Professor Seminar, St Louis School of Medicine, Washington University, “Personalized Immunotherapy for Non-Small Cell Lung Cancer,” St Louis, MO, 12/9/2014

University of California Los Angeles (UCLA), Clinical and Translational Science Institute Seminar Series, “Personalized Immunotherapy for Advanced Non-Small Cell Lung Cancer,” Los Angeles, CA, 2/18/2015

UT-MDACC, Waun Ki Hong Visiting Professorship Division of Cancer Medicine Grand Rounds; Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From BATTLE to Immunotherapy, Houston, TX 8/4/2015

Opening Symposium for the Yale/ Shanghai Jiao Tong University Biostatistics Center. Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From BATTLE to Master Protocols to Immunotherapy. Shanghai, China, 11/14/2015

Columbia University Grand Rounds. Personalized Therapy for Advanced Non-Small Cell Lung Cancer: From BATTLE to Master Protocols. New York, NY. 2/3/2016.

Methods in Clinical Cancer Research, AACR/ASCO, Vail, CO, 7/23-29/2016

Methods in Clinical Cancer Research, AACR/ASCO, Vail, CO, 7/30-8/4/2017

The Moross Integrated Cancer Center, Seizmann Institute of Science, Cancer Research Club. Personalized Immunotherapy for Lung Cancer. Rehovot, Israel. 8/8/2017

Hackensack UMC Oncology Grand Rounds. Personalized Immuno-therapy for Lung Cancer. Hackensack, NJ. 09/14/2017

Cleveland Clinic Cancer Center Bruell Memorial Lung Cancer Lecture, Grand Rounds. Personalized Immuno Therapy for Advances Non-Small Cell Lung Cancer. Cleveland, OH, 10/27/2017

Robert L Krigel Endowed Memorial Lecture. Personalized Targeted Therapties and Immunotherapies for Lung Cancer. Philadelphia, PA. 04/30/2018

Mount Sinai Hematology/Medical Oncology Grand Rounds. Personalized Immunotherapies for Lung Cancer: From BATTLE to KEYNOTE. New York, NY 06/28/2018

Methods in Clinical Cancer Research, AACR/ASCO, Vail, CO, 7/28-8/3/2018

Keynote Lecture- Personalized Therapy for Lung Cancer: From Battle to Immunotherapy and Back Again. 7th Annual Lung Cancer Symposium at Sidney Kimmel Cancer Center. Philadelphia, PA. 3/8/2019.

Keynote: Immunotherapy for NSCLC: Understanding Sensitivity and Resistance. Annual Baylor College of Medicine and MD Anderson Cancer Center Joint Symposium on Drug Development. Houston, TX. 06/20/2019.

Other Presentations at State and Local Conferences Angiogenesis in Lung Cancer, Prognostic Factors, and Therapeutic Implications, Grand Rounds, UT-MDACC, Houston, TX, 7/1/1998

Angiogenesis in Lung Cancer-Prognostic Factors and Therapeutic Implications, 11th Annual Clinical Community Oncology Program (CCOP) Meeting, Clinical Community Oncology Program, Houston, TX, 9/1/1998

Clinical Trial Design with Antiangiogenesis Agents, Workshop on Differentiating Agents in Head and Neck Cancer, Society of Differentiation, Houston, TX, 10/3/1998

Advances in the Treatment of Non-small Cell Lung Cancer, Grand Rounds, Methodist Hospital, Houston, TX, 10/7/1998


Page 97 of 103

Non-small Cell Lung Cancer: Update 1998, Northeast Regional Medical Center, Humble, TX, 11/1/1998

Antiangiogenesis, Agents: Truths versus Myths, Advanced Practice Nurse Oncology Education Meeting, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/18/1998

The Treatment of Non-small Cell Lung Cancer: Multimodality and New Drug Approaches-Update 1998, Texas Academy of Family Physicians, Houston, TX, 12/1/1998

Antiangiogenic Agents with Solid Tumors, Houston Oncology Nursing Association, Houston, TX, 2/17/1999

Angiogenesis and Current Therapies, Department of Bioimmunotherapy, UT-MDACC, Houston, TX, 3/1/1999

Focus on Care: Medicine Science and Research, Living Fully with Cancer Conference, UT-MDACC, Houston, TX, 9/25/1999

Angiogenesis Studies and Endostatin, Partners In Knowledge, News in Cancer Conference, UT-MDACC, Houston, TX, 10/5/1999

Trial Design Issues with Antiangiogenic Agents, Institutional Grand Rounds-Session, UT-MDACC, Houston, TX, 8/18/2000

Innovative Clinical Trials for Lung Cancer Patients. Living Fully with Cancer Conference, UT-MDACC, Houston, TX, 9/8/2000

Clinical and Laboratory Studies of Lung Cancer Metastasis, Institutional Grand Rounds, UT-MDACC, Houston, TX, 5/18/2001

Angiogenesis as a Novel Target in Cancer Therapy, 23rd Annual Pharmacy Symposium on Cancer Chemotherapy, UT-MDACC, Houston, TX, 9/30/2001

Clinical Studies with the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody IMC-C225 in Head and neck and Lung Cancer, Institutional Grand Rounds, UT-MDACC, Houston, TX, 10/19/2001

Angiogenesis Inhibitors, UT-MDACC, Houston, TX, 1/18/2002

Molecular Targeted Therapy For Non-Small Cell Lung Cancer: A Status Report, Institutional Grand Rounds, UT-MDACC, Houston, TX, 3/7/2003

Angiogenesis Inhibitors, Advances in the Management of Breast Cancer, UT-MDACC, Houston, TX, 3/18/2003

New Approaches to Development of Targeted Agents, Current Trends in Lung Cancer Conference, Houston, TX, 3/29/2003

Molecular Targeted Therapy of Lung Cancer: Update on the Epidermal Growth Factor Receptor Family, Institutional Grand Rounds, UT-MDACC, Houston, TX, 9/1/2003

Lung Cancer Facts & Fallacies, Living Fully with Cancer Conference, UT-MDACC, Houston, TX, 9/6/2003

Targeted Therapy for NSCLC, Department of Experimental Radiation Oncology Seminar, UT-MDACC, Houston, TX, 11/1/2004

Recent Advances with HER1/EGFR-Targeting Therapies for NSCLC, Houston, TX, 12/15/2004

Targeted Therapy in Lung Cancer, 2005 Update in Lung Medicine Conference, Houston, TX, 1/12/2005


Page 98 of 103

Targeted Therapy for Non-small Cell Lung Cancer: From the Lab to the Clinic and Back Again, Grand Rounds, UT-MDACC, Houston, TX, 7/15/2005

Pharmacodynamic Phase I Studies with Antiangiogenic Agents at M. D. Anderson Cancer Center, Grand Rounds-Early Clinical Trials at M. D. Anderson Cancer Center - Past, Present and Future, UT-MDACC, Houston, TX, 8/19/2005

Challenges for Implementation of Molecular Markers into Clinical Trials, 58th Annual Symposium on Fundamental Cancer Research-Discovery, Validation, and Integration of Molecular Markers and Molecular Imaging: Toward an Implementation into Clinical Practice, UT-MDACC, Houston, TX, 10/28/2005

Integrating Angiogenesis Inhibitors into Treatment of NSCLC, Current Trends in Lung Cancer and Head Neck Cancer, Houston, TX, 5/6/2006

Antivascular Therapy for NSCLC, Grand Rounds, UT-MDACC, Division of Cancer Medicine, Houston, TX, 7/11/2006

Treatment of NSCLC: Medical Therapy Chemo and Molecular Targeted Therapy, Society of Interventional Radiology Meeting, Houston, TX, 1/18/2007

Integration of Angiogenesis Inhibitors into Treatment of NSCLC, Current Trends in Lung Cancer and Head Neck Cancer, Houston, TX, 3/3/2007

Pharmacogenomic Approaches to Lung Cancer Therapy, Current Trends in Lung Cancer and Head Neck Cancer, Houston, TX, 3/10/2007

Co-Chairman, Third Annual Series of Educational Symposia on Advances in Oncology Emerging Trends, Targets, and Approaches to Solid Tumors, Houston, TX, 3/17/2007

Target Therapy in Oncology: Tyrosine Kinase Inhibitors and their Effects on the Cardiovascular System, Grand Rounds, UT-MDACC, Houston, TX, 5/1/2007

To Kill a Tumor: Recent Advances in the Development of Apoptosis - Targeted Therapies, Clinical Trails Faculty Meeting, UT-MDACC, Houston, TX, 7/11/2007

Toward Personalized Therapy in Lung Cancer, 60th Annual Symposium on Cancer Research, UT-MDACC, Houston, TX, 10/13/2007

Toward Personalized Therapy for Lung Cancer, New Frontiers Lecture, 55th Annual Scientific Meeting, American Society of Cytopathology, Houston, TX, 11/4/2007

Toward Personalized Therapy for Lung Cancer, Mechanisms in Cancer Therapeutics, Pediatric Grand Rounds, UT-MDACC, Houston, TX, 4/28/2008

The BATTLE-2 Clinical Trail – Lessons Learned from BATTLE-1, Advances in Oncology Institutional Grand Rounds, UT-MDACC, Houston, TX, 8/6/2010

Non-Small Cell Lung Cancer, From Theory to Practice An Update on Prostate, Head and Neck, and Non-Small Cell Lung Cancers, VA Grand Rounds Meeting, Quintiles Medical Education, Houston, TX, 9/28/2010

Personalized Therapy for Advanced Non-small Cell Lung Cancer 3/23/2011, Yale Grand Rounds, New Haven, CT

Screening and Teaching 4/26/2011, Yale Cancer Center, New Haven, CT

What Will It Take to Curb the Tobacco Epidemic? Moderator, Yale Cancer Center, New Haven, CT

Personalized Therapy for Advanced Non-Small Cell Lung Cancer: Lessons Learned from the Battle Trials, Famri Seminar Series, Johns Hopkins, Baltimore, MD, 2/27/2012


Page 99 of 103

Division of Cancer Medicine Grand Rounds Presentation, UT-MDACC, Houston, TX, 4/23-24/2012

From Molecular Mechanisms to Targeted Cancer Therapy, DFG Hinterzartener Kreis fur Krebsforschung, Villa La Collina, Cadenabbia, Italy, 4/26-29/2012

State-of-the-art Clinical Trials in 2012, Opportunities and Challenges in Lung Cancer Symposium, Manchester, England, 4/29-5/2/2012

Molecular and Mutational Testing in the NSCLC Setting, The Pulmonary Personalized Medicine Challenge, American Thoracic Society, Chicago, IL, 5/22-23/2012

Personalized, genotype-directed therapy for Early Stage NSCLC. New York General Thoracic Surgical Club (NYGTSC) Spring 2016 Meeting. New York, NY, 4/14/2016

PROFESSIONAL MEMBERSHIPS/ACTIVITIES Professional Society Activities, with Offices Held

National and International American Medical Association (AMA)

Member, 1991−present

Alliance for Lung Cancer Advocacy, Support, and Education (ALCASE)

Member, Medical Advisory Committee, 2003

American Association for Cancer Research (AACR)


Member, Career Development Award Committee, 2002−2003

Member, Phase I, II, and III Adult Clinical Trials Section of the Clinical Research Subcommittee of the 2003 Program Committee, 2003

Co-Chairman, Translational Research -- Molecular Biology in the Clinic Subcommittee of the Clinical Research Section of the 2006 AACR Program Committee, 2006

Member, AACR Grants Committee -- Chairman, Sub-Committee on Multidisciplinary Research -- Selection for the AACR-Gertrude B. Elion Cancer Research Award, 2006−2007

Member, 2007-2008 Selection Committee for the Dorothy P. Landon-AACR Prize for Translational Cancer Research, 2007−2008

Member, AACR Special Conferences Committee, 2007−2011

Chairperson, Multidisciplinary Grants Review Committee, 2008

Member, Phase II and Phase III Adult Clinical Trials Subcommittee of the Clinical Research Section of the 2008 Program Committee, 2008

Co-Chairperson, Program Committee for the 2009 Annual Meeting of the AACR, 2008−2009

Member, AACR Clinical Research and Experimental Therapeutics (CRET) Awards Selection Committee, 2008−2009

Member, Clinical Research and Experimental Therapeutics Awards Selection Committee, 2008−2010

Chairperson, Phase II and Phase III Adult Clinical Trials Subcommittee of the Clinical Research Section of the 2009 AACR Program Committee, 2009


Page 100 of 103

Section Chairperson, Phase II and Phase III Adult Clinical Trials Subcommittee of the Clinical Research Section of the 2009 AACR Program Committee, 2009

Member, Clinical and Translational Research Committee, 2009−2012

Chairperson, AACR Task Force on Tobacco and Cancer, 2009−present

Member, AACR Science Policy and Legislative Affairs Committee, 10/2009−4/2012

Co-Chairperson, AACR-IASLC Joint Conference on Molecular origins of Lung Cancer: Biology, Therapy, and personalized Medicine, San Diego, CA 1/8-11, 2012

Science Policy and Legislative Affairs Committee, AACR Vice Chair, March 2012 to present

Cancer Patient Tobacco Use Assessment Task Force, 2013-present

Member, AACR Cancer Progress Report 2018 Steering Committee, 2017-present

American Association for the Advancement of Science (AAAS)


American College of Physicians (ACP)


Fellow, 2010−present

American Society of Clinical Oncology (ASCO)


Member, Lung Program Committee, 2000−2002

Chairman, Lung Cancer Program Subcommittee, 2001−2002

Guest Planner, Annual Meeting Education Program, 2003

Member, Cancer Communications Committee, 2003−2006

Member, Molecular Targeted Therapy Program Committee, 2004−2005

Chairman, Cancer Communication Committee, 2005−2006

Editor, JCO Editorial Board, 2005-2008

Member, Editorial Board, Clinical Cancer Advances, 2006-2008

Elected Member, Nominating Committee, 2010−2013

Member, Cancer Research Committee, 2011 – 2014

Chair, Lung Cancer Clinically Meaningful Outcomes Committee, 2012-2013

Member, Genomics Working Group, Cancer Research Committee, 2013-2015

Member, Conquer Cancer Foundation of ASCO Grants Selection Committee, 2015-present

Member, Working Group & Advisory Council, ASCO-SITC Clinical Immuno-Oncology Symposium Planning Team, 2016-2017

Member, Meeting and Member Publications Editorial Board, 2017-present

Member, 2018 Annual Meeting Scientific Program Committee. 4/2017 to present


Page 101 of 103

Fellow of the American Society of Clinical Oncology (FASCO), 2018 -

ASCO/AACR Workshop on Methods in Clinical Cancer Research

Member, Program Committee, 2007−2009

Faculty, 2012-present

Association of American Physicians

Elected Member, 2015-present

Coalition of Cancer Cooperative Groups (CCCG)

Member, Lung Cancer Scientific Leadership Council, 2005

Member, 2007

Commission on Cancer/National Cancer Data Base Thoracic Oncology Team


Friends of Cancer Research, Chair of Steering Committee

Member, 2012-present

Chair, Lung Master Protocol Working Group, 2012

Gilead Sciences, Inc.

Member, Joint Steering Committee, 2014-present

Institute of Medicine (IOM) -- National Cancer Policy Forum

Member, 2007−2015

Co-chair, Personalized Medicine Workshop Planning Committee, 2009

Member, Workshop Planning Committee, 2010, 2011, 2014

Chair, Tobacco Workshop Planning Committee, 2012

Member, Summit Planning Committee, 2013

Interurban Clinical Club

Elected member, 2018-present

International Association for the Study of Lung Cancer (IASLC)

Chairman, Targeted Therapy Division of the Translational Research & Targeted Therapy Sub-Committee, 2003

Member, Organizing Committee for the 2005 IASLC Conference, 2003−2005

Chairman, Targeted Therapy Division of the Translational Research & Targeted Therapy Sub-Committee, 2005

Member, Core Program Committee - Medical Oncology, 2007−2009

Member, International Scientific Committee, 2007−2009

Co-chair, Annual Targeted Therapies of the Treatment of Lung Cancer Meeting, 2007 -present


Page 102 of 103

Co-Chairperson, AACR-IASLC Joint Conference, Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy, 2008−2010

Member, Medical Oncology Section of the Core Program Committee for the World Conference on Lung Cancer 2009, 2008

Chairman, Communications Committee, 2010−present

North America Member, Board of Directors, 2019-

Investigational Drug Steering Committee (IDSC)

Member, Angiogenesis Task Force, 2006−present

Co-chair, Angiogenesis Task Force, 2008−2010

Lung Cancer Research Foundation (LCRF)

Member, Medical Advisory Board, 2007-present

National Cancer Institute (NCI)

Member, Lung Cancer Concept Evaluation Panel, 2002−2003

External Reviewer, CTEP Concept Review Committee, 2005

Ad Hoc Member, Clinical Oncology Study Section (CONC), 2008−present

Reviewer, Clinical Oncology Study Section (CONC), 2008−present

Co-Chair, Investigational Drug Steering Committee Task Force, 9/2010−9/2012

Special Expert, Thoracic Malignancy Steering Committee (TMSC), 2014 to 2018

SWOG Representative, Thoracic Malignancy Steering Committee (TMSC), 2018 to present

Elected member, N of 1 Lung Strategy Committee, 2012-present

Member, Cancer Diagnosis Program (CDP), Program for the Assessment of Clinical Cancer Tests (PACCT) Strategy Group, 2015-present

Radiation Therapy Oncology Group (RTOG)

Member, Chemoprevention Committee, 1999−2003

Vice Chairman, Lung Committee, 2002−2009

Society for Immunotherapy of Cancer (SITC)

Chair, Cancer Immunotherapy Guidelines (CIG): Lung Cancer Guidelines Committee, 4/2015-present

Southwest Oncology Group (SWOG)

Group Leader, Developmental Therapeutics, Lung Committee, 2002- present

Vice-Chair, Lung Committee, 2018 -

SWOG Lung Master Protocol (Lung MAP), associated with protocol SWOG1400, NIH/NCI

Steering Committee Chair, 2014-

Drug Selection Committee Chair, 2014-


Page 103 of 103

University of Florida Cancer Center

Member External Advisory Board, 2015-present

University of Michigan Cancer Center

Member, CCSG External Advisory Board, 2015-present

Local/State Statewide Clinical Trials Network of Texas (CTNeT), TX

Member, Working Group, 10/2010 - 2011

Texas Medical Association (TMA), TX


UNIQUE ACTIVITIES Food and Drug Administration-Center for Drug Evaluation and Research, Participation at Oncologic Drugs Advisory Committee: New drug application-ALIMTA, presentation title “Alimta Development,” Rockville, MD, 7/2/2004

Founding PI, Statewide Clinical Trials network of Texas (CTNeT), Texas, 2010

Thesis Review Committee, April 2014: Gerald Goh, “Discovery of Novel Driver Genes in Adrenocortical Tumors by Exome Sequencing”

DATE OF LAST CV UPDATE July 18, 2019

Documents

CURRICULUM VITAE PRESENT TITLE AND AFFILIATION Ensign ... 2019-07-22.pdf · Thoracic Oncology Research Award, Dana Farber Cancer Institute, 1997 Young Investigator Award, American